

## Curriculum Vitae - GODFREY D. PEARLSON

DATE OF BIRTH: January 30, 1950  
PLACE OF BIRTH: Sunderland, England  
TELEPHONE: (860) 545-7757  
EMAIL: [godfrey.pearlson@yale.edu](mailto:godfrey.pearlson@yale.edu)  
[godfrey.pearlson@hhchealth.org](mailto:godfrey.pearlson@hhchealth.org)

WEBSITES: <http://www.nrc-iol.org/> (Olin Website)  
[godfreypearlson.com](http://godfreypearlson.com) (GP Books)  
[b-snip.org](http://b-snip.org) (B-SNIP multicenter trials)

OFFICES: Olin Neuropsychiatry Research Center  
The Institute of Living  
200 Retreat Avenue  
Hartford, CT 06106

Yale University  
Clinical Neuroscience Research Unit  
Abraham Ribicoff Research Facilities  
Connecticut Mental Health Center  
34 Park Street  
New Haven, CT 06519

### EDUCATION

1969-1974 Newcastle Upon Tyne University Medical School, England, M.B., B.S. Medicine: (equivalent to U.S. MD degree)

1975-1976 Columbia University, Graduate School of Arts and Sciences, New York. M.A. (Philosophy of Science)

### CAREER

2022- Present Member, Wu Tsai Institute, Yale University

2018- Present Research Director, Institute of Living, Hartford, CT

2013- Present Adjunct Faculty, Lieber Institute, Johns Hopkins University.

2009 –Present Professor, Department of Neuroscience, Yale University School of Medicine.

2002 –Present Professor, (fulltime, tenured) Department of Psychiatry, Yale University School of Medicine, New Haven, CT.

2002 – Present Founding Director, Olin Neuropsychiatry Research Center, Institute of Living, Hartford, CT.

1993 – 2002 Professor, full-time faculty, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. (2002-2012, part-time appt). Joint Appointment, Professor, Department of Mental Hygiene, Johns Hopkins University School of Public Health, Baltimore, Maryland.

1991 – 2002 Founding Director, Division of Psychiatry Neuro-Imaging, Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland.

1987 – 1992 Associate Professor, full-time faculty, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.

1987 – 1992 Joint Appointment, Associate Professor, Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.

1981 – 1987 Assistant Professor, Full-time faculty, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.

1980 – 1981	Postdoctoral Instructor in Psychiatry. Laboratory of Dr. Robert G. Robinson, Johns Hopkins University School of Medicine. Baltimore, Maryland.
1979 – 2002	Psychiatrist, Active Staff, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
2002 – Present	Psychiatrist, Part-Time Staff, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
1978 – 1979	Chief Resident in Psychiatry, The Johns Hopkins Hospital, Baltimore, Maryland.
1976 – 1979	Resident in Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.
1974 – 1975	Intern in General Internal Medicine, Newcastle Royal Victoria Infirmary, and in General Surgery, Newcastle General Hospital, England.

## **CERTIFICATIONS**

American Board of Neurology and Psychiatry (in psychiatry), 1980 (#21511)

Medical License State of Connecticut, 040622 (2002)

Medical License State of Maryland, D21805 (1977)

E.C.F.M.G. (#221-420-3)

F.L.E.X. (Maryland State Board of Medical Examiners) (#D-21805)

### **Brief summary of research interests:**

I am a physician researcher with a 35+ year history in clinical, translational neuroscience, including extensive experience in organizing and supervising large-scale research studies that apply novel imaging acquisition and analysis methods to enhance our understanding of brain function and behavior related to assessment of disease liability in substance use and psychosis. I am currently the Director of IOL's 50-person Olin Neuropsychiatry Research Center, and director of the COBBRA neuroimaging/biomarkers lab within the Center. My current major research interests are (a). Behavioral effects of cannabinoids, particularly on neuro-cognition, and resulting effects on motor vehicle driving, and (b). The subtyping of psychotic illnesses using biological measures. Collectively, these projects involve extensive use of tools including sMRI, fMRI, EEG, pharmacokinetics, genetics, and clinical-behavioral data collection and analysis.

I have been continuously funded by NIH for over three decades and was recognized with an NIMH MERIT award for continuous funding in psychosis research.

Substance abuse-related research activities include: 1. PI of both NIDA- and NHTSA-funded investigations of cannabis-impaired driving and developing roadside tests for cannabis-intoxicated drivers. 2. PI of an fMRI project in John Krystal's NIAAA CTNA P50 alcoholism Center at Yale, and 3. PI of the 2100-subject NIAAA-funded BARCS project on college student alcoholism predictors and consequences, and cannabis use effects on academic and brain measures. I recently published a popular science book on cannabis (*Weed Science: Cannabis Controversies and Challenges*, Elsevier/Academic press 2020, being republished by Johns Hopkins University press in 2024). I am a member of the Board of Physicians that advises the CT Department of Public Health on medical cannabis indications and a founding member and chair of the neuroscience committee for the Research Society on Marijuana (RSMj). I am especially interested in public health aspects of cannabis legalization and was a co-author on the recent 2022 consensus paper of the WFSBP Task Force on Cannabis, Cannabinoids and Psychosis.

I gave a TEDx talk on cannabis-intoxicated driving <https://www.youtube.com/watch?v=wzwHOUX6KIM>  
From >900 total peer-reviewed publications, I have >150 in various addictions.

Psychosis-related research activities includes being a principal investigator of the Connecticut site of the B-SNIP initiative and its various NIMH-funded offshoots, including a recent biotype-based clinical trial of clozapine, and the BICEPS initiative of first-break psychotic individuals. In addition I am PI of the Hartford site for the PRONet international investigation of the psychosis prodrome, and of an international study of social isolation in older individuals with psychotic illnesses

## **PROFESSIONAL HONORS AND AWARDS**

1973	Distinction, Medical Finals Part I, University of Newcastle Upon Tyne, England.
1974	Dickinson Scholarship (Surgery), University of Newcastle Upon Tyne, England.
1974	Wilfred Kingdon Prize (Psychiatry), University of Newcastle Upon Tyne, England.
1986	Lundbeck Lecturer, University of Newcastle Upon Tyne, England
1987	Mental Health Sciences Affiliations, Principal Lecturer. Hahnemann University, Pennsylvania.
1987	Fellowship, American Psychopathological Association.
1989	Distinguished Fellow, American Psychiatric Association.
1990	Annual Lecture, American Academy of Clinical Psychiatrists.
1991	Invited Lectures - Annual NIMH CRC Directors Meeting; Royal College of Psychiatrists, and Institute of Psychiatry, U.K.
1993	Invited Authorship and Lecture - American Psychiatric Association 12th Annual Review of Psychiatry, 1993. "Psychiatric Applications of MRI".
1993	Membership, American College of Neuropsychopharmacology
1993	Invited Lectures - Royal College of Psychiatrists, Institute of Psychiatry, U.K.
1996	Ziskin-Somerfeld Award, Society of Biological Psychiatry, U.S.
1997	Martell Gold Medal, UK
1999	Fellowship, ACNP
2000	Michael Visiting Professorship, Weizmann Institute, Rehovot, Israel
2000	NARSAD Distinguished Investigator Award
2001	Bernard Sisskin Annual Neurology Lecture, Lenox Hill/NYU
2002	Mysell Lecture, Harvard University
2003	ISI – Most Highly Cited Publications,
2003	Israel Biological Psychiatry Mentor Program
2003 – 2005	Society of Biological Psychiatry- Scientific Program Ctee
2004	Frontiers of Science Lecturer, 2004 Annual APA Meeting
2005 - 2014	MERIT award, NIMH
2006	NARSAD Scientific Council, ACNP Program Ctee
2008	30 <sup>th</sup> Albert Beile Memorial Award, Jefferson Medical College
2009	NeuroImage- Top 10 top cited scientific articles 2008 American College of Psychiatrists, Member
2011	National Academy of Neuropsychology. Nelson Butters Award, for Research Contributions to Clinical Neuropsychology.
2013-2018	APA Scientific Program Committee, ICOSR Scientific Program Ctee (to 2015)
2014	Distinguished Life Fellow, American Psychiatric Association
2015	Stanley Dean Award for Schizophrenia Research, American College of Psychiatrists
2015	Johns Hopkins Society of Scholars (distinguished alumni)
2015-current	Board of Physicians Advisory Ctee to CT DPH on Medical Marijuana.
2016-current	Research Society on Marijuana: Chair, Neuroscience Committee.
2019	American Psychiatric Association: APAF/AACDP Research Mentorship Award

## **DEPARTMENTAL, MEDICAL SCHOOL AND UNIVERSITY COMMITTEES**

### **YALE UNIVERSITY COMMITTEES**

2002 – Present	Faculty/Promotions Committee, Psychiatry, plus various ad hoc committees at the Dean's discretion
2003 – 2008	Donaghue/PRIME Research Committee

### **HARTFORD HOSPITAL COMMITTEES**

2002 – Present	HHC Research Committee
2002 – Present	Neuroscience Services Committee
2002 – Present	Psychiatry Research Committee

### **OTHER PROFESSIONAL ACTIVITIES**

2003 – 2008	Donaghue Foundation Scientific Research Review Panel
-------------	--

### **NATIONAL REVIEW COMMITTEES**

1994 – 1997	Review Panel: Scottish Rite Schizophrenia Research Program
1997 – Present	Ad Hoc scientific Review APA Annual Meeting
2003 – Present	NARSAD/BBRF proposal review committee
1991 – 1994	Reviewer, National Institute of Mental Health, Clinical Neurosciences Review Committee (formerly Clinical Biology Subcommittee, NPAS)
1989 – Present	Ad-hoc reviewer, National Institute on Drug Abuse.
1988	Advisor: Work group on Psychotic Disorders for DSM IV - Late life onset Schizophrenia. Advisor: DSM -IV work group on schizophrenia and related psychoses.
1986 – 1998	American Medical Association-Diagnostic and Therapeutic Technology Assessment Program of the Council on Scientific Affairs.
1985 – Present	Frequent ad-hoc reviewer, National Institute of Mental Health, Special Review Committees (NPAS, PCB-2, TDA-3) NIMH/NIAAA
2014–2018	American Psychiatric Association, Scientific Review Committee

### **INTERNATIONAL SCIENTIFIC REVIEW**

1995 – Present	Canadian Medical Research Council
1995 – Present	International Human Frontier Science Program (HFSP)
1995 – Present	Swiss National Science Foundation
1993 – Present	UK - Medical Research Council ad Hoc Scientific Review
1993 – Present	Wellcome Trust (UK)

### **ADVISORY COMMITTEES**

1997 – 2002	NARSAD/Stanley Neurobiology review panel at JHU.
1988 – 2002	Depression and Related Disorders Association (DRADA), Scientific Advisory Committee.

### **SOCIETY MEMBERSHIPS**

American Association for the Advancement of Science  
American College of Neuropsychopharmacology. (Fellow)  
American Psychiatric Association (Distinguished Life Fellow)  
American Psychopathological Association (Fellow)  
International Society for Neuroimaging in Psychiatry  
Johns Hopkins Medical and Surgical Association  
Society of Biological Psychiatry

### **MISCELLANEOUS**

International Congress on Schizophrenia Research - Program Consultant 1996, 2013, 2015.

University of Pittsburgh Medical Center – Interventional Mental Health CRS for Study of Late - Life Mood Disorders: External Advisory Board 1995 - 2000  
AAGP, Alzheimer’s Association, American Geriatrics Soc. Expert Advisory Panel- Use of Neuroimaging in early diagnosis of Alzheimer’s disease, (see report in JAMA, 278: 1363-1371, 1997). 2004 Program Chair, ECNS-ISONIP joint meeting, Irvine CA.

**EDITORIAL BOARDS**

Schizophrenia Research (Deputy Editor)  
Cannabis (Associate Editor)  
Biological Psychiatry to 2022  
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging  
Schizophrenia Bulletin  
Brain Imaging and Behavior  
Psychiatry Research: Neuro-imaging.  
J. Adv. Schizophrenia and Brain Research

**REVIEWER - JOURNALS**

Archives of General Psychiatry	Journal of Abnormal Psychology
Psychiatry Research	American Journal of Psychiatry
Neuroimage	Journal of Nervous & Mental Disease
Schizophrenia Bulletin	Psychosomatics
Archives of Neurology	New England Journal of Medicine
Science	PNAS, HBM

**COMMUNITY SERVICE**

**The BrainDance Awards** [http://www.nrc-iol.org/Braindance/onrc\\_braindance.asp](http://www.nrc-iol.org/Braindance/onrc_braindance.asp)  
Dr. Pearlson is co-founder of the annual BrainDance Competition, started in 2004, which is open to high school students across New England. The BrainDance Awards encourage students to gain knowledge about psychiatric diseases and to develop a more tolerant and realistic perspective toward people with severe psychiatric problems by offering awards for art, essays and scientific projects related to mental illness. Winners attend an annual lecture related to mental illness and/or stigma and showcase their work.

**Jessie’s Community Gardens Project** <https://www.facebook.com/pages/Jessies-Community-Gardens/>  
As a CT Certified Master Gardener, Dr. Pearlson founded and continues to direct the B’nai Tikvoh Shalom branch of this community garden project in 2014, that grows and harvests vegetable crops for donation to local food banks for homeless/needy persons.

**THE OLIN CENTER**

The Olin Neuropsychiatry Research Center <http://www.nrc-iol.org/> is a 50-person center on the grounds of the Institute of Living in Hartford Connecticut. Faculty members have primary appointments either in the Yale University medical school system, or at Hartford Healthcare. Currently the Olin center comprises 6 individual laboratories led respectively by Drs. Godfrey Pearlson (psychosis, abused substances), David Glahn (neuroimaging genetics), Michal Assaf (autism spectrum research), Michael Stevens (neurodevelopmental disorders/adolescents), Jimmy Choi (cognitive rehabilitation), and Alecia Dager (MR spectroscopy/substance abuse). Since inception the Center has garnered approximately \$40 million in NIH funds.

## Research Protégés

(Format: mentee name, year(s) of training/supervision/mentorship, current degree, mentee's host institution at time of supervision, research topic area, current professional status).

### **A. Undergraduate/BA Research Supervision (10 examples from ~55)**

1. Paul Moberg, 1983-4. Loyola University Maryland, Olfactory memory in Huntington's disease and in schizophrenia. Currently PhD, Professor of Neuropsychiatry at University of Pennsylvania Department of psychiatry. Multiple NIH RO1s.
2. Vincent McGinty, 1999. Johns Hopkins University, Virtual Driving/fMRI. Currently PhD Assistant Professor, Center for Molecular and Behavioral Neuroscience, Behavioral Electrophysiology, Rutgers University.
3. Daniel Roche, 2004-5. Trinity College CT: College alcohol project. Currently, PhD. Assistant Prof. University of Maryland Medical Center, Psychiatry, Substance Abuse Research Division.
4. Abigail Garrity, 2006. Trinity College, Default mode fMRI in schizophrenia. Currently PhD. Neuroscience researcher, Dept of Molecular Cell Development, University of Michigan.
5. Brian Castelluccio, 2006-2009. Trinity College, fMRI of Go/No-go task in cocaine abusers. Currently, PhD intern, clinical psychology University of Connecticut Storrs.
6. Patrick Worhunsky, 2010, IOL. fMRI of impulsivity and alcoholism risk/design of an improved monetary incentive delay task. Currently DPhil, Assistant Prof. Yale University Department of Psychiatry
7. Meredith K Ginley, 2012-2013. IOL College alcohol project. Currently PhD, postdoctoral fellowship University of Connecticut Health Center on addiction/gambling.
8. Alex Bednarek, 2013. Trinity College, Effects of alcohol consumption on brain connectivity in college students. Current, neuroscience microgravity effects on LTP (molecular model for learning and memory) in hippocampus.
9. Geoff Bocobo, 2016. Trinity College, Diffusion Tensor Imaging biomarkers in the diagnosis of psychotic disorders. Currently, Biomedical Research, Brigham & Women's Hospital, Harvard.
10. Molly Ryan, 2017. Trinity College. Determining covariation between impulsivity measures and alcohol use and their effects on fMRI regional homogeneity using multimodal fusion of functional and structural MRI.
11. Natalie Bush, 2019. Trinity College. Neurological/fMRI discrepancies between schizophrenia, schizoaffective disorder and bipolar disorder.

### **B. Pre-Doctoral Research/PhD Thesis Advisor**

1. D.J. Garbacz, 1982-1983. VBR-clinical correlates in bipolar disorder. Loyola College Psychology, MA Program. Currently, emergency medical services, State of New Hampshire.
2. S.C. Levin, 1983-1985. Structural CT change in bipolar disorder assessed by image processing: relationship to cognitive abnormalities. Thesis advisor. Howard University Neuropsychology Ph.D. Program. Currently, clinical neuropsychology.
3. Nicholas Yatron, 1984-1985. Loyola College Psychology MA Program: Cognitive distortion and depressed mood in chronic pain. Deceased.
4. Marnie Haden, 1986. Loyola College Psychology MA Program: Electrodermal non-responding and VBR in schizophrenia. Currently, clinical psychology practice.
5. Dorothy Houlihan 1988 Loyola College Psychology MA Program: Longitudinal follow-up of 350 chronic pain patients and controls. Currently, clinical psychology practice.

6. Gordon Harris, 1988. Computer reconstruction and registration of SPECT image sets (Ph.D. thesis advisor). Currently, Professor, Radiology, Harvard University/Director MGH 3-D Imaging Lab. NIH Awardee.
7. Natalia Ojeda PhD., 1995. Pre-doctoral fellowship: structural MRI and cognition in schizophrenia. Currently Tenured Professor, University of Deusto, Spain Neuroscience/Neuroimaging, WHO expert committee on schizophrenia disability.
8. Bram Stiltjes, 1999-2000. pre-doctoral student, DTI Atlas project. Currently MD PhD, Group Leader Basel University Hospital Departments of Radiology and Nuclear Medicine.
9. Michael Yassa, 1999. Johns Hopkins University MA program, fMRI/memory. Currently PhD, Professor University Of California, Irvine Department of Neurobiology, and Director, Center for Neurobiology Language and Memory.
10. Vince Calhoun, 2000-2002. Application of Independent component analysis to virtual driving/fMRI. (Ph.D. thesis advisor University of Maryland, Baltimore County). Currently, Director Mind Institute Albuquerque, Distinguished Professor, Departments of Computer Science and Engineering, University Of New Mexico. NIMH, NSF, NIBIB, multiple RO1 awardee. ACNP Elkes Award 2013.
11. Kanchanana Jagannathan MS., 2003-2007. fMRI analysis. Currently Scientist at University of Pennsylvania Department of Psychiatry, Substance Abuse Group.
12. Rivkah Rosen, UConn. College alcohol project. Currently PhD, quality control editor at Research Square, Hartford, Connecticut.
13. Lanxin Ji, 2018. Pre-Doctoral Student Center for Biomedical Imaging Research, Tsinghua U. Cognitive Reserve. Currently pre-doctoral fellowship, Yale University.
14. Karina Guzman 2018. Pre-doctoral student, University Veracruz. Evoked potential abnormalities in psychosis. Currently pre-doctoral fellowship, Yale University.
15. Nique Pichette- 2022-Pre-doctoral student Salve Regina University. Creation of a novel, comprehensive cannabis use disorder questionnaire.

### **C. Postdoctoral Research Supervision**

1. Elizabeth Aylward, 1989. PhD. Quantitative brain atrophy measures in Huntington's disease on MRI and CT scans. Current, Director, Office of Science-Industry Partnerships, Seattle Children's Research Institute (SCRI). Previously Assistant to associate professor JHU. Assoc. Director, Seattle SCRI Center for Integrative Brain Research. Professor, Radiology, U. Washington Seattle. NIH Awardee, HDSA Awardee, multiple NIH awards.
2. Nancy Honeycutt PhD, 1995-1996. Amygdala and hippocampus in schizophrenia. Assistant Professor, Johns Hopkins Univ., Quantitative MRI research. NIH Awardee. Currently freelance research.
3. Jin-Suh Kim MD, 2001-2002. Diffusion tensor imaging. Currently academic Radiology, U. Iowa
4. Michal Assaf MD, 2001-2003. fMRI in thought disorder. Current, Adjunct Associate Prof., Yale University School of Medicine, Senior scientist/lab chief, Olin Center IOL.
5. Kristen McKiernan PhD, 2002-4. Task-induced deactivation in fMRI. Formerly, Sr. Scientist ONRC, Asst Clin Professor, Yale U. Dept Psychiatry NIA R21 Awardee. Current, research staff, State of Connecticut.
6. Michael Stevens PhD, 2004-current, fMRI of impulsivity, (K Award primary mentor) Sr. Scientist ONRC, Clin Professor, Yale U. Dept Psychiatry. NIMH K Awardee, multiple RO1 Awardee.
7. Bradley Folley PhD., 2006-2007. Postdoctoral fellowship: fMRI maze learning in schizophrenia. Currently, Norton Neuroscience Institute, Louisville Kentucky.

8. Beth Turner Anderson PhD, 2007. Amphetamine interactions with COMT Genotype. Current, Staff Scientist, Prometheus Corporation NIDA Awardee.
9. Melina Griss PhD, 2009. Postdoctoral fellowship, schizophrenia endophenotypes. Currently Senior clinical psychologist, Gaylord Rehab Hospital, Connecticut.
10. Sharna Jamadar PhD, 2010-2011, fMRI in Schizophrenia Junior biomedical imaging faculty, Monash University, Australia. ARC Discovery Early Career Research Award.
11. Janet Ng PhD, 2012-13 . Neuroscience of Obesity. Current, Associate Director, Health Psychology Postdoctoral Training, Samaritan Health Services Oregon.
12. Haley Yarosh, PhD 2012-13. Yale University postdoctoral fellow, T32 student. Neurobiology of Impulsive/Risky Choice. Current, Tech startup, San Francisco.
13. Shizhong Han, PhD, 2013. Postdoctoral fellowship Yale University – neuroimaging genetics project. Currently Associate Professor of Psychiatry and Behavioral Sciences Johns Hopkins University
14. Iris Balodis PhD, 2015-2016. Yale University, postdoctoral fellowship. Currently Assistant Prof. of McMaster University, Center for Addiction Research.
15. Barbara Banz PhD, 2016. PhD, postdoctoral fellowship Yale University, substance abuse. Currently, Associate Scientist, Developmental Neuro-Cognition Driving Simulation Research Program, Yale University School of Medicine.
16. Elise DeVito, PhD. 2014. Postdoctoral fellowship Yale University, impulsivity and alcoholism risk. Current, Associate Research Scientist in Psychiatry, Yale University School of medicine. Sr. Scientist ONRC, Asst Clin Professor, Yale U. Dept Psychiatry. NAAR, Donaghue Foundation Awardee. NIMH R01 Awardee.
17. Ozlem Ozemen-Okur PhD. 2016. Postdoctoral fellow. Application of machine learning methods to Biotype classification Current, Institute of Living.
18. Emma Knowles PhD. 2017 NARSAD awardee, advisor, MR spectroscopy in major depressive disorder. Current, Assistant Professor, Yale University.
19. Ronald Janssen, PhD. 2018. Baysean classification of psychosis biomarkers. Current Yale Postdoctoral fellow.
20. Marinka Koenis, PhD 2018. Functional MRI prediction of bariatric surgery outcome. Current Yale-to-IOL Postdoctoral fellow.

#### **D. Psychiatry Resident Research**

1. Jeffrey Moore, 1986-7. Negative symptoms in late-life onset schizophrenic patients. Academic psychiatrist, Ohio.
2. \* Alistair Burns, 1986. Centrum semiovale white matter density in late life schizophrenia, AD, normal aging. Vice Dean for Clinical Affairs and Professor of Geriatric Psychiatry, Manchester University, U.K., formerly Wellcome Lectureship, Dr. Raymond Levy, Institute of Psychiatry (Geriatrics) London, U.K. 1989 IPA Psycho-geriatrics Research Award.
3. \* Martin Deahl, 1987. Cerebral atrophy measures in schizo-phrenia and affective disorder. Currently, Consultant Psychiatrist, Researcher, Denis Hill Unit, Bethlem Hosp., London, U.K.
4. Richard Powers, 1987. MRI atlas construction. Current, University of Alabama, Birmingham, Deputy Chief, Psychogeriatrics,. NIH awardee.
5. \*Jeremy Broadhead, 1987. Temporal ventricular horn assessment in schizophrenics versus controls. Consultant psychiatrist, U.K. Research in neuropathology of amygdala.
6. Patrick Barta, 1988. Computer-based segmentation applied to MRI images in schizophrenia, MRI display software. Current, Associate Professor, Biomedical Engineering Department Johns Hopkins Univ. NIH FIRST, R01's, NARSAD, Scottish Rite awardee.



7. Christopher Ross, 1988. Dopamine D2 receptor PET scans in schizophrenia vs. bipolar illness. NIH RO1s. Pew Scholar. Current, Professor, Psychiatry, Neuroscience, Johns Hopkins Univ., Director, Huntington's Disease Project.
8. Steven Machlin, 1989. MRI and SPECT changes in patients with obsessive-compulsive disorder. Private practice, FL.
9. Laura Marsh, 1990. MRI in schizophrenia: Replication of post-mortem studies. Johns Hopkins U. Parkinson's disease research. Research Fellowship, Dr. Daniel Weinberger, NIH Intramural. MRI research. Young Investigator Award, Third Interl. Congress on Schizophrenia Research, 1991. NIH Awardee. Current, Professor, Dept of Neurology, Baylor University, Texas.
10. \* Raj Persaud, 1990. MRI in schizophrenia: Basal ganglia. Current, Professor, Maudsley Hospital, London, U.K. MRI research in affective disorder. Author.
11. Frederick Schaerf 1990. Imaging in HIV dementia. Current, Private practice, Ft. Myers, Fla.
12. \*Peter Woodruff, 1991. MRI in schizophrenia: Corpus callosum. Formerly Professor & Head of Division of Psychiatry Neuroimaging, Sheffield University, UK. Prev. Faculty, Maudsley Hospital, London, U.K. Functional Brain Imaging Research, Wellcome Awardee, Fulbright Awardee. Currently, Prof. of Psychiatry, Weill Cornell Medical College.
13. Benjamin Greenberg, 1991. MRI of basal ganglia in HIV dementia. Prev., prev. Research Faculty, Lab. of Dr. D. Murphy, NIMH. Society of Biological Psychiatry, Dista Fellowship, 1991. NIH Awardee. Current, Professor of psychiatry, Brown University.
14. \*Rajiv Menon, 1991. MRI of superior temporal gyrus in schizophrenia. Senior Faculty, Psychogeriatrics, Chelsea, Maudsley Hospital, London, U.K.
15. J. Thomas Noga, 1991. MRI of cingulate gyrus in schizophrenia. Prev. fellow, NIMH/St. Eliz., Washington, D.C. (Lab of Dr. D. Weinberger and Dr. Joel Kleinman). Current, Faculty, Emory University Atlanta, GA.
16. Thomas Schlaepfer, 1991-1992 and 1993-1996. PET in cocaine abusers, SPECT in opiate abuse. Prior, Dean of Medical Education, Professor, and Vice-Chair, Dept. Psychiatry, U. Bonn, Germany. Awardee - Swiss Nat. Sci. Foundation. Current, Full professor, Interventional Biological Psychology, Medical Center University Freiburg, Germany.
17. \*Iain McGilchrist, 1992. Parietal cortical reconstruction from 3 D MRI. Faculty, Maudsley Hospital, London, U.K. Brain Imaging Research. Author, *The Master and His Emissary*.
18. \*Richard Petty, 1992. Planum temporale reconstruction from 3 D MRI. Faculty, University of Pennsylvania, Lab of Dr. Raquel Gur. Current, Pharmaceutical industry.
19. \*Sophia Frangou, 1994. Superior temporal gyrus in schizophrenia and Down syndrome NYC. Prev. Research/Clinical Faculty, Institute of Psychiatry, London, U.K., Awardee - Wellcome Foundation, NIMH R01. Current, Professor Psychiatry and Chief of Psychosis Research Program Mt. Sinai School of Medicine, NYC
20. \*Tonmoy Sharma, 1994-1995. Cortical grey matter in schizophrenics and their families. Previously, Faculty, Institute of Psychiatry, London, U.K., MRC Awardee. Current, Director, Cognitive Psychopharm. Lab.
21. Melissa Frederikse, 1995-1997. IPL in schizophrenia. Current, Associate Professor/UMDNJ,.
22. Andrej Marusic, 1997. Statistical parametric mapping applied to SPECT rCBF in early AD. Deceased. Former National Director, Psychiatric Research Institute. Republic of Slovenia.
23. Paul Rivkin, 1997-1998. fMRI in presymptomatic AD. Faculty, Johns Hopkins University. fMRI research, NIH Awardee.
24. \*Paula Dazzan, 1997-1998. Cortical surface area in schizophrenia. Faculty, King's College Psychiatry, London, U.K. Head, Div of Early Psychosis Research.
25. Sergio Nicastrì, 1998-99. rCBF in cocaine abusers. Humphrey Fellow. Current, Psychiatry Faculty, University of Sao Paulo, Brazil

26. Laura Amodei, 2000-2001. Diffusion tensor imaging of language circuits in schizophrenia. Radiology Johns Hopkins University.
27. Sarah Reading, 2001-2002. fMRI of attentional networks in schizophrenia Hopkins Dept. NIMH K Awardee. Currently, Mary and psychiatric Veterans Administration system.
28. \* Richard Kanaan, 2001-2002. fMRI of verbal binding in schizophrenia. Faculty, Dept of Psychiatry, London, UK DTI research. Currently,
29. Rogerio Ramos, 2008. Institute of Living psychiatry resident research program. College alcohol abuse. Subsequently, Yale Addiction Fellowship. Currently addiction medicine.
30. Marco Solomi, 2009. Visiting scholar, University of Padua: Eating Disorders fMRI. Current, neuroscience research, Department of Psychiatry, University of Padua.
31. Mohammed Mokhtari, 2013. IOL residency research. 2013 American Psychiatric Institute Award for Research and Education/Janssen Scholars Program, examining genetic underpinnings of the P50 electrophysiologic potential. Currently, private research foundation.
32. Ashley Bullock, 2018. Institute of Living psychiatry resident research program; marijuana-intoxicated driving– Currently accepted, fellowship Yale University substance abuse program.
33. Shilpa Lad, 2019. Institute of Living psychiatry resident research program; developing presurgical predictors of bariatric surgery outcome.
34. Kyle Shepard, 2019. Institute of Living psychiatry resident research program; exploration of childhood abuse in psychosis development in the B-SNIP sample.
35. Aaron Alexander-Block, 2019. Yale University Psychiatry Department research residency program. K-award mentor. Exploring brain surface morphology in psychosis categorization across multiple large-scale data sets.
36. Robert Kohler 2022. Yale Psychiatry Department T32 Postdoc. Co-mentor with Sarah Yip. Large-scale data mining to determine biosignatures of alcoholism risk.

*\*Psychiatry Residency exchange fellow, Institute of psychiatry/Maudsley Hospital United Kingdom – Johns Hopkins University Department of Psychiatry.*

#### **E. Junior Faculty Research Supervision**

1. Charles Hong, 2000. Johns Hopkins University, underrepresented minority fellowship. fMRI of REM sleep. Currently, adjunct faculty Johns Hopkins University
2. Wendy Kates, 2000-2001. Johns Hopkins University disability fellowship. MRI studies of velo-cardio-facial syndrome (22q.11 deletion). Professor, Dept of Psychiatry, SUNY Upstate. Director, Developmental Imaging Laboratory. NIH R01 awardee.
3. Gregory Book, IT design specialist. 2004 – current. Institute of Living, Senior scientist.
4. Dr. Matthew Kurtz, 2004-6. FMRI of cognitive rehabilitation in schizophrenia, (K Award advisor). Current, Prof, & Chair of Psychology, Wesleyan U adjunct Assoc Clin Professor, Yale U. Dept Psychiatry. NIMH K Awardee.
5. Hedy Kober, PhD., 2014. Prediction of outcomes, bariatric surgery. Currently Yale University, Assistant Prof., Psychiatry and Psychology.
6. Alecia Dager, 2011. Alcohol cue reactivity on fMRI as a predictor of subsequent alcohol use disorder in college students. Currently, assistant professor, Department of Psychiatry Yale University. K awardee.
7. Balaji Narayanan PhD. Parallel independent component analysis of EEG/genetics. Currently, Senior, scientist satellite imaging/crop genetics, Monsanto chemical company, Iowa.
8. Jimmy Choi, 2015. Cognitive remediation in schizophrenia. Currently, Director, schizophrenia rehabilitation program, Institute of Living.
9. Sarah Yip PhD, 2017. Data mining in multiple alcohol data sets. Current, Assistant Professor Department of Psychiatry Yale University School of Medicine.

10. Miryana Domakonda MD, 2018. Effects of morbid obesity reversal on cognitive measures  
Current, junior faculty, Institute of Living, adjunct assistant professor Yale University  
Department of Psychiatry.
11. Helen Pushkarskaya PhD, 2018. K award mentor, Current, Assistant Prof., Department of  
Psychiatry, Yale University school of medicine.
12. Sarah Lichenstein PhD. 2022 – current. Biosignatures of cannabis use disorder in large  
adolescent cohorts.
13. Vaughn Steele. 2021-current. Use of rTMS as a tool to altered neural circuits underlying  
substance use disorders.

## RESEARCH FUNDING

### **Ongoing Research Support – Pearlson, Godfrey D. (Annual Direct \$)**

#### **Examining the Feasibility of a Field Sobriety Test for THC.**

Major Goals: This proposal will assess optimum roadside sobriety tests to detect impaired driving abilities following marijuana intoxication, using medium and high-potency inhaled vaporized marijuana, compared to placebo in a double-blind design that measures driving-related cognitive abilities, and driving performance in a realistic simulator. In addition effects of alcohol/marijuana combinations will be quantified. All types of measures are assessed repeatedly over several hours following acute intoxication to assess longitudinal progression of impairment, in conjunction with blood and saliva measures of THC and its metabolites. Status of support: active. NHTSA DTNH2216R00036 Research Contract, National Highway and Traffic Safety Administration. (PI's Pearlson/Stevens). 10/01/16-9/30/23 \$530,000

#### **ProNET: Psychosis-Risk Outcomes Network**

\*Major Goals: In partnership with the Data Processing, Analysis, and Coordinating Center, we will contribute to analyses to dissect the heterogeneity of clinical high risk for psychosis (CHR) and develop tools for outcome definition and patient stratification. \*Status of Support: Active Project Number: **U01MH124639** Name of overall consortium PD/PI: **Scott Woods, Hartford site PIs, Pearlson/Choi** \*Source of Support: National Institutes of Mental Health (NIMH) \*Primary Place of Performance: Hartford Hospital, Hartford CT Project/Proposal Start and End Date: (MM/YYYY) (if available): 7/2020 – 5/2025 \* Total Award Amount (including Indirect Costs): \$697,082 \* Person Months (Calendar/Academic/Summer) per budget period. Year (YYYY) Person Months 2. 2022 1.2 3. 2023 1.2 4. 2024 1.2 5. 2025 1.2

#### **3/5 Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)**

\*Major Goals: Test the ability of biomarker and Biotype data, as developed and replicated in the B-SNIP project, to predict which individuals with psychosis will respond therapeutically to clozapine treatment. \*Status of Support: Active Project Number: **1R01MH124802-01** Name of PD/PI: **Godfrey Pearlson** \*Source of Support: National Institutes of Mental Health (NIMH) \*Primary Place of Performance: Hartford Hospital, Hartford CT \*Project/Proposal Start and End Date: (MM/YYYY) (if available): 5/2021 – 4/2026 \* Total Award Amount (including Indirect Costs): \$376,378 \* Person Months (Calendar/Academic/Summer) per budget period. Year (YYYY) Person Months 2. 2022 .96 3. 2023 .96 4. 2024 .96 5. 2025 .96

#### **The impact of social isolation on aging health in schizophrenia**

1R01MH127971-01A1 (Multisite PI: **Velthorst**) 08/15/22 – 05/31/27. NIMH

Contact PD/PI: **Pearlson, Godfrey D**

**Overview.** Applying an accelerated follow-up design we will test whether and how social isolation contributes to the health challenges of individuals with schizophrenia-related disorders as they age. This study may show that in SZ socialization in midlife can reduce the risk for poor health outcomes and ultimately facilitate much-needed preventive targeted therapies to reduce early-age mortality in SZ. Role: Site PI

#### **3/5 Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)**

1R01MH127158-01A1 (Multisite PI, **Keshavan MS, Site PI: Pearlson**) 08/15/22 – 06/30/27  
NIMH

**Overview.** This proposal seeks to characterize the early course of psychotic disorders and to identify clinical and biological predictors of outcome. Role: Site PI

#### **Center for the Translational Neuroscience of Alcoholism**

\*Major Goals: Functional neuroimaging of alcoholism vulnerability: probing glutamate and reward using the mGluR5 inhibitor mavoglurant. Alcohol use disorder (AUD) is prevalent and a major cause of morbidity and mortality; a portion of the risk for the condition is familial. A significant portion of inherited risk for AUD likely involves dominance of glutamate over dopamine in brain circuits governing certain types of reward responsiveness, impulsivity and learning. Project 2 will use the mGluR5 negative allosteric modulator drug mavoglurant as a probe in conjunction with 4 functional MRI paradigms to understand how the drug targets the brain systems implicated in familial alcoholism risk. \*Status of Support: Active Project Number: **2 P50 AA 012870-21**

Name of Center PD/PI: **John Krystal, MD, Hartford Project PI, Pearlson.** \*Source of Support: National Institute on Alcohol and Abuse (NIAA) \*Primary Place of Performance: Hartford Hospital, Hartford CT Project/Proposal Start and End Date: (MM/YYYY) (if available): 6/2001 – 5/2022 \* Total Award Amount (including Indirect Costs): \$410,101 \* Person Months (Calendar/Academic/Summer) per budget period. Year (YYYY) Person Month

**Neural Architecture of Social Emotional Processing and Regulation in Autism Spectrum Disorder: A Dynamic Connectivity Perspective**

\*Major Goals: The goals of this study are to delineate the temporal dynamics of the neural networks subserving social perception, cognition and regulation in relation to social phenotypes and the diagnosis of autism spectrum disorder (ASD), and to characterize the neural mechanism of explicit emotion-regulation (ER) behavioral manipulation across social and ER traits. \*Status of Support: Active Project Number: **5R01MH119069-04** Name of PD/PI: **Michal Assaf** \*Source of Support: National Institutes of Mental Health (NIMH) \*Primary Place of Performance: Hartford Hospital, Hartford CT Project/Proposal Start and End Date: (MM/YYYY) (if available): 4/2019 – 1/2024 \* Total Award Amount (including Indirect Costs): \$641,713 \* Person Months (Calendar/Academic/Summer) per budget period. Year (YYYY) Person Months 3. 2022 .6 4. 2023 .6 5. 2024 .

**Dynamic imaging-genetic models for characterizing and predicting psychosis and mood disorders**

\*Major Goals: Detailed cognitive and clinical information is also gathered on subjects. Dr. Pearlson will make these data available for use in the current proposal, as well as providing input on interpretation of clinical psychiatric and substance use data. \*Status of Support: Active Project Number: **5R01MH118695-04** Name of PD/PI: **Vince Calhoun** \*Source of Support: National Institutes of Mental Health (NIMH) \*Primary Place of Performance: Hartford Hospital, Hartford CT Project/Proposal Start and End Date: (MM/YYYY) (if available): 5/2019 – 1/2024 \* Total Award Amount (including Indirect Costs): \$705,172 \* Person Months (Calendar/Academic/Summer) per budget period. Year (YYYY) Person Months 3. 2022 .6 4. 2023 .6 5. 2024 .

**Computational Modeling-Informed Reward Subgroups in Adolescent ADHD**

\*Major Goals: The goal of this study is to provide convincing evidence that there are several discrete neurobiological defined 'pathways' to ADHD symptom expression that can be distinguished by how different neural systems-level abnormalities in the brain's reward system predict distinct types of atypical reward behavior. \*Status of Support: Active Project Number: **1R01MH119815-03** Name of PD/PI: **Michael Stevens** \*Source of Support: National Institutes of Mental Health (NIMH) \*Primary Place of Performance: Hartford Hospital, Hartford CT Project/Proposal Start and End Date: (MM/YYYY) (if available): 3/2020 – 12/2024 \* Total Award Amount (including Indirect Costs): \$612,866 \* Person Months (Calendar/Academic/Summer) per budget period. Year (YYYY) Person Months 3. 2022 .6 4. 2023 .6 5. 2024 .6

**Multivariate methods for identifying multitask/multimodal brain imaging biomarkers**

\*Major Goals: The focus of this supplement request is to leverage and reinforce our ongoing biomarker identification work with methods specifically focusing on Alzheimer's disease (AD) and related disorders (ADRD). Deep learning methods that we are developing in the parent grant can produce an optimal performance based on learning end-to-end directly from the data. Our goal is to leverage models trained to classify AD from the full brain fMRI dynamics for capturing novel dynamic biomarkers of AD via trained model introspection. \*Status of Support: Active Project Number: **2R01EB006841-14** Name of PD/PI: **Vince Calhoun** \*Source of Support: National Institutes of Mental Health (NIMH) \*Primary Place of Performance: Hartford Hospital, Hartford CT Project/Proposal Start and End Date: (MM/YYYY) (if available): 9/2012 – 6/2024 \* Total Award Amount (including Indirect Costs): \$233,267 \* Person Months (Calendar/Academic/Summer) per budget period. Year (YYYY) Person Months 3. 2022 .6 4. 2023 .6 5. 2024 .

**Data-driven solutions for temporal, spatial, and spatiotemporal dynamic functional connectivity**

\*Major Goals: We propose a novel family of models that builds on the well-structured framework of joint blind source separation to capture a more complete characterization of (potentially nonlinear) spatio-temporal dynamics while providing a way to relax other limiting assumptions. Our models will also produce a rich set of metrics to characterize the available dynamics and enable in depth comparison with currently available models including those that are model based. We will extensively validate our approaches in a variety of ways including simulations and evaluation of rigor and robustness in large normative data sets. Finally, we will apply the developed tools to study the important area of dynamic

properties in mental illnesses including schizophrenia, bipolar disorder, and the autism spectrum. \*Status of Support: Active Project Number: 1R01MH123610-01A1 Name of PD/PI: **Vince Calhoun** \*Source of Support: National Institutes of Mental Health (NIMH) \*Primary Place of Performance: Hartford Hospital, Hartford CT Project/Proposal Start and End Date: (MM/YYYY) (if available): 3/2021 – 1/2026 \* Total Award Amount (including Indirect Costs): \$625,428 \* Person Months (Calendar/Academic/Summer) per budget period. Year (YYYY) Person Months 2. 2022 .6 3. 2023 .6 4. 2024 .6 5. 2025 .6

**NIDDK 1R01DK113408 Neuroimaging Predictors Of Bariatric Surgical Outcomes. (PI's Pearlson/Papasavas), 07/25/18-6/30/23 \$493,512**

Bariatric surgery is an important treatment option for morbidly obese patients; however, 20-50% of patients either regain significant weight or fail to lose the anticipated amount of weight. Prior attempts to predict the degree of weight loss have had only modest success. Our pilot data suggest that individual differences on pre- surgical functional MRI (fMRI) neural activity reliably predict weight loss and other bariatric patient-specific health outcomes up to 1 year later. We will assess individual differences in these neural pathways that exert a powerful effect on sustained weight loss at up to 5 years post-surgery, and thus provide important insights into mechanisms of weight loss and health outcomes

### **Recently Completed Research**

NIMH 2R01MH077945-05A1 (PI: Pearlson) \$814,589 annually 4/01/2014 – 3/31/2019  
3/5 Bipolar-Schizophrenia Network for Intermediate Phenotypes 2 (B-SNIP-2) AN:3592533 (2.4)  
The DSM major psychosis diagnoses (schizophrenia, schizoaffective disorder, bipolar disorder with psychosis) overlap extensively on symptoms, neurobiology and genetics. Our collaborative group (called B-SNIP) developed a psychosis classification scheme (which we called Biotypes) using biological measures that was superior to DSM diagnoses for capturing neurobiological similarities and differences. In this project, we will extend this work to refine our neurobiological Biotype definitions, and characterize unique molecular and genetic features of the Biotypes.

NIDA 1R01DA038807. (PI's Pearlson/Stevens). Neuroscience of Marijuana-Impaired Driving. 8/01/15 – 5/31/21, \$569,892

This proposal will assess driving abilities following marijuana intoxication, using medium and high-potency inhaled vaporized marijuana, compared to placebo in both occasional and frequent drug users, with a double-blind design that measures driving-related cognitive abilities, driving performance in a realistic simulator, and virtual driving plus other relevant cognitive tasks in an fMRI scanner. All three types of measures are assessed repeatedly over several hours following intoxication to assess longitudinal progression of impairment, along with saliva and plasma measures of THC.

2P50 AA012870-15 (Krystal) 6/1/2016 – 5/30/2020  
NIAAA (Krystal, Center PI) Role: Pearlson Project 2 PI \$180,000  
Center for the Translational Neuroscience of Alcoholism

Project 2: Functional neuroimaging of alcoholism vulnerability; effects of Saracatinib

The major goals of the project are to examine effects of selective NMDA receptor blockade accomplished by Saracatinib, a FYN kinase inhibitor on fMRI activation patterns in reward and impulsivity tasks that may be vulnerability markers for familial alcoholism risk. The overall PO1 examines neurotransmitter, genetic, imaging and electrophysiologic alcoholism vulnerability markers

1R01MH102854-01A1 (PI:Stevens) 12/15/14 – 11/30/2018  
NIMH Role: Co - Investigator \$728,737

Neural Architecture of Emotion Regulation, Adolescent Development and Depression

The goals of this study are (1) To use fMRI effective connectivity analyses to confirm and specify which top-down PFC→amygdala influences underlie ER, to test novel hypotheses about alternative pathways involved in ER, and to evaluate their specificity to different emotional valences and ER tactics (2) To identify what kinds of ER neural system causal interaction weaknesses underlie ineffective ER. (3) To determine if specific impaired ER neural network interactions represent risk and/or state-related

dysfunction biomarkers for adolescent Major Depressive Disorder

NIH/NIDA R01 MH106324-01 (PI: **Glahn/Blangero/Poldrack**) 2/01/14 – 08/31-19  
Gene Networks Influencing Psychotic Dysconnectivity in African Americans Role: \$777,370  
Co - Investigator

Structural and functional brain dysconnectivity is a hallmark of psychotic disorders, primarily schizophrenia and bipolar disorders. By examining gene networks previously associated with psychosis risk, our study will provide novel insights into the biology of psychotic illness, improving the potential for intervention and treatment. The study will focus on African Americans, a group that has traditionally been understudied in psychiatric genetics and neuroscience

1R01DA035058-S1 (PI: Potenza, Carroll) 08/01/13 - 07/31/17  
NIDA \$110,614

Neural Mechanisms of CBT in Cocaine Dependence

Dr. Pearson is an investigator on this supplement to generate a neuroinformatic database of fMRI reward data from multiple collaborating sites.

1R01MH096957-01 (PI: Pearson) 06/1/13 - 5/31/17  
NIMH \$782,021

3/4-Psychosis and Affective Research Domains and Intermediate Phenotypes (PARDIP)

The Psychosis and Affective Research Domains and Intermediate Phenotypes (PARDIP) project takes a systematic approach of reducing heterogeneity in bipolar disorder by first examining psychosis and affective dimensions separately, defining the underlying, heritable physiological deficits that mark risk for each of the pathological domains (i.e., endophenotypes), and collecting blood samples for future genetic/biomarker studies.

1R01MH095888-01A1 (PI: Assaf) 07/1/12 - 06/30/2017  
NIMH \$425,170

Title: The Social Brain in Schizophrenia and Autism Spectrum Disorders

The goals of this study are (1) to characterize the commonalities and differences related to social-processes between autism spectrum disorders (ASDs) and schizophrenia (SZ) patients, by directly comparing their social functions and fMRI and ERP brain activity during several social cognitive process tasks; and (2) to use the neurophysiological features of social cognition as a dimensional classifier of patients into more natural and meaningful sub-groups.

HHC Research Institute (Pearlson) 07/01/2012 - 06/30/15  
HH Interdisciplinary Center on Obesity Research \$870,000

This project is collaboration between the Olin Center and the HH Surgical Weight Loss Center (SWLC) to examine the ability of pre-surgical neuroimaging & neuroendocrine testing to predict 12-month post-surgical outcome in patients undergoing surgical weight-loss procedures, (comprising laparoscopic gastric banding, sleeve gastrectomy and Roux-en-Y gastric bypass). The project assesses metabolic aspects of obesity and satiety, physiology of feeding behavior, impulsivity, and addiction measures and regulation of craving. Neuroimaging is re-assessed 12 months following surgery.

2P50 AA012870-15 (Krystal) 6/1/2016 – 5/30/2020  
NIAAA (Krystal, Center PI) Role: Pearlson Project PI \$180,000

Center for the Translational Neuroscience of Alcoholism

Project 2: Functional neuroimaging of alcoholism vulnerability; effects of Saracatinib

The major goals of the project are to examine effects of selective NMDA receptor blockade accomplished by Saracatinib, a FYN kinase inhibitor on fMRI activation patterns in reward and impulsivity tasks that may be vulnerability markers for familial alcoholism risk. The overall PO1 examines neurotransmitter, genetic, imaging and electrophysiologic alcoholism vulnerability markers

2P50 AA012870-11 (Krystal) 6/1/2011 – 5/30/2016  
NIAAA (Krystal, Center PI) Role: Project PI \$180,812

Center for the Translational Neuroscience of Alcoholism

Project 3: Functional neuroimaging of alcoholism vulnerability; glutamate, reward, impulsivity and

Pavlovian-Instrumental Transfer (PIT)

The major goals of the project are to examine effects of NMDA receptor blockade on fMRI activation patterns in reward and impulsivity tasks that may be vulnerability markers for alcoholism risk. The overall PO1 examines neurotransmitter, genetic, imaging and electrophysiologic alcoholism vulnerability markers

1R01MH096957-02S1 (PI:Pearlson) 8/26/24 - 6/30/2016

NIMH \$222,911

RDoC-db data submissions and data dictionaries for BSNIP-1 and PARDIP

The goals of this study is to prepare data for sharing in the RDoC Database by defining data structures, cleaning, and formatting the data, and uploading to the RDoC-db

C0RR028654-01 (Project Liason- Pearlson) 01/29/10 - 01/28/13 NCRR \$2,700,000

Olin Research Center: Addition for New MRI Scanner and Research Staff

Construct and /or renovate the following facilities on the Institute of Living Campus at Hartford Hospital:

1. To construct a new 1500 – 2000 square foot building addition (Magnet Addition) to house a new 3T Siemens Skyra wide-bore, fast MRI scanner at the North end of the existing White Hall Building
2. To construct a new 6700 square foot, two story research facility (Research Staff Addition) at the location of the existing Huntington Building, to accommodate scanner-related research staff and testing, exam and sample processing rooms for subjects who participate in MRI research.

R01AA016599 (Pearlson) 09/30/08 – 08/31/14

NIAAA

Alcohol Use in College Students: Cognition and fMRI (BARCS study)

US college students are at high risk for problem drinking. This project will recruit and test cognitively 2000 first-year students from local colleges in Connecticut, fMRI scan a representative sub-sample and assess alcohol and drug use by web-based reporting over 2 years, when all students will be retested/rescanned. Findings from this study will provide important insights on risk factors for problem drinking and how alcohol use impacts the developing adolescent brain.

R01 MH077945 (Pearlson) 9/29/07 - 5/31/13

NIMH

Bipolar & Schizophrenia Consortium for Parsing Endophenotypes (BSNIP-1 study)

The major goals of this multi-site collaboration will enroll 3000 patients with schizophrenia, psychotic bipolar illness and their unaffected siblings, to assess multiple imaging physiologic and cognitive endophenotypes and examine specificity.

01EB005846 (Calhoun) 8/1/05 - 5/30/13

NIH/NIBIB

Informed Data-Driven Fusion of Behavior, Brain Function, and Genes

To develop data fusion approaches for fMRI, EEG, behavior and whole genome SNP array & CNV data.

R01MH080956-01 (Stevens) 04/01/08 - 03/31/13

NIMH

Characterizing Two Distinct ADHD Neurobiologies with fMRI

This study uses functional imaging, genetic analysis, and neuropsychological assessment to examine whether there are two separate profiles of neurobiological impairment underlying impulsive behavior in ADHD.

5 R37 MH43775 (Pearlson) 08/01/09 - 05/31/14

NIMH

Quantitative Neuroimaging in Psychosis MERIT Award

The major goals of this project are to investigate circuit-wide abnormalities in schizophrenia using functional and structural brain MRI in schizophrenia and healthy controls.

(Pearlson) 06/01/12 - 05/31/14

Competitive Supplement to above grant.



R01 MH081969 (Stevens)

07/01/08 - 06/30/13

NIMH

Adolescent Maturation of Brain Network Integration for Executive Control Abilities

A study using fMRI analyses of neural network connectivity and neuropsychological assessment to examine the neural substrates of three domains of 'executive' cognitive abilities and to track their development across early adolescent to early adult maturation in healthy persons.

R01 MH082022 (Woods)

09/01/08 – 08/31/13

NIMH

8/8 Predictors and Mechanisms of Conversion to Psychosis

The major goals of this project are to identify predictors and mechanisms of conversion to psychosis in a new sample of adolescents.

R03 DA027893 (Anderson)

3/1/11 – 2/29/13

NIDA

Simulated Driving Under the Influence of Marijuana: an fMRI Study

The major goals of this project uses a psycho-pharmacologic repeated measures fMRI design to identify brain circuits used in driving that re most affected by marijuana in a dose-dependent manner and are related to intoxicated driving. Role: Investigator

R01HL098085 (Parker)

3/1/10 – 2/28/14

NHLBI

The Effect of High-Dose Atorvastatin on Neuronal Activity and cognition in Humans

The major goal of this study is to investigate the effects of atorvastatin therapy on neuronal activation and cognition in healthy adults. Role: Investigator

R01DA027615-03S1 (Petry/Pearlson)

09/01/11-08/31/13

NIH/NIDA

Reinforcing Exercise in Cocaine Abusers (Exercise and Cognition Supplement)

The purpose of this study is to examine the association between exercise and cognitive functioning.

Role: Investigator

**PARTICIPATION: NATIONAL/INTERNATIONAL CONSORTIA** BSNIP, ENIGMA

## PEER-REVIEWED BIBLIOGRAPHY (last updated April 2023)

**Mendeley h index= 151. i10=609, Most cited paper: Calhoun et al HBM 2001 >2950 citations**

1. Slavney PR, Rich G, **Pearlson GD**, and Mchugh PR. Phencyclidine abuse and symptomatic mania. Biological Psychiatry, 12: 697-700, 1977
2. Wilkinson PW, Parkin JM, Strong M, **Pearlson GD**, Sykes P. Energy intake and physical activity in obese children. British Medical Journal, 756-758, March 19, 1977.
3. Wilkinson PW, Parkin JM, **Pearlson GD**, Philips PR, Sykes P. Obesity in childhood: A community study in Newcastle upon Tyne. Lancet, Feb 12, 8007: 350-352, 1977.
4. Tune LE, Creese I, Coyle JT, **Pearlson GD**, Snyder SH. Low neuroleptic serum levels in patients receiving fluphenazine decanoate. American Journal of Psychiatry, 137: 80-82, 1980.
5. **Pearlson GD**, Flournoy LH, Simonson M, Slavney PR. Body image in obese adults. Psychological Medicine, 11: 147-154, 1981.
6. **Pearlson GD**, Veroff AE. Computerized tomographic scan changes in manic-depressive illness. Lancet, 8244, II: 470 1981.
7. **Pearlson GD**. Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Medical Journal, 148: 25-33, 1981.
8. **Pearlson GD** and Robinson RG. Suction lesions of the frontal cerebral cortex in the rat induce asymmetrical behavioral and catecholaminergic responses. Brain Research, 218: 233-242, 1981.
9. **Pearlson GD**, Veroff AE, McHugh PR. The use of computed tomography in psychiatry: Recent applications to schizophrenia, manic-depressive illness and dementia syndromes. Johns Hopkins Medical Journal, 149: 194-202, 1981.
10. Veroff AE, **Pearlson GD**, Ahn HS. CT scan and neuropsychological correlates of Alzheimer's disease and Huntington's disease. Brain and Cognition, 1: 177-184, 1982.
11. Kubos KL, **Pearlson GD**, Robinson RG. Intracortical kainic acid induces an asymmetrical behavioral response in the rat. Brain Research, 239: 303-309, 1982.
12. **Pearlson GD**, Veroff AE, Wise TN. The use of CT scanning in psychiatry. Psychosomatics, 23: 993-1004, 1982.
13. **Pearlson GD**, Garbacz DJ, Tompkins RH. Imaging of the brain: Aiding the search for physical correlates of mental illness. Integrative Psychiatry, 1: 134-138, 1983.
14. Lipsey JR, Robinson RG, **Pearlson GD**, Rao K, and Price TR. Mood change following bilateral hemisphere brain injury. British Journal Psychiatry, 293: 241-250, 1983.
15. **Pearlson GD**, Garbacz DJ, Tompkins RH, Ahn HS, Gutterman DF, DePaulo JR. Lateral ventricular enlargement in affective disorder: Clinical correlates. American Journal of Psychiatry, 141: 253-256, 1984.
16. **Pearlson GD**, Garbacz DJ, Breakey WR, Ahn HS, DePaulo JR. Relationship of lateral ventricular enlargement on CT scan to chronic unemployment in schizophrenia and affective disorder. Psychiatry Research, 12:1-9, 1984.
17. Lipsey JR, Robinson RG, **Pearlson GD**, Rao K, and Price TR. Nortriptyline treatment of post stroke depression: A double blind treatment trial. Lancet, I: 297-300, 1984.

18. Brady JY, Griffiths RR, Hienz RD, Bigelow GE, Emurian HH, Lukas SE, Ator NA, Nellis MJ, Ray RI, **Pearlson GD**. Abuse liability and behavioral toxicity assessment: Progress report from the behavioral biology laboratories of the Johns Hopkins University School of Medicine. NIDA Res Monogr. 1984 Mar;49:92-108.
19. **Pearlson GD**, McHugh PR. Significance of enlarged lateral ventricles, (ltr. to ed.) Psychosomatics, 25: 707, 1984.
20. Robinson RG, Lipsey JR, **Pearlson GD**. The occurrence and treatment of post-stroke mood disorders. Comprehensive Therapy, 10:19-24, 1984.
21. **Pearlson GD**, Kubos KL, Robinson RG. Effects of anterior-posterior lesion location on the asymmetrical behavioral and biochemical response to cortical suction ablations in the rat. Brain Research, 293: 241-250, 1984.
22. **Pearlson GD**, Garbacz DJ, Moberg P, Ahn HS, DePaulo JR. Symptomatic, familial, perinatal and social correlates of CT changes in schizophrenics and bipolars. Journal Nervous and Mental Disorders, 173: 42-50, 1985.
23. Lipsey JR, Robinson RG, **Pearlson GD**, Rao K, Price TR. The dexamethasone suppression test and mood following stroke. American Journal of Psychiatry, 142: 318-323, 1985.
24. Wong DF, Wagner HN, Jr., **Pearlson GD**, Dannals RF, Tune LE. Dopamine receptor binding of C-11 N Methylspiperone in the caudate in schizophrenia and bipolar illness: A preliminary report. Psychopharmacology Bulletin, 21: 595-598, 1985.
25. Robinson RG, Lipsey JR, Bolla-Wilson K, Bolduc PL, **Pearlson GD**, Rao K, Price TR. Mood disorders in left-handed stroke patients. American Journal of Psychiatry, 142: 1424-1429, 1985.
26. Wong DF, Wagner HN, Jr., Tune LE, Dannals RF, **Pearlson GD**. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science, 239:1473-1624, 1986.
27. **Pearlson GD** and Tune LE. Cerebral ventricular size and cerebrospinal fluid acetylcholinesterase levels in senile dementia of the Alzheimer Type. Psychiatry Research, 17: 23-29, 1986.
28. Rabins PV, Brooks BR, O'Donnell P, **Pearlson GD**, Moberg PJ, Jubelt B, Coyle P, Dalos N, Folstein MF. Structural brain correlates of emotional and cognitive disorder in multiple sclerosis. Brain, 109: 585-597, 1986.
29. Moran TH, Zern KA, **Pearlson GD**, Kubos KL, Robinson RG. Cold water stress abolishes hyperactivity produced by cortical suction lesions without altering NE depletions. Behavioral Neuroscience, 100: 422-426, 1986.
30. Moberg PJ, **Pearlson GD**, Folstein SE, Speedie LJ, Lipsey JR. Olfactory recognition: Differential impairments in early and late Huntington's and Alzheimer's diseases. Journal of Clinical & Experimental Neuropsychology, 9: 650-664, 1987.
31. Rabins PV, **Pearlson GD**, Jayaram G, Steele CS, Tune LE. Elevated VBR in late-onset schizophrenia. American Journal of Psychiatry, 144: 1216-1218, 1987.
32. Starkstein SE, **Pearlson GD**, Boston J, Robinson RG. Mania after brain injury: A controlled study of etiological factors. Archives of Neurology. 44: 1069-1073, 1987.
33. Foltin RW, Fischman MW, Pedroso JJ, **Pearlson GD**. Marijuana and cocaine interactions in humans: Cardiovascular consequences. Pharmacology and Biochemical Behavior, 28:459-464, 1987.
34. Foltin RW, Fischman MW, Pedroso JJ, **Pearlson GD**. Repeated intranasal cocaine administration: Lack of tolerance to pressor effects. Drug & Alcohol Dependence, 22: 169-177, 1988.

35. Wong DF, Wagner HN Jr, Links JM, Dannals RF, Folstein S, Ravert HT, Tune L, **Pearlson GDD**, Frost JJ, Folstein M, et al. Positron emission tomography imaging of dopamine and serotonin receptors in Huntington's chorea. Am J Physiol Imaging. 1988;3(1):51
36. Jeste DV, Harris MJ, **Pearlson GD**, Rabins PV, Lesser I, Miller B, Coles C, Yassa R: Late Onset Schizophrenia - Studying Clinical Validity. Psychiatric Clin. N. America, Psychosis and Depression in the Elderly, 11: 1-13, 1988.
37. Starkstein SE, Brandt J, Folstein SE, Strauss ME, Berthier ML, **Pearlson GD**, Wong DF, McDonnell A, Folstein MF. Neuropsychological and neuroradiological correlates in Huntington's disease. Journal Neurology, Neurosurgery and Psychiatry, 51: 1259-1263, 1988.
38. LaFrance ND, **Pearlson GD**, Schaerf FW, McArthur JC, Polk BF, Links JM, Bascom MJ, Knowles MC, Galen SS. Iodine-123 single photon emission computed tomography in HIV-related dementia. Advances in Functional Neuro-Imaging, 1: 9-15, 1988.
39. **Pearlson GD**, Rabins PV. The Late onset psychoses - possible risk factors. Psychiatric Clin. N. America, Psychosis and Depression in the Elderly, 11: 15-33, 1988.
40. Wong DF, Gjedde J, Wagner HN, Dannals RF, Links JM, Tune LE, **Pearlson GD**. Elevated D2 dopamine receptors in drug naive schizophrenics. (Ltr. to Ed.) Science, 241: 790-791, 1988.
41. **Pearlson GD**, Warren A. (ltr. to ed.) Brain atrophy in aging Down's syndrome patients. Neurology, 39: 1407-1408,1989.
42. **Pearlson GD**, Fischman MW, Foltin RW, Cornell E and Pedroso JJ. Cocaine-induced delirium versus delusional disorder. Biological Psychiatry, 26:847-858, 1989.
43. **Pearlson GD**, Warren AC. Aging and brain weight in Down's syndrome. Neurology. 1989 Oct;39(10):1407-8
44. **Pearlson GD**, Rabins PV, Kim WS, Speedie LJ, Moberg PJ, Burns A, and Bascom MJ. Structural brain CT changes and cognitive deficits in elderly depressives with and without reversible dementia. Psychological Medicine, 19: 573-584, 1989.
45. **Pearlson GD**, Kreger L, Rabins PV, Chase GA, Cohen B, Wirth JB, Schlaepfer TB, Tune LE. Late life onset schizophrenia: A chart review study. American Journal of Psychiatry, 146: 1568-1574, 1989.
46. Starkstein SE, Folstein SE, Brandt J, **Pearlson GD**, McDonnell A, Folstein MF. Brain atrophy in Huntington's disease. NeuroRadiology, 31: 156-159, 1989.
47. **Pearlson GD**, Kim WS, Kubos KL, Jayaram G, Heyler G, Chase, GA, Goldfinger AD, Tune LE. VBR, CT density and brain area in 50 schizophrenics. Archives of General Psychiatry, 46: 690-697, 1989.
48. **Pearlson GD**, Warren A, Starkstein SE, Aylward EH, Kumar AJ, Chase GA, Folstein MF. Brain atrophy in 18 patients with Down's syndrome. American Journal of Neuro-Radiology, 11: 811-816, 1990.
49. Foltin RW, Fischman MW, Nestadt G, Stromberger H, Cornell EE, **Pearlson GD**. Demonstration of naturalistic methods for cocaine smoking by human volunteers. Drug Alcohol Depend. 1990 Oct;26(2):145-54
50. Barta PE, **Pearlson GD**, Powers RE, Richards SS, Tune LE. Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. American Journal of Psychiatry. 1990 Nov;147(11):1457-62

51. Piven J, Berthier ML, Starkstein SE, Nehme E, **Pearlson GD**, Folstein SE. Magnetic resonance imaging evidence for a defect in cerebral cortical development in autism. American Journal of Psychiatry, 147: 734-739, 1990.
52. Fischman MW, Foltin RW, Nestadt G and **Pearlson GD**. Effects of desipramine maintenance on cocaine self-administration in humans. Journal of Pharmacology and Experimental Therapeutics, 253: 760-770, 1990.
53. Speedie L, Rabins PV, **Pearlson GD**, Moberg P. Confrontation naming deficit in dementia of depression. J. Neuropsychiatry & Clinical Neurosciences, 2: 59-63, 1990.
54. **Pearlson GD**, Rabins PV (ltr. to ed.) Late-life onset schizophrenia. American Journal of Psychiatry, 147: 1383, 1990.
55. **Pearlson GD**, Ross CA, Lohr WD, Rovner BW, Tune LE, Folstein MF. Family history of affective disorder is associated with the depressive syndrome of Alzheimer's disease American Journal of Psychiatry, 147: 452-456, 1990.
56. **Pearlson GD**, Ross CA. (ltr. to ed.) Family history of depression and alcoholism in Alzheimer patients and age-matched controls. International Journal of Geriatric Psychiatry 5: 344-345, 1990.
57. Harris GJ, Rhew EH, Noga JT, **Pearlson GD**. A user-friendly method for rapid brain and CSF volume calculation using transaxial MRI images. Psychiatry Research Brain Imaging, 40: 61-68, 1991.
58. Aylward EH, Schwartz J, Machlin SR and **Pearlson GD**. Bicaudate ratio as a measure of caudate volume in MRI. American Journal of Neuroradiology, 12: 1217-1222, 1991.
59. Harris GJ, Links JM, **Pearlson GD**, Camargo EE. Cortical circumferential profiles: An objective approach to the analysis of the distribution of radioactivity in cerebral emission computed tomography. Application to a study of Alzheimer's disease. Psychiatry Research NeuroImaging, 40: 167-180, 1991.
60. Hoehn-Saric R, Harris GJ, **Pearlson GD**, Cox CS, Machlin SR, and Camargo EE. A fluoxetine induced frontal lobe syndrome in an obsessive-compulsive patient. J Clinical Psychiatry, 52: 131-133, 1991.
61. Harris GJ, Rhew EH, Noga T, **Pearlson GD**. User-friendly method for rapid brain and CSF volume calculation using transaxial MRI images. Psychiatry Res. 1991 May;40(1):61-8
62. Machlin S, Harris GJ, **Pearlson GD**, et al. Elevated frontal cerebral blood flow in obsessive-compulsive patients: A SPECT study. American Journal of Psychiatry, 148: 1240-1242, 1991.
63. Hoehn-Saric R, **Pearlson GD**, Harris GJ, et al. Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive disorder. American Journal of Psychiatry, 148: 1243-1245, 1991.
64. **Pearlson GD**, Barta PE, Schraml FV, Chase GA, Tune LE. (ltr. to ed.) Brain size in schizophrenia. Archives of General Psychiatry, 48: 179-180, 1991.
65. Aylward EH, Schwartz J, Machlin S, **Pearlson GD**. Bicaudate ratio as a measure of caudate volume on MR images. AJNR Am J Neuroradiol. 1991 Nov-Dec;12(6):1217-22
66. **Pearlson GD**. PET scans in schizophrenia: What have we learned? Annals of Clinical Psychiatry, 3: 97-101, 1991.
67. Strauss ME, Novakovic T, Tien AY, Bylsma F, **Pearlson GD**. Disengagement of attention in schizophrenia. Psychiatry Research, 37: 139-146, 1991.
68. Aylward EA, Karagiozis H, **Pearlson GD**, and Folstein MF. Suprasellar cistern measures as a reflection of dementia in Alzheimer's disease but not Huntington's disease. Journal of Psychiatric Research, 25: 31-47, 1991.

69. Tune LE, Brandt J, Frost JJ, Harris G, Mayberg H, Steele C, Burns A, Sapp J, Folstein MF, Wagner HN, **Pearlson GD**. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatr Scand, Supplement 366: 61-65, 1991.
70. Cascella N, **Pearlson GD**, Wong DF, Brousolle E, Nagoshi C, Margolin RA, London ED. Effects of substance abuse on ventricular and sulcal measures assessed by computed tomography. British Journal of Psychiatry, 159: 217-221, 1991.
71. **Pearlson GD**, Rabins PV, Burns A. CT changes in centrum semiovale white matter in dementia of depression. Psychological Medicine, 21: 321-328, 1991.
72. Rabins PV, **Pearlson GD**, Aylward EH, Kumar AJ, Dowell K. Cortical MRI changes in elderly inpatients with major depression. American Journal of Psychiatry, 148: 617-620, 1991.
73. Piven J, Nehme E, Simon J, Barta P, **Pearlson GD**, Folstein SE. Magnetic resonance imaging in autism: Measurement of the cerebellum, pons and fourth ventricle. Biological Psychiatry, 31: 491-504, 1992.
74. Rabins PV, **Pearlson GD**, Aylward EH. Magnetic resonance imaging in the diagnosis of dementia (ltr. to ed.). American Journal of Psychiatry, 149: 419, 1992.
75. **Pearlson GD**, Harris GJ, Powers RE, Barta PE, Camargo EE, Chase GA, Noga JT, Tune LE. Quantitative changes in mesial temporal volume, regional cerebral bloodflow and cognition in Alzheimer's disease. Archives of General Psychiatry, 49: 402-408, 1992.
76. Harris GJ, **Pearlson GD**, Peyser C, Aylward E, Folstein SE. Putamen volume measured on MRI completely discriminates early Huntington's disease patients from controls. Annals of Neurology, 31: 69-75, 1992.
77. Tien AY, **Pearlson GD**, Machlin SR, Bylsma RW, Hoehn-Saric R. Oculomotor performance in obsessive compulsive disorder. American Journal of Psychiatry, 149: 641-646, 1992.
78. Schwartz J, Aylward E, Barta PE, Tune LE, **Pearlson GD**. Increased sylvian fissure size in schizophrenia using the CERAD MRI rating protocol. American J Psychiatry, 149: 1195-1198, 1992.
79. Woodruff P, **Pearlson GD**, Barta PE, Chilcoat H. Corpus callosum MRI measures in schizophrenia. Psychological Medicine, 23: 45-56, 1993.
80. Aylward EH, **Pearlson GD**, Rabins PV. Differences in early and late onset schizophrenia (letter to ed.). American Journal of Psychiatry, 150: 846-847, 1993.
81. Gur R and **Pearlson GD**. Neuroimaging in schizophrenia. Schizophrenia Bulletin, Special Issue, Schizophrenia, 19: 337-354, 1993.
82. Tune LE, Wong DF, **Pearlson GD**, Strauss ME, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J, Cooper T, Chase GA, Wagner HN Jr. Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with 11C-N-Methylspiperone. Psychiatry Research, 49: 219-237, 1993.
83. Harris GJ, **Pearlson GD**, Hoehn-Saric R. Caudate nucleus in obsessive-compulsive disorder patients appears structurally and functionally normal using MRI and SPECT (Letter to ed.). Archives of General Psychiatry, 50: 498-499, 1993.
84. **Pearlson GD**, Jeffery P, Harris GJ, Ross CA, Fischman M, Camargo EE. Local cocaine-induced cerebral bloodflow changes: Correlation with subjective effects. American Journal of Psychiatry, 150: 495-497, 1993.

85. **Pearlson GD**, Tune LE, Wong DF, Aylward EH, Barta PE, Powers RE, Chase GA, Harris GJ, Rabins PV. Quantitative D2 dopamine receptor PET and structural MRI changes in late onset schizophrenia. Schizophrenia Bulletin, 19: 783-795, 1993.
86. Harris GJ, **Pearlson GD**. MRI-guided region of interest placement on emission computed tomograms. Psychiatry Research Neuroimaging, 50: 57-63, 1993.
87. Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE, and **Pearlson GD**. Reduced basal ganglia volume in HIV-1 associated dementia complex: results from quantitative neuroimaging. Neurology, 43: 2099-3104, 1993.
88. Harris GJ, **Pearlson GD**, McArthur JC, Zeger S, LaFrance ND. Altered cortical blood flow in HIV seropositive individuals with and without dementia: A SPECT study. AIDS, 8: 495-499, 1994.
89. Harris GJ, Hoehn-Saric RH, Lewis R, **Pearlson GD**, Streeter G. Mapping of SPECT regional cerebral perfusion abnormalities in obsessive-compulsive disorder. Human Brain Mapping, 237-248, 1994.
90. Harris GJ, Barta PE, Peng L, Lee S, Brettschneider PD, Shah A, Henderer JD, **Pearlson GD**. MRI gray and white matter volume segmentation using manual thresholding: dependence on image brightness. American Journal Neuroradiology, 15: 225-230, 1994.
91. Aylward EH, Roberts-Twillie JV, Barta PE, Kumar AJ, Harris GJ, Geer M, Peyser CE, **Pearlson GD**. Basal ganglia volumes and white matter hyperintensities in bipolar disorder. American Journal of Psychiatry, 151: 687-693, 1994.
92. Habbak R, Warren A, Aylward E, Jerram M, **Pearlson GD**. Synkinesias are common in Down syndrome. Journal of Nervous and Mental Disease, 182: 667, 1994.
93. Harris GH, Schlaepfer TE, Peng LW, Lee S, Federman EB, **Pearlson GD**. Magnetic resonance imaging evaluation of the effects of aging on grey-white ratio in the human brain. Neuropathology and Applied Neurobiology, 20: 290-293, 1994.
94. Schlaepfer TE, Harris GJ, Tien AY, Federman EB, Peng LW, Lee S, and **Pearlson GD**. Pattern of decreased regional cortical gray matter volume using magnetic resonance imaging in schizophrenia. American Journal of Psychiatry, 151: 842-848, 1994.
95. Aylward E, Reiss A, Barta P, Tien A, Han W, Lee J, **Pearlson GD**. MRI Measurement of posterior fossa structures in schizophrenia. American Journal of Psychiatry, 151: 1448-1452, 1994.
96. Petty RG, Barta PE, **Pearlson GD**, McGilchrist IK, Lewis RW, Tien AY, Pulver A, Vaughn DD, Casanova MF, Powers RE. Reversal of asymmetry of the planum temporale in schizophrenia. American Journal of Psychiatry, 152: 715-721, 1995.
97. Menon RR, Barta PE, Aylward EH, Richards SS, Vaughn DD, Tien AY, **Pearlson GD**. Posterior superior temporal gyrus in schizophrenia: grey matter changes and clinical correlates. Schizophrenia Research, 16: 127-135, 1995.
98. Noga JT, Aylward EH, Barta PE, **Pearlson GD**. Cingulate gyrus in schizophrenia and controls. Psychiatry Research Neuroimaging, 61: 201-208, 1995.
99. Schlaepfer TE, Harris GJ, Aylward EH, McArthur HC, Peng LW, Lee S, **Pearlson GD**. Structure differences in the cerebral cortex of normal male and female subjects. Psychiatry Research - Neuroimaging, 61: 129-135, 1995.
100. Barta PE, Petty RG, McGilchrist I, Lewis RW, Jerram M, Casanova MF, Powers RE, Brill, III LB, **Pearlson GD**. Asymmetry of the planum temporale: Methodologic considerations. Psychiatry Research Neuroimaging, 61: 137-150, 1995.

101. **Pearlson GD**, Wong DF, Tune LE, Ross CA, Chase GA, Links JM, Dannals RF, Wilson AA, Ravert HT, Wagner HN, Jr, DePaulo JR. C-11 NMSP PET scans in psychotic and non-psychotic bipolars. Archives of General Psychiatry, 52: 471-477, 1995.
102. Schlaepfer TE, **Pearlson GD**. Pitfalls of SPECT studies of acute ethanol-induced changes in cerebral blood flow. (Ltr. to the Editor) American Journal of Psychiatry, 152: 111, 1995.
103. Aylward E, Brettschneider PD, McArthur JC, Harris GJ, Schlaepfer TE, Henderer JD, Barta PE, Tien AY, **Pearlson GD**. MRI gray matter volumes reductions in HIV-1 dementia. American Journal of Psychiatry, 152: 987-994, 1995.
104. Davison SE, Aylward EH, McArthur JC, Selnes O, Lyketsos C, Barta PE, **Pearlson GD**. A quantitative MRI study of the basal ganglia in depression with HIV infection. Journal of Neuro-AIDS, 1: 29-41, 1996.
105. Schlaepfer TE, Strain EC, Bigelow GE, Lancaster E, Preston KL, **Pearlson GD**. Differential cerebral blood flow effects caused by mu versus kappa opioid agonists. NIDA Res Monogr, 162: 194, 1996.
106. Holder JL, Habbak RA, **Pearlson GD**, Aylward EA, Pulsifer M, Warren AC. Reduced survival of apolipoprotein E4 homozygotes in Down's syndrome? NeuroReport, 7: 2455-2456, 1996.
107. Aylward EH, Harris GH, Hoehn-Saric R, Barta PE, Machlin S, **Pearlson GD**. Normal caudate nucleus in obsessive compulsive disorder assessed by quantitative neuro-imaging. Archives of General Psychiatry, 53: 577-584, 1996.
108. Aylward EH, Rasmusson DX, Brandt J, Raimundo L, Folstein M, **Pearlson GD**. CT measurement of suprasellar cistern predicts rate of cognitive decline in Alzheimer's disease. Journal of the International Neuropsychological Society, 2: 89-95, 1996.
109. Hooten WM, **Pearlson GD**. Delirium caused by tacrine and ibuprofen interaction. (Letter to the Editor), American Journal of Psychiatry, 153: 6, 1996.
110. Lyketsos CG, Tune LE, **Pearlson GD**, Steele C. Major depression in Alzheimer's disease. An interaction between gender and family history. Psychosomatics, 37: 380-384, 1996.
111. **Pearlson GD**, Petty RG, Ross CA and Tien AY. Schizophrenia: A disease of heteromodal association cortex? Neuropsychopharmacology, 14: 1-17, 1996.
112. Ross CA, **Pearlson GD**. Schizophrenia, the heteromodal association neocortex and development: Potential for a neurogenetic approach. Trends In Neurosciences 19: 171-176, 1996.
113. Tien AY, Eaton WE, Schlaepfer TE, McGilchrist I, Menon RR, Powers RE, Aylward EH, Barta PE, Strauss ME, **Pearlson GD**. Exploratory factor analysis of MRI brain structure measures in schizophrenia. Schizophrenia Research, 19: 93-101, 1996.
114. Tune LT, Barta P, Wong D, Powers PE, **Pearlson GD**, Tien A, Wagner HN. Striatal D2 receptor quantification and superior temporal gyrus volume determination in 14 chronic schizophrenic subjects. Psychiatric Research - Neuroimaging, 67: 155-158, 1996.
115. Tien, AY, Ross D, **Pearlson GD**, Strauss ME. Eye movements and psychopathology in schizophrenia and bipolar disorder. Journal of Nervous and Mental Disease, 184: 331-338, 1996.
116. Harris GJ, Aylward EH, Peyser CE, **Pearlson GD**, Brandt J, Roberts-Twillie JV, Folstein SE. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Archives of Neurology, 53: 316-324, 1996.
117. Aylward E, Codori AM, Barta PE, **Pearlson GD**, Harris G, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington's disease. Archives of Neurology, 53: 1293-1296, 1996.



118. Tien AY, Spevack TV, Jones DW, **Pearlson GD**, Schlaepfer TE, Strauss ME. Computerized Wisconsin Card Sorting Test: Comparison With Manual Administration. Kaohsiung Journal of Medical Sciences, 12: 479-485, 1996.
119. Ross CA, **Pearlson GD**. (Letter to Editor) Glutamate receptors and schizophrenia. Trends In Neurosciences, 19: 416-417, 1996.
120. **Pearlson GD**, Barta PE, Powers RE, Menon RR, Richards SS, Aylward EH, Federman EB, Chase GA, Petty RG, Tien AY. Medial and superior temporal gyral volumes and cerebral asymmetry in schizophrenia versus bipolar disorder. Biological Psychiatry, 41: 1-14, 1997. **Winner, 1996 Ziskind-Somerfeldt Research Award.**
121. **Pearlson GD**, Schlaepfer TE. (Ltr. to the Ed.) Cortex and sex differences in schizophrenia. Archives of General Psychiatry, 54: 189, 1997.
122. Barta PE, **Pearlson GD**, Brill LB, Royall R, McGilchrist IK, Pulver AE, Powers RE, Casanova MF, Tien AY, Frangou S, and Petty RG. Planum temporale asymmetry reversal in schizophrenia: replication and relationship to gray matter abnormalities. Am J Psychiatry, 154: 661-666, 1997.
123. Frangou S, Sharma T, Sigmudsson T, Barta P, **Pearlson GD**, Murray RM. The Maudsley Family Study 4. Normal planum temporale asymmetry in familial schizophrenia. British Journal of Psychiatry, 170: 328-333, 1997.
124. **Pearlson GD**. Superior temporal gyrus and planum temporale in schizophrenia. Prog. Neuro-Psycho pharmacology and Biol. Psychiatry, 21: 1203-1229, 1997.
125. **Pearlson GD**. Schizophrenia. Editorial, International J. Psychiatry, 9: 317-319, 1997.
126. Aylward E, Habbak R, Warren A, Pulsifer MB, Barta PE, Jerram M, **Pearlson GD**. Cerebellar volume in adults with Down Syndrome. Archives of Neurology, 54: 209-212, 1997.
127. Frangou S, Aylward EH, Warren AC, Sharma T, Barta PE, **Pearlson GD**. Planum temporale in Down's syndrome. American Journal of Psychiatry, 154: 1424-1429, 1997.
128. Aylward E, Li Q, Habbak R, Warren A, Pulsifer MB, Barta PE, Jerram M, **Pearlson GD**. Basal ganglia volume in adults with Down Syndrome. Psychiatry Research - Neuroimaging, 74: 73-82, 1997.
129. Aylward EH, Augustine AM, Li Q, Barta PE, **Pearlson GD**. Measurement of frontal lobe volume on MRI scans. Psychiatry Research Neuroimaging, 75: 23-30, 1997.
130. Barta PE, **Pearlson GD**, Powers RE, Aylward EH, Chase GA, Harris GJ, Rabins PV, Raimundo LD, Tune LE. Quantitative MRI volume changes in late-onset schizophrenia and Alzheimer's disease compared to normal controls. Psychiatry Research - Neuroimaging, 68: 65-75, 1997.
131. Wong WF, **Pearlson GD**, Tune LE, Young LT, Meltzer CC, Dannals RF, Ravert HY, Reith J, Kuhar MJ, Gjedde A. Quantification of neuroreceptors in the living human brain. IV. Effect of aging in elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab, 17: 331-342, 1997.
132. Schlaepfer TE, **Pearlson GD**, Wong DF, Marenco S, Dannals RF. Intravenous cocaine competes with [11C]-raclopride at dopamine receptors in human subjects: A PET study. American Journal of Psychiatry 154: 1209-1213, 1997.
133. Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, Bylsma FW, **Pearlson GD**, Ross CA. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology, 48: 394-399, 1997.

134. Aylward EH, Anderson NB, Bylsma FW , Wagster MV, Barta PE, Sherr M , Feeney J, Davis A, Rosenblatt A, **Pearlson GD**, Ross CA. Frontal lobe volume in patients with Huntington's disease. Neurology, 50:252-258, 1998.
135. Rivkin P and **Pearlson GD**. An unusual presentation of Huntington's disease. Psychosomatics, 39:291-294, 1998.
136. Schlaepfer TE, Strain EC, Greenberg BD, Preston KL, Lancaster E, Bigelow GE, Barta PE, **Pearlson GD**. Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. American Journal of Psychiatry 155:470-473, 1998.
137. Honeycutt NA, Smith PD, Aylward E, Li Q, Chan M, Barta PE, **Pearlson GD**. Mesial temporal lobe measurements on magnetic resonance imaging scans. Psychiatry Research: Neuroimaging, 83: 85-94, 1998.
138. Tien AY, Schlaepfer TE, Orr W, **Pearlson GD**. 1998 SPECT brain blood flow changes with continuous ligand infusion during previously learned WCST performance. Psychiatry Research 82: 47-52.
139. **Pearlson GD**, Breiter SN, Aylward EH, Warren AC, Grygorcewicz M, Frangou S, Barta PE, Pulsifer M. MRI brain changes in Down syndrome patients with and without dementia. Developmental Medicine and Child Neurology, 40:326-334, 1998.
140. Buchanan RW, Vladar K, Barta PE, **Pearlson GD**. Structural evaluation of the prefrontal cortex in schizophrenia. Am J Psychiatry 155: 1049-1055, 1998.
141. Sharma T, Lancaster E, Lee D, Lewis S, Sigmundsson T, Takei N, Gurling H, Barta P, **Pearlson GD**, Murray R. Brain changes in schizophrenia: Volumetric MRI study of families multiply affected with schizophrenia - The Maudsley Family Study 5. British J Psychiatry, 173: 132-138, 1998.
142. Aylward EH, Li Q, Honeycutt NA, Warren AC, Pulsifer MB, Barta PE, Chan MD, Smith PD, Jerram M, **Pearlson GD**. MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. Am J Psychiatry, 156: 564-568, 1999.
143. Aylward EH, Minshew NJ, Goldstein G, Honeycutt NA, Augustine AM, Yates KO, Barta PE, **Pearlson GD**. MRI MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults. Neurology 53: 2145-2150, 1999.
144. **Pearlson GD**. Structural and functional brain imaging in bipolar disorder: a selective review. Schizophrenia Research, 39: 133-140, 1999.
145. Frederikse ME, Lu A, Aylward EA, Barta PE, **Pearlson, GD**: Sex differences in the inferior parietal lobule. Cerebral Cortex 9: 896-901, 1999.
146. Barta PE, **Pearlson GD**, Vladar K, Buchanan RW. Demonstration of a simple, accurate method for measuring the volumes of cortical gyri, illustrated by an application to the frontal lobes. Psychiatry Research Neuroimaging, in press.
147. **Pearlson GD**, Marsh L. Structural brain imaging changes in schizophrenia. A selective review. Biological Psychiatry, 46: 627-649, 1999
148. Sharma T, Lancaster E, Sigmundsson T, Lewis S, Takei N, Gurling H, Barta P, **Pearlson GD**, Murray R. Lack of normal pattern of cerebral asymmetry in familial schizophrenic patients and their relatives: The Maudsley Family Study. Schizophrenia Research, 40: 111-120, 1999.
149. **Pearlson GD**. New insights on the neuroanatomy of schizophrenia. Curr Psychiatry Rep. 1: 41-45, 1999.
150. Frederikse M, Lu A, Aylward EH, Barta PE, Sharma T, **Pearlson GD**. Sex differences in inferior parietal lobe volume in schizophrenia. American J. Psychiatry, 157: 422-427, 2000.

151. **Pearlson GD.** Neurobiology of Schizophrenia. Annals of Neurology, 48: 556-566, 2000.
152. Mori S, Kaufmann W, **Pearlson GD**, Crain BJ, Stieltjes B, Solaiyappan M, van Zijl PCM. In vivo visualization of human neural pathways by MRI. Annals of Neurology, 47: 412-4, 2000.
153. Calhoun V, Adali T, Kraut M, **Pearlson GD.** A weighted-least squares algorithm for estimation and visualization of relative latencies in event-related functional MRI. Magnetic Resonance in Medicine, 44: 947-954, 2000.
154. Rabins PV, Aylward E, Holroyd S, Chase GA, **Pearlson GD.** MRI findings differentiate between late-onset schizophrenia and late-life mood disorder. Journal of Nervous and Mental Disease, 15: 954-960, 2000.
155. Rivkin P, **Pearlson GD**, Barta PE, Anthony JC, Arria AM. Comparison of white matter hyperintensities in age-matched groups of controls and subjects with late-onset and early-onset schizophrenia. International Journal of Geriatric Psychiatry, 15: 1085-1089, 2000.
156. Honeycutt NA, Musick A, Barta PE, **Pearlson GD.** Measurement of the planum temporale on magnetic resonance imaging scans: Temporal PT alone and with parietal extension. Psychiatry Research: Neuroimaging, 98: 103-116, 2000.
157. Aylward, E.H, Codori, A.M., Rosenblatt, A., Sherr, M., Brandt, J., Stine, O.C., Barta, P.E., **Pearlson, G.D.**, Ross, C.A. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Movement Disorders, 15:552-560, 2000.
158. Schretlen D, **Pearlson GD**, Anthony JC, Aylward EH, Augustine AM, Davis A, Barta P. Elucidating the contributions of processing speed, executive ability, and frontal lobe volume to normal age-related differences in fluid intelligence. J Int Neuropsychol Soc., 6:52-61, 2000.
159. Schretlen DJ, **Pearlson GD**, Anthony JC, Yates KO. Determinants of Benton facial recognition test performance in normal adults. Neuropsychology, 15: 405-410, 2001.
160. Hoehn-Saric R, Schlaepfer TE, Greenberg BD, McLeod DR, **Pearlson GD**, Wong SH. Cerebral blood flow in obsessive-compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders. Psychiatry Research, 108: 89-100, 2001.
161. Calhoun VD Adali T, Kraut M, **Pearlson GD.** Spatial and temporal independent component analysis of functional MRI data containing a pair of task-related waveforms. Human Brain Mapping, 13: 43-53, 2001.
162. Calhoun VD, Adali T, **Pearlson GD**, and Pekar JJ. A method for making group inferences from functional MRI data using independent component analysis. Human Brain Mapping, 14: 140-451, 2001.
163. Calhoun VD, Adali T, McGinty VB, Pekar JJ, Watson TD, and **Pearlson GD.** fMRI activation in a visual-perception task: Network of areas detected using the general linear model and independent components analysis. Neuroimage, 14: 1080-1088, 2001.
164. Stieltjes B, Kaufmann WE, van Zijl PC, Fredericksen K, **Pearlson GD**, Solaiyappan M, Mori S. Diffusion tensor imaging and axonal tracking in the human brainstem. Neuroimage, 14: 723-735, 2001.
165. Potash JB, Willour VL, Chiu YF, Simpson SG, MacKinnon DF, **Pearlson GD**, DePaulo JR Jr, McInnis MG. The familial aggregation of psychotic symptoms in bipolar disorder pedigrees. Am J Psychiatry, 158: 1258-1264, 2001.
166. WR Kates, CP Burnette, E Jabs, J Rutberg, AM Murphy, MA Grados, M, Geraghty, WE Kaufmann, **Pearlson, GD.** Regional cortical white matter reductions in velocardiofacial syndrome: A volumetric MRI analysis. Biological Psychiatry 49: 677-684, 2001.

167. Naidu S, Kaufmann WE, Abrams MT, **Pearlson GD**, Lanham DC, Fredericksen KA, Barker PB, Horska A, Golay X, Mori S, Wong DF, Yablonski M, Moser HW, Johnston MV. Neuroimaging studies in Rett syndrome. Brain Development S62-S71, 2001.
168. Calhoun V, McGinty V, Pekar J, Watson T, **Pearlson GD**. Investigation of Marinol (THC) Effects on fMRI activation during active and passive driving using independent component analysis and SPM. Neuroimage, 13: 6, 388, 2001.
169. Calhoun VD, Pekar JJ, McGinty VB, Adali T, Watson TD, **Pearlson GD**. Different activation dynamics in multiple neural systems during simulated driving. Hum Brain Mapping 16(3):158-67, 2002.
170. Kates WR, Frederikse M, Mostofsky SH, Folley BS, Cooper K, Mazur-Hopkins P, Kofman O, Singer HS, Denckla MB, **Pearlson GD**, Kaufmann WE. MRI parcellation of the frontal lobe in boys with attention deficit hyperactivity disorder or Tourette syndrome. Psychiatry Res, 116(1-2):63-81, 2002.
171. Calhoun VD, Adali T, **Pearlson GD**, van Zijl PC, Pekar JJ. Independent component analysis of fMRI data in the complex domain. Magn Reson Med.; 48(1):180-92, 2002.
172. Mori S, Kaufmann WE, Davatzikos C, Stieltjes B, Amodei L, Fredericksen K, **Pearlson GD**, Melhem ER, Solaiyappan M, Raymond GV, Moser HW, van Zijl PC. Imaging cortical association tracts in the human brain using diffusion-tensor-based axonal tracking. Magn Reson Med.; 47(2):215-23, 2002.
173. Calhoun VD, Adali T, Pekar JJ, **Pearlson GD**. Latency (in)sensitive ICA. Group independent component analysis of fMRI data in the temporal frequency domain. Neuroimage. Nov;20(3):1661-9, 2003.
174. Ratnanather JT, Barta PE, Honeycutt NA, Lee N, Morris HM, Dziorny AC, Hurdal MK, **Pearlson GD**, Miller MI. Dynamic programming generation of boundaries of local coordinatized submanifolds in the neocortex: application to the planum temporale. Neuroimage, 20(1):359-77, 2003.
175. Schretlen DJ, Munro CA, Anthony JC, **Pearlson GD**. Examining the range of normal intra-individual variability in neuropsychological test performance. J Int Neuropsychol Soc, 9(6):864-70, 2003.
176. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, Perkins DO, **Pearlson GD**, Woods SW. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull.;29(4):703-15, 2003.
177. Calhoun VD, Kiehl KA, Liddle PF, **Pearlson GD**. Aberrant localization of synchronous hemodynamic activity in auditory cortex reliably characterizes schizophrenia. Biol Psychiatry. Apr 15;55(8):842-9, 2004.
178. Kates WR, Burnette CP, Eliez S, Strunge LA, Kaplan D, Landa R, Reiss AL, **Pearlson GD**. Neuroanatomic variation in monozygotic twin pairs discordant for the narrow phenotype for autism. Am J Psychiatry, 161(3):539-46, 2004.
179. Kates WR, Burnette CP, Bessette BA, Folley BS, Strunge L, Jabs EW, **Pearlson GD**. Frontal and caudate alterations in velocardiofacial syndrome (deletion at chromosome 22q11.2). J Child Neurol, 19(5):337-42, 2004.
180. Buchanan RW, Francis A, Arango C, Miller K, Lefkowitz DM, McMahon RP, Barta PE, **Pearlson GD**. Morphometric assessment of the heteromodal association cortex in schizophrenia. Am J Psychiatry.;161(2):322-31, 2004.
181. Buchanan RW, **Pearlson GD**. Prefrontal cortex, structural analysis: segmenting the prefrontal cortex. Am J Psychiatry. Nov;161(11):1978, 2004.
182. Diaz-Asper CM, Schretlen DJ, **Pearlson GD**. How well does IQ predict neuropsychological test performance in normal adults? J Int Neuropsychol Soc. Jan;10(1):82-90, 2004.

183. Hawkins, K.A., Dean, D., & Pearlson, GD. Alternative forms of the Rey Auditory Verbal Learning Test: A review. Behavioural Neurology, 15(3-4):99-107, 2004.
184. Reading SA, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V, Rosenblatt A, Margolis RL, Pekar JJ, **Pearlson GD**, Aylward E, Brandt J, Bassett SS, Ross CA. Functional brain changes in presymptomatic Huntington's disease. Ann Neurol, 55(6):879-83, 2004.
185. Kim JS, Reading SA, Brashers-Krug T, Calhoun VD, Ross CA, **Pearlson GD**. Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res,131(1):23-30, 2004.
186. Calhoun VD, Stevens MC, **Pearlson GD**, Kiehl KA. fMRI analysis with the general linear model: removal of latency-induced amplitude bias by incorporation of hemodynamic derivative terms. Neuroimage. May;22(1):252-7, 2004.
187. Calhoun VD, Altschul D, McGinty V, Shih R, Scott D, Sears E, **Pearlson GD**. Alcohol intoxication effects on visual perception: an fMRI study. Hum Brain Mapp. Jan;21(1):15-26, 2004. Erratum in: Hum Brain Mapp. Apr;21(4):298-9, 2004. (Cover issue)
188. Calhoun VD, Pekar JJ, **Pearlson GD**. Alcohol intoxication effects on simulated driving: exploring alcohol-dose effects on brain activation using functional MRI. Neuropsychopharmacology, 29(11):2097-17, 2004.
189. Schlaepfer TE, Lancaster E, Heidbreder R, Strain EC, Kosel M, Fisch HU, **Pearlson GD**. Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol, 1-7, 2005.
190. Calhoun VD, Carvalho K, Astur R, **Pearlson GD**. Using virtual reality to study alcohol intoxication effects on the neural correlates of simulated driving. Appl Psychophysiol Biofeedback, 30(3):285-306, 2005.
191. Hong B, **Pearlson GD**, Calhoun VD. Source density-driven independent component analysis approach for fMRI data. Human Brain Mapping. 2005.
192. Kiehl KA, Stevens MC, Laurens KR, **Pearlson GD**, Calhoun VD, Liddle PF. An adaptive reflexive processing model of neurocognitive function: supporting evidence from a large scale (n = 100) fMRI study of an auditory oddball task. Neuroimage, 15;25(3):899-915, 2005
193. Calhoun VD, Adali T, **Pearlson GD**, Kiehl KA. Neuronal chronometry of target detection: Fusion of hemodynamic and event-related potential data. Neuroimage, 2005.
194. Astur RS, St Germain SA, Baker EK, Calhoun V, **Pearlson GD**, Constable RT. fMRI hippocampal activity during a virtual radial arm maze. Appl Psychophysiol Biofeedback, 30(3):307-17, 2005.
195. Strasser HC, Lilyestrom J, Ashby ER, Honeycutt NA, Schretlen DJ, Pulver AE, Hopkins RO, Depaulo JR, Potash JB, Schweizer B, Yates KO, Kurian E, Barta PE, **Pearlson GD**. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects. Biol Psychiatry, 57:633-639, 2005.
196. Giuliani NR, Calhoun VD, **Pearlson GD**, Francis A, Buchanan RW. Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophrenia Research.;74:135-147. 2005.
197. St. Germain SS, Astur RA, **Pearlson GD**. Driving in schizophrenia. Results on a driving simulator. Schizophrenia Research, 1;74(1):121-2, 2005.
198. Assaf M, Rivkin PR, Kuzu CH, Calhoun VD, Kraut MA, Groth KM, Yassa MA, Hart J Jr, **Pearlson GD**. Abnormal object recall and anterior cingulate over-activation correlate with formal thought disorder in schizophrenia. Biol Psychiatry. 2005.

199. Kanaan RA, Kim JS, Kaufmann WE, **Pearlson GD**, Barker GJ, McGuire PK. Diffusion tensor imaging in schizophrenia. Biol Psychiatry. 2005;58(12):921-929. (Cover Issue)
200. Schretlen DJ, Buffington AL, Meyer SM, **Pearlson GD**. The use of word-reading to estimate "premorbid" ability in cognitive domains other than intelligence. J Int Neuropsychol Soc., 11(6):784-7, 2005.
201. Calhoun VD, Adali T, Giuliani NR, Pekar JJ, Kiehl KA, **Pearlson GD**. Method for multimodal analysis of independent source differences in schizophrenia: Combining gray matter structural and auditory oddball functional data. Hum Brain Mapping. 27(1):47-62.2006.
202. Krystal JH, D'Souza DC, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, **Pearlson GD**. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotox Res. 2006;10(3-4):235-52.
203. Johnson MR, Morris NA, Astur RS, Calhoun VD, Mathalon DH, Kiehl KA, **Pearlson GD**. A functional magnetic resonance imaging study of working memory abnormalities in schizophrenia. Biol Psychiatry. 2006;60: 11-21.
204. Calhoun VD, Adali T, Kiehl KA, Astur R, Pekar JJ, **Pearlson GD**. A method for multitask fMRI data fusion applied to schizophrenia. Hum Brain Mapp. 2006;27(7):598-610.
205. Assaf M, Calhoun VD, Kuzu CH, Kraut MA, Rivkin PR, Hart J Jr, **Pearlson GD**. Neural correlates of the object-recall process in semantic memory. Psychiatry Res. 2006 Oct 30;147(2-3):115-26.
206. Jiang H, van Zijl PC, Kim J, **Pearlson GD**, Mori S. DTI-Studio: resource program for diffusion tensor computation and fiber bundle tracking. Comput Methods Programs Biomed. 2006;81(2):106-16.
207. Krystal J, D'Souza D, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, **Pearlson GD**. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotoxicology Research,10(3-4):235-252 2006.
208. Garrity AG, **Pearlson GD**, McKiernan K, Lloyd D, Kiehl KA, Calhoun VD. Aberrant "default mode" functional connectivity in schizophrenia. Am J Psychiatry. 2007;164 (3):450-7.
209. Schretlen DJ, Cascella NG, Meyer SM, Kingery LR, Testa SM, Munro CA, Pulver AE, Rivkin P, Rao VA, Diaz-Asper CM, Dickerson FB, Yolken RH, **Pearlson GD**. Neuropsychological functioning in bipolar disorder and schizophrenia. Biol Psychiatry. 2007;62(2):179-186.
210. Keshavan MS, Prasad KM, **Pearlson GD**. Are brain structural abnormalities useful as endophenotypes in schizophrenia? Int Rev Psychiatry. 2007;19(4):397-406.
211. Kurtz MM, Baker E, **Pearlson GD**, Astur RS. A virtual reality apartment as a measure of medication management skills in patients with schizophrenia: A Pilot Study. Schizophr Bull. 2007;33(5):1162-70.
212. **Pearlson GD**, Calhoun V. Structural and functional magnetic resonance imaging in psychiatric disorders. Can J Psychiatry. 2007 Mar;52(3):158-66.
213. Stevens MC, Kiehl KA, **Pearlson GD**, Calhoun VD. Functional neural circuits for mental timekeeping. Hum Brain Mapp. 2007 May;28(5):394-408.
214. Stevens MC, Kiehl KA, **Pearlson GD**, Calhoun VD. Functional neural networks underlying response inhibition in adolescents and adults. Behav Brain Res. 2007 Jul 19;181(1):12-22.
215. Ruano G, Blair CL, Bower B, Windemuth A, Kocherla M, Aleman Y, **Pearlson GD**, Goethe JW, Schwartz HI. Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism deficiencies. Conn Med. 2007 Apr; 71(4):197-200.

216. Stevens MC, **Pearlson GD**, Kiehl KA. An auditory oddball study of combined-subtype attention deficit hyperactivity disorder. Am J Psychiatry. 2007 Nov; 164(11):1737-49.
217. Manning KJ, Gordon B, **Pearlson GD**, Schretlen DJ. The relationship of recency discrimination to explicit memory and executive functioning. J Int Neuropsychol Soc. 2007 Jul;13(4):710-5.
218. Schretlen DJ, Inscore AB, Jinnah HA, Rao V, Gordon B, **Pearlson GD**. Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology. 2007;21(1):136-40.
219. Manning KJ, Gordon B, **Pearlson GD**, Schretlen DJ. The relationship of recency discrimination to explicit memory and executive functioning. J Int Neuropsychol Soc. 2007 Jul;13(4):710-5.
220. Schretlen DJ, Inscore AB, Vannorsdall TD, Kraut M, **Pearlson GD**, Gordon B, Jinnah HA. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007 Oct 2;69(14):1418-23.
221. Windemuth A, Calhoun VD, **Pearlson GD**, Kocherla M, Jagannathan K, Ruaño G. Physiogenomic analysis of localized fMRI brain activity in schizophrenia. Annals of Biomedical Engineering, 2008; 36(6):877-88.
222. **Pearlson GD**, Folley BS. Schizophrenia, psychiatric genetics, and Darwinian psychiatry: an evolutionary framework. Schizophr Bull. 2008;34(4):722-33.
223. **Pearlson GD**, Folley BS. Endophenotypes, dimensions, risks: is psychosis analogous to common inherited medical illnesses? Clin EEG Neurosci. 2008;39(2):73-7.
224. Meda SA, Giuliani NR, Calhoun VD, Jagannathan K, Schretlen DJ, Pulver A, Cascella N, Keshavan M, Kates W, Buchanan R, Sharma T, **Pearlson GD**. A large scale (N=400) investigation of gray matter differences in schizophrenia using optimized voxel-based morphometry. Schizophr Res. 2008;101(1-3):95-105.
225. Arango C, McMahon RP, Lefkowitz DM, **Pearlson GD**, Kirkpatrick B, Buchanan RW. Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res. 2008 28;162(2):91-100.
226. Jafri MJ, **Pearlson GD**, Stevens M, Calhoun VD. A method for functional network connectivity among spatially independent resting-state components in schizophrenia. Neuroimage. 2008 15;39(4):1666-81.
227. Skelly LR, Calhoun V, Meda SA, Kim J, Mathalon DH, **Pearlson GD**. Diffusion tensor imaging in schizophrenia: relationship to symptoms. Schizophr Res. 2008;98(1-3):157-62.
228. Kim D, **Pearlson GD**, Kiehl KA, Bedrick E, Demirci O, Calhoun VD. A method for multi-group inter-participant correlation: abnormal synchrony in patients with schizophrenia during auditory target detection. Neuroimage. 2008 1;39(3):1129-41.
229. Calhoun VD, Maciejewski PK, **Pearlson GD**, Kiehl KA. Temporal lobe and "default" hemodynamic brain modes discriminate between schizophrenia and bipolar disorder. Hum Brain Mapp. 2008;29(11):1265-75
230. Cascella NG, Testa SM, Meyer SM, Rao VA, Diaz-Asper CM, **Pearlson GD**, Schretlen DJ. Neuropsychological impairment in deficit vs. non-deficit schizophrenia. J Psychiatr Res. 2008;42(11):930-7.
231. Kim D, Burge J, Lane T, **Pearlson GD**, Kiehl KA, Calhoun VD. Hybrid ICA-Bayesian network approach reveals distinct effective connectivity differences in schizophrenia. Neuroimage. 2008, 42;(4);1560-1568.
232. Caprihan A, **Pearlson GD**, Calhoun VD. Application of principal component analysis to distinguish patients with schizophrenia from healthy controls based on fractional anisotropy measurements. Neuroimage. 2008, 42(2)675-682.

233. Meda SA, Bhattarai M, Morris NA, Astur RS, Calhoun VD, Mathalon DH, Kiehl KA, **Pearlson GD**. An fMRI study of working memory in first-degree unaffected relatives of schizophrenia patients. Schizophrenia Res. 2008;104(1-3):85-95.
234. Demirci O, Clark VP, Magnotta VA, Andreasen NC, Lauriello J, Kiehl KA, **Pearlson GD**, Calhoun VD. A review of challenges in the use of fMRI for disease classification / Characterization and a projection pursuit application from multi-site fMRI schizophrenia study. Brain Imaging Behav. 2008 1;2:147-226.
235. Calhoun VD, Kiehl KA, **Pearlson GD**. Modulation of temporally coherent brain networks estimated using ICA at rest and during cognitive tasks. Hum Brain Mapp. 2008 Jul;29(7):828-38.
236. Skudlarski P, Jagannathan K, Calhoun VD, Hampson M, Skudlarska BA, **Pearlson GD**. Measuring brain connectivity: diffusion tensor imaging validates resting state temporal correlations. Neuroimage. 2008 15; 43(3):554-61.
237. Meda SA, Gelernter J, Gruen JR, Calhoun VD, Meng H, Cope NA, **Pearlson GD**. Polymorphism of DCDC2 reveals differences in cortical morphology of healthy individuals- A preliminary voxel based morphometry study. Brain Imaging Behav. 2008;2(1):21-26.
238. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, **Pearlson GD**, Reese HE, Cannistraro P, Jenike MA, Rauch SL. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008 Mar;165(3):335-41.
239. Schretlen DJ, Testa SM, Winicki JM, **Pearlson GD**, Gordon B. Frequency and bases of abnormal performance by healthy adults on neuropsychological testing. J Int Neuropsychol Soc. 2008 May;14(3):436-45.
240. Otto MW, Tolin DF, Simon NM, **Pearlson GD**, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH. Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2009
241. Testa SM, Winicki JM, **Pearlson GD**, Gordon B, Schretlen DJ. Accounting for estimated IQ in neuropsychological test performance with regression-based techniques. J Int Neuropsychol Soc. 2009;15(6):1012-22.
242. Meda SA, Stevens MC, Potenza MN, Pittman B, Gueorguieva R, Andrews MM, Thomas AD, Muska C, Hylton JL, **Pearlson GD**. Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol. Sep;20(5-6):390-399; 2009.
243. Meda SA, Calhoun VD, Astur RS, Turner BM, Ruopp K, **Pearlson GD**. Alcohol dose effects on brain circuits during simulated driving: an fMRI study. Hum Brain Mapp. 2009;30(4):1257-70.
244. Allen AJ, Meda SA, Skudlarski P, Calhoun VD, Astur R, Ruopp KC, **Pearlson GD**. Effects of alcohol on performance on a distraction task during simulated driving. Alcohol Clin Exp Res. 2009;33(4):617-25.
245. Stevens MC, Kiehl KA, **Pearlson GD**, Calhoun VD. Brain network dynamics during error commission. Hum Brain Mapp. 2009 Jan;30(1):24-37.
246. Hong CC, Harris JC, **Pearlson GD**, Kim JS, Calhoun VD, Fallon JH, Golay X, Gillen JS, Simmonds DJ, van Zijl PC, Zee DS, Pekar JJ. fMRI evidence for multisensory recruitment associated with rapid eye movements during sleep. Hum Brain Mapp. 2009 May; 30(5):1705-22.
247. Liu J, Kiehl KA, **Pearlson GD**, Perrone-Bizzozero NI, Eichele T, Calhoun VD. Genetic determinants of target and novelty-related event-related potentials in the auditory oddball response. NeuroImage. 2009 1;46(3):809-16.



248. Goldstein G, Panchalingam K, McClure RJ, Stanley JA, Calhoun VD, **Pearlson GD**, Pettegrew JW. Molecular neurodevelopment: an in vivo 31P-1H MRSI study. J Int Neuropsychol Soc. 2009;15:671-83
249. Stevens MC, Skudlarski P, **Pearlson GD**, Calhoun VD. Age-related cognitive gains are mediated by the effects of white matter development on brain network integration. Neuroimage. 2009;48:738-46.
250. Sui J, Adali T, **Pearlson GD**, Calhoun VD. An ICA-based method for the identification of optimal fMRI features and components using combined group-discriminative techniques. Neuroimage. 2009 15;46(1):73-86.
251. Assaf M, Jagannathan K, Calhoun V, Kraut M, Hart J Jr, **Pearlson GD**. Temporal sequence of hemispheric network activation during semantic processing: a functional network connectivity analysis. Brain Cogn. 2009;70(2):238-46.
252. Stevens MC, **Pearlson GD**, Calhoun VD. Changes in the interaction of resting-state neural networks from adolescence to adulthood. Hum Brain Mapp. 2009;30 (8):2356-66.
253. Hong CC, Harris JC, **Pearlson GD**, Kim JS, Calhoun VD, Fallon JH, Golay X, Gillen JS, Simmonds DJ, van Zijl PC, Zee DS, Pekar JJ. fMRI evidence for multisensory recruitment associated with rapid eye movements during sleep. Hum Brain Mapp. 2009;30(5):1705-22.
254. Gordon RJ, Seamon JG, **Pearlson GD**. An fMRI study of neurocognitive functioning in schizophrenia with a mere exposure paradigm. Schizophr Res. 2009; 108(1-3):290-2.
255. **Pearlson GD**. Multisite collaborations and large databases in psychiatric neuroimaging: advantages, problems and challenges. Schizophrenia Bull. 2009; 35(1):1-2.
256. Liu J, **Pearlson GD**, Windemuth A, Ruano G, Perrone-Bizzozero NI, Calhoun V. Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Hum Brain Mapp. 2009; 30(1):241-55.
257. Calhoun VD, Eichele T, **Pearlson GD**. Functional brain networks in schizophrenia: a review. Front Hum Neurosci. 2009; 3:17. In Press.
258. Demirci O, Stevens MC, Andreasen NC, Michael A, Liu J, White T, **Pearlson GD**, Clark VP, Calhoun VD. Investigation of relationships between fMRI brain networks in the spectral domain using ICA and Granger causality reveals distinct differences between schizophrenia patients and healthy controls. NeuroImage. 2009; 46(2):419-31.
259. Allen AJ, Griss ME, Folley BS, Hawkins KA, **Pearlson GD**. Endophenotypes in schizophrenia: a selective review. Schizophr Res. 2009; 109(1-3):24-37.
260. Sui J, Adali T, **Pearlson GD**, Clark VP, Calhoun VD. A method for accurate group difference detection by constraining the mixing coefficients in an ICA framework. Hum Brain Mapp. 2009; 30:2953-70.
261. Xu L, **Pearlson GD**, Calhoun VD. Joint source based morphometry identifies linked gray and white matter group differences. Neuroimage. 2009 1; 44(3):777-89.
262. Meda SA, Stevens MC, Folley BS, Calhoun VD, **Pearlson GD**. Evidence for anomalous network connectivity during working memory encoding in schizophrenia: An ICA based analysis. PLoS One. 2009 Nov 19; 4(11).
263. **Pearlson GD D**, Calhoun V D, Convergent approaches for defining functional imaging endophenotypes in schizophrenia, Frontiers in Human Neuroscience, 2009; 3:37 1-11.
264. Xu L, Groth KM, **Pearlson GD**, Schretlen DJ, Calhoun VD. Source-based morphometry: the use of independent component analysis to identify gray matter differences with application to schizophrenia. Hum Brain Mapp. 2009; 30(3):711-24.

265. Anderson BM, Rizzo M, Block RI, **Pearlson GD**, O'leary DS. Sex differences in the effects of marijuana on simulated driving performance. J Psychoactive Drugs. 2010 Mar; 42(1):19-30.
266. Otto MWW, Tolin DF, Simon NM, **Pearlson GD**, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH. Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010 Feb 15; 67(4):365-70.
267. Folley BS, Astur R, Jagannathan K, Calhoun VD, **Pearlson GD**. Anomalous neural circuit function in schizophrenia during a virtual morris water task. Neuroimage. 2010 Feb 15; 49(4):3373-84.
268. Christman AL, Vannorsdall TD, **Pearlson GD**, Hill-Briggs F, Schretlen DJ. Cranial volume, mild cognitive deficits, and functional limitations associated with diabetes in a community sample. Arch Clin Neuropsychol. 2010 Feb; 25(1):49-59.
269. Wakefield DB, Moscufo N, Guttmann CR, Kuchel GA, Kaplan RF, **Pearlson GD**, Wolfson L. White matter hyperintensities predict functional decline in voiding, mobility, and cognition in older adults. J Am Geriatr Soc. 2010 Feb; 58(2):275-81.
270. Michael AM, Baum SA, White T, Demirci O, Andreasen NC, Segall JM, Jung REE, **Pearlson GD**, Clark VP, L, Schulz SC, L, O, Ho BC, Bockholt HJ, Calhoun VD. Does function follow form? Methods to fuse structural and functional brain images show decreased linkage in schizophrenia. Neuroimage. 2010 Feb 1; 49(3):2626-37.
271. *Rimol LM, et al; Alzheimer's Disease Neuroimaging Initiative. Sex-dependent association of common variants of microcephaly genes with brain structure. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):384-8. ADNI*
272. *Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A; Alzheimer's Disease Neuroimaging Initiative. A robust method to estimate the intracranial volume across MRI field strengths (1.5t And 3t). Neuroimage. 2010 May 1;50(4):1427-37. ADNI*
273. Vannorsdall TD, Cascella NG, Rao V, **Pearlson GD**, Gordon B, Schretlen DJ. A morphometric analysis of neuroanatomic abnormalities in traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2010 Spring; 22(2):173-81.
274. Rzepecki-Smith CI, Meda SA, Calhoun VD, Stevens MC, Jafri MJ, Astur RS, **Pearlson GD**. Disruptions in functional network connectivity during alcohol intoxicated driving. Alcohol Clin Exp Res. 2010 Mar 1;34(3):479-87.
275. *Ho Aj, Et Al; Alzheimer's Disease Neuroimaging Initiative. A commonly carried allele of the obesity-related Fto gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8404-9. ADNI*
276. Meda SA, Jagannathan K, Gelernter J, Calhoun VD, Liu J, Stevens MC, **Pearlson GD**. A pilot multivariate parallel ICA study to investigate differential linkage between neural networks and genetic profiles in schizophrenia. Neuroimage. 2010 Nov 15;53(3):1007-15.
277. Assaf M, Jagannathan K, Calhoun VD, Miller L, Stevens MC, Sahl R, O'boyle JG, Schultz RT, **Pearlson GD**. Abnormal functional connectivity of default mode sub-networks in autism spectrum disorder patients. Neuroimage. 2010 Oct 15;53(1):247-56.
278. Jagannathan K, Calhoun VD, Gelernter J, Stevens MC, Liu J, Bolognani F, Windemuth A, Ruaño G, Assaf M, **Pearlson GD**. Genetic associations of brain structural networks in schizophrenia: A preliminary study. Biol Psychiatry. 2010 Oct 1;68(7):657-66.
279. Calhoun V, Wu L, Kiehl K, Eichele T, **Pearlson GDD**. Aberrant processing of deviant stimuli in schizophrenia revealed by fusion of fMRI and EEG data. Acta Neuropsychiatr. 2010 Jun;22(3):127-138.

280. Witt ST, Lovejoy DW, **Pearlson GD**, Stevens MC. Decreased prefrontal cortex activity in mild traumatic brain injury during performance of an auditory oddball task. Brain Imaging Behav. 2010 Dec;4(3-4):232-47.
281. Schretlen DJ, Van Der Hulst EJ, **Pearlson GD**, Gordon B. A neuropsychological study of personality: Trait openness in relation to intelligence, fluency, and executive functioning. J Clin Exp Neuropsychol. 2010 Dec;32(10):1068-73.
282. *Vounou M, Nichols TE, Montana G; Alzheimer's Disease Neuroimaging Initiative. Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage. 2010 Nov 15;53(3):1147-59. ADNI*
283. Anderson BM, Rizzo M, Block RI, **Pearlson GD**, O'leary DS. Sex, drugs, and cognition: Effects of marijuana. J Psychoactive Drugs. 2010 Dec;42(4):413-24.
284. Folley BS, Astur R, Jagannathan K, Calhoun VD, **Pearlson GD**. Anomalous neural circuit function in schizophrenia during a virtual Morris water task. Neuroimage. 2010; 49 (4) 3373-3384.
286. Cascella NG, Fieldstone SC, Rao VA, **Pearlson GD**, Sawa A, Schretlen DJ. Gray-matter abnormalities in deficit schizophrenia. Schizophr Res. 2010 Jul;120(1-3):63-70.
287. Sakoğlu U, **Pearlson GD**, Kiehl KA, Wang YM, Michael AM, Calhoun VD. A method for evaluating dynamic functional network connectivity and task-modulation: application to schizophrenia. Magn Res Materials in Physics, Biology and Medicine (MAGMA). In Press, 2010.
288. Sui J, Adali T, **Pearlson GD**, Yang H, Sponheim SR, White T, Calhoun VD. A CCA+ICA based model for multi-task brain imaging data fusion and its application to schizophrenia. Neuroimage. 2010;15;51(1):123-34.
289. Skudlarski P, Jagannathan K, Anderson K, Stevens MC, Calhoun VD, Skudlarska BA, **Pearlson GD**. Brain connectivity is not only lower but different in schizophrenia: a combined anatomical and functional approach. Biol Psychiatry. 2010; 68(1):61-9.
290. Lui S, Li T, Deng W, Jiang L, Wu Q, Tang H, Yue Q, Huang X, Chan RC, Collier DA, Meda SA, **Pearlson GD**, Mechelli A, Sweeney JA, Gong Q. Short-term effects of antipsychotic treatment on cerebral function in drug-naïve first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. Arch Gen Psychiatry. 2010;67(8):783-92.
291. Jia Z, Worhunsky PD, Carroll KM, Rounsaville BJ, Stevens MC, **Pearlson GD**, Potenza MN. An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence. Biol Psychiatry. 2011 Sep 15;70(6):553-60.
292. *Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang S, Jack Cr Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology. 2011 Jun; 259(3):844-51. ADNI*
293. Parker BA, Thompson PD, Jordan KC, Grimaldi AS, Assaf M, Jagannathan K, **Pearlson GD**. Effect of exercise training on hippocampal volume in humans: A Pilot Study. Res Q Exerc Sport. 2011 Sep; 82(3):585-91.
294. Andrews MM, Meda SA, Thomas AD, Potenza MN, Krystal JH, Worhunsky P, Stevens MC, O'malley S, Book GA, Reynolds B, **Pearlson GD**. Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. Biol Psychiatry. 2011 Apr 1; 69(7):675-83.
295. Swanson N, Eichele T, **Pearlson GD**, Kiehl K, Yu Q, Calhoun VD. Lateral differences in the default mode network in healthy controls and patients with schizophrenia. Hum Brain Mapp. 2011 Apr; 32(4):654-64.

296. Castro E, Martínez-Ramón M, **Pearlson GD**, Sui J, Calhoun VD. Characterization of groups using composite kernels and multi-source fMRI analysis data: application to schizophrenia. *Neuroimage*. 2011 Sep 15; 58(2):526-36.
297. Sui J, **Pearlson GDD**, Caprihan A, Adali T, Kiehl KA, Liu J, Yamamoto J, Calhoun VD. Discriminating schizophrenia and bipolar disorder by fusing fMRI and DTI in a multimodal CCA+ joint ICA model. *Neuroimage*. 2011 Aug 1; 57(3):839-55.
298. Abbott C, Juárez M, White T, Gollub RL, **Pearlson GD**, Bustillo J, Lauriello J, Ho B, Bockholt HJ, Clark VP, Magnotta V, Calhoun VD. Antipsychotic dose and diminished neural modulation: A multi-site fMRI study. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011 Mar 30; 35(2):473-82.
299. Allen EA, Erhardt E, Damaraju E, Gruner W, Segall J, Silva R, Havlicek M, Rachakonda S, Fries J, Kalyanam R, Michael A, Caprihan A, Turner J, Eichele T, Adelsheim S, Bryan A, Bustillo J, Clark V, Ewing S, Filbey F, Ford C, Hutchison K, Jung R, Kiehl K, Kodituwakku P, Komesu Y, Mayer A, **Pearlson GD**, Phillips J, Sadek J, Stevens MC, Teuscher U, Thomas R, Calhoun V. A baseline for the multivariate comparison of resting-state Networks. *Front Syst Neurosci*. 2011 Feb 4;5:2.
300. Jamadar S, Powers NR, Meda SA, Gelernter J, Gruen JR, **Pearlson GD**. Genetic influences of cortical gray matter in language-related regions in healthy controls and schizophrenia. *Schizophr Res*. 2011 Jul;129(2-3):141-8
301. Hawkins KA, Cromer JR, Piotrowski AS, **Pearlson GD**. Mini-Mental State Exam performance of older African Americans: effect of age, gender, education, hypertension, diabetes, and the inclusion of serial 7s subtraction versus "world" backward on score. *Arch Clin Neuropsychol*. 2011 Nov;26(7):645-52.
302. Hawkins KA, **Pearlson GD**. Age and gender but not common chronic illnesses predict odor identification in older African Americans. *Am J Geriatr Psychiatry*. 2011 Sep;19(9):777-82.
303. Yu Q, Sui J, Rachakonda S, He H, Gruner W, **Pearlson GD**, Kiehl KA, Calhoun VD. Altered topological properties of functional network connectivity in schizophrenia during resting state: a small-world brain network study. *PLoS One*. 2011;6(9):e25423.
304. *Mattila J, Koikkalainen J, Virkki A, van Gils M, Lötjönen J; Alzheimer's Disease Neuroimaging Initiative. Design and application of a generic clinical decision support system for multiscale data. IEEE Trans Biomed Eng*. 2012 Jan;59(1):234-40. ADNI
305. Keshavan MS, Morris DW, Sweeney JA, **Pearlson GD**, Thaker G, Seidman LJ, Eack SM, Tamminga C. A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: the Schizo-Bipolar Scale. *Schizophr Res*. 2011 Dec;133(1-3):250-4.
306. *Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology*. 2011 Oct 25;77(17):1619-28. ADNI
307. *Wolz R, Julkunen V, Koikkalainen J, Niskanen E, Zhang DP, Rueckert D, Soininen H, Lötjönen J; Alzheimer's Disease Neuroimaging Initiative. Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One*. 2011; 6(10):e25446. ADNI
308. White WB, Wolfson L, Wakefield DB, Hall CB, Campbell P, Moscufo N, Schmidt J, Kaplan RF, **Pearlson GD**, Guttmann CR. Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. *Circulation*. 2011 Nov 22; 124(21):2312-9.
309. *Vidoni ED, Townley RA, Honea RA, Burns JM; Alzheimer's Disease Neuroimaging Initiative. Alzheimer disease biomarkers are associated with body mass index. Neurology*. 2011 Nov 22; 77(21):1913-20. ADNI

310. Yu Q, Plis SM, Erhardt EB, Allen EA, Sui J, Kiehl KA, **Pearlson GD**, Calhoun VD. Modular organization of functional network connectivity in healthy controls and patients with schizophrenia during the resting state. *Front Syst Neurosci*. 2011; 5:103.
311. Calhoun VD, Sui J, Kiehl K, Turner J, Allen E, **Pearlson GD**. Exploring the psychosis functional connectome: aberrant intrinsic networks in schizophrenia and bipolar disorder. *Front Psychiatry*. 2011; 2:75.
312. Caprihan A, Abbott C, Yamamoto J, **Pearlson GD**, Perrone-Bizzozero N, Sui J, Calhoun VD. Source-based morphometry analysis of group differences in fractional anisotropy in schizophrenia. *Brain Connect*. 2011; 1(2):133-45.
313. Michael AM, King MD, Ehrlich S, **Pearlson GD**, White T, Holt DJ, Andreasen NC, Sakoglu U, Ho BC, Schulz SC, Calhoun VD. A data-driven investigation of gray matter-function correlations in schizophrenia during a working memory task. *Front Hum Neurosci*. 2011; 5:71.
314. Khullar S, Michael AM, Cahill ND, Kiehl KA, **Pearlson GD**, Baum SA, Calhoun VD. ICA-fNORM: spatial normalization of fMRI data using intrinsic group-ICA networks. *Front Syst Neurosci*. 2011; 5:93.
315. Allen EA, Liu J, Kiehl KA, Gelernter J, **Pearlson GD**, Perrone-Bizzozero NI, Calhoun VD. Components of cross-frequency modulation in health and disease. *Front Syst Neurosci*. 2011; 5:59.
316. Anderson BM, Stevens MC, Meda SA, Jordan K, Calhoun VD, **Pearlson GD**. Functional imaging of cognitive control during acute alcohol intoxication. *Alcohol Clin Exp Res*. 2011 Jan; 35(1):156-65.
317. Kim S, *Et Al*; Alzheimer's Disease Neuroimaging Initiative. Genome-wide association study of CSF biomarkers A $\beta$ 1-42, T-Tau, And P-Tau181p in The ADNI Cohort. *Neurology*. 2011 Jan 4;76(1):69-79. ADNI
318. Lo RY, Hubbard AE, Shaw LM, Trojanowski JG, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Longitudinal change of biomarkers in cognitive decline. *Arch Neurol*. 2011 Oct;68(10):1257-66. ADNI
319. Chu C, Hsu AL, Chou KH, Bandettini P, Lin C; Alzheimer's Disease Neuroimaging Initiative. Does feature selection improve classification accuracy? Impact of sample size and feature selection on classification using anatomical magnetic resonance images. *Neuroimage*. 2012 Mar;60(1):59-70. ADNI
320. Hamm JP, Ethridge LE, Shapiro JR, Stevens MC, Boutros NN, Summerfelt AT, Keshavan MS, Sweeney JA, **Pearlson GD**, Tamminga CA, Thaker G, Clementz BA.I. Spatiotemporal and frequency domain analysis of auditory paired stimuli processing in schizophrenia and bipolar disorder with psychosis. *Psychophysiology*. 2012 Apr;49(4):522-30.
321. Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. *Neurology*. 2012 Jan 10;78(2):84-90. ADNI
322. Meda SA, Narayanan B, Liu J, Perrone-Bizzozero NI, Stevens MC, Calhoun VD, Glahn DC, Shen L, Risacher SL, Saykin AJ, **Pearlson GD**. A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer's disease in the ADNI cohort. *Neuroimage*. 2012 Apr 15; 60(3):1608-21.
323. Jamadar S, DeVito EE, Jiantonio RE, Meda SA, Stevens MC, Potenza MN, Krystal JH, **Pearlson GD**. Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism. *Psychopharmacology (Berl)*. 2012 Jul;222(1):129-40.

324. Balodis IM, Kober H, Worhunsky PD, Stevens MC, **Pearlson GD**, Potenza MN. Diminished frontostriatal activity during processing of monetary rewards and losses in pathological gambling. Biol Psychiatry. 2012 Apr 15;71(8):749-57.
325. Fischer BA, Keller WR, Arango C, **Pearlson GD**, McMahon RP, Meyer WA, Francis A, Kirkpatrick B, Carpenter WT, Buchanan RW. Cortical structural abnormalities in deficit versus nondéficit schizophrenia. Schizophr Res. 2012 Apr;136(1-3):51-4.
326. Bakken TE, et al. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3985-90. ADNI
327. Koikkalainen J, Pölönen H, Mattila J, van Gils M, Soininen H, Lötjönen J; Alzheimer's Disease Neuroimaging Initiative. Improved classification of Alzheimer's disease data via removal of nuisance variability. PLoS One. 2012;7(2):e31112. ADNI
328. Sui J, Yu Q, He H, **Pearlson GD**, Calhoun VD. A selective review of multimodal fusion methods in schizophrenia. Front Hum Neurosci. 2012;6:27.
329. Sung K, Gordon B, Vannorsdall TD, Ledoux K, Pickett EJ, **Pearlson GD**, Schretlen DJ. Semantic clustering of category fluency in schizophrenia examined with singular value decomposition. J Int Neuropsychol Soc. 2012 May;18(3):565-75.
330. Meda SA, Gill A, Stevens MC, Lorenzoni RP, Glahn DC, Calhoun VD, Sweeney JA, Tamminga CA, Keshavan MS, Thaker G, **Pearlson GD**. Differences in resting-state functional magnetic resonance imaging functional network connectivity between schizophrenia and psychotic bipolar probands and their unaffected first-degree relatives. Biol Psychiatry. 2012 May 15;71(10):881-9.
331. Chen J, Calhoun VD, **Pearlson GD**, Ehrlich S, Turner JA, Ho BC, Wassink TH, Michael AM, Liu J. Multifaceted genomic risk for brain function in schizophrenia. Neuroimage. 2012 Jul 16;61(4):866-75.
332. Luo L, Xu L, Jung R, **Pearlson GD**, Adali T, Calhoun VD. Constrained source-based morphometry identifies structural networks associated with default mode network. Brain Connect. 2012;2(1):33-43.
333. Johnstone D, Milward EA, Berretta R, Moscato P; Alzheimer's Disease Neuroimaging Initiative. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One. 2012;7(4):e34341. ADNI
334. Lo RY, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Predicting missing biomarker data in a longitudinal study of Alzheimer disease. Neurology. 2012 May 1;78(18):1376-82. ADNI
335. Yuan L, Wang Y, Thompson PM, Narayan VA, Ye J; Alzheimer's Disease Neuroimaging Initiative. Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. Neuroimage. 2012 Jul 2;61(3):622-32. ADNI
336. Silver M, Montana G; Alzheimer's Disease Neuroimaging Initiative. Fast identification of biological pathways associated with a quantitative trait using group lasso with overlaps. Stat Appl Genet Mol Biol. 2012 Jan 6;11(1):Article 7. ADNI
337. Stein JL, et al; Enhancing Neuro Imaging Genetics through Meta-Analysis Consortium. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet. 2012 Apr 15;44(5):552-61. ADNI
338. Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, Dale AM; Alzheimer's Disease Neuroimaging Initiative. Amyloid- $\beta$ —associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012 Jun;69(6):709-13. ADNI
339. Ethridge LE, Hamm JP, Shapiro JR, Summerfelt AT, Keedy SK, Stevens MC, **Pearlson GD**, Tamminga CA, Boutros NN, Sweeney JA, Keshavan MS, Thaker G, Clementz BA. Neural

- activations during auditory oddball processing discriminating schizophrenia and psychotic bipolar disorder. Biol Psychiatry. 2012 Nov 1;72(9):766-74.
340. Kerestes R, Bhagwagar Z, Nathan PJ, Meda SA, Ladouceur CD, Maloney K, Matuskey D, Ruf B, Saricicek A, Wang F, **Pearlson GD**, Phillips ML, Blumberg HP. Prefrontal cortical response to emotional faces in individuals with major depressive disorder in remission. Psychiatry Res. 2012 Apr 30;202(1):30-7.
341. Hyatt CJ, Assaf M, Muska CE, Rosen RI, Thomas AD, Johnson MR, Hylton JL, Andrews MM, Reynolds BA, Krystal JH, Potenza MN, **Pearlson GD**. Reward-related dorsal striatal activity differences between former and current cocaine dependent individuals during an interactive competitive game. PLoS One. 2012;7(5):e34917.
342. Jamadar S, Powers NR, Meda SA, Calhoun VD, Gelernter J, Gruen JR, **Pearlson GD**. Genetic influences of resting state fMRI activity in language-related brain regions in healthy controls and schizophrenia patients: a pilot study. Brain Imaging Behav. 2013 March;7(1):15-27.
343. *Wang H, Nie F, Huang H, Risacher SL, Saykin AJ, Shen L; Alzheimer's Disease Neuroimaging Initiative. Identifying disease sensitive and quantitative trait-relevant biomarkers from multidimensional heterogeneous imaging genetics data via sparse multimodal multitask learning. Bioinformatics. 2012 Jun 15;28(12):i127-36. ADNI*
344. *Damoiseaux JS, Seeley WW, Zhou J, Shiner WR, Coppola G, Karydas A, Rosen HJ, Miller BL, Kramer JH, Greicius MD; Alzheimer's Disease Neuroimaging Initiative. Gender modulates the APOE  $\epsilon$ 4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci. 2012 Jun 13;32(24):8254-62. ADNI*
345. Arbabshirani MR, Havlicek M, Kiehl KA, **Pearlson GD**, Calhoun VD. Functional network connectivity during rest and task conditions: A comparative study. Hum Brain Mapp. 2012 Jun 26. In press
346. Worhunsky PD, Stevens MC, Carroll KM, Rounsaville BJ, Calhoun VD, **Pearlson GD**, Potenza MN. Functional brain networks associated with cognitive control, cocaine dependence, and treatment outcome. Psychol Addict Behav. 2013 Jun;27(2):477-88.
347. Balodis IM, Kober H, Worhunsky PD, Stevens MC, **Pearlson GD**, Potenza MN. Attending to Striatal Ups and Downs in Addictions. Biol Psychiatry. 2012 Jul 11. In press
348. Tolin DF, Stevens MC, Villavicencio AL, Norberg MM, Calhoun VD, Frost RO, Steketee G, Rauch SL, **Pearlson GD**. Neural mechanisms of decision making in hoarding disorder. Arch Gen Psychiatry. 2012 Aug;69(8):832-41.
349. *Holland D, Desikan RS, Dale AM, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative. Rates of decline in Alzheimer disease decrease with age. PLoS One. 2012;7(8):e42325. ADNI*
350. Patel KT, Stevens MC, **Pearlson GD**, Winkler AM, Hawkins KA, Skudlarski P, Bauer LO. Default mode network activity and white matter integrity in healthy middle-aged ApoE4 carriers. Brain Imaging Behav. 2012 Jul 25. In press
351. Jamadar S, O'Neil KM, **Pearlson GD**, Ansari M, Gill A, Jagannathan K, Assaf M. Impairment in semantic retrieval is associated with symptoms in schizophrenia but not bipolar disorder. Biol Psychiatry. 2012 Sep 15. In press
352. Anticevic A, Brumbaugh MS, Winkler AM, Lombardo LE, Barrett J, Corlett PR, Kober H, Gruber J, Repovs G, Cole MW, Krystal JH, **Pearlson GD**, Glahn DC. Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history. Biol Psychiatry. 2013 March;73(6):565-73.
353. Jamadar S, Assaf M, Jagannathan K, Anderson K, **Pearlson GD**. Figural memory performance and functional magnetic resonance imaging activity across the adult lifespan. Neurobiol Aging. 2012 Aug 15. In press

354. Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, Minthon L, Trojanowski JG, Shaw LM, Faluyi YO, Vellas B, Dubois B, Blennow K, Buerger K, Teipel SJ, Weiner M, Hampel H; Alzheimer's Disease Neuroimaging Initiative. Body Mass Index Is Associated With Biological Csf Markers Of Core Brain Pathology Of Alzheimer's Disease. *Neurobiol Aging*. 2012 Aug;33(8):1599-608. ADNI
355. Xu J, Kober H, Carroll KM, Rounsaville BJ, **Pearlson GD**, Potenza MN. White matter integrity and behavioral activation in healthy subjects. *Hum Brain Mapp*. 2012 Apr;33(4):994-1002.
356. Moscufo N, Wolfson L, Meier D, Liguori M, Hildenbrand PG, Wakefield D, Schmidt JA, **Pearlson GD**, Guttman CR. Mobility decline in the elderly relates to lesion accrual in the splenium of the corpus callosum. *Age (Dordr)*. 2012 Apr;34(2):405-14.
357. Du W, Calhoun VD, Li H, MA S, Eichele T, Kiehl KA, **Pearlson GD**, Adali T. High classification accuracy for schizophrenia with rest and task fMRI Data. *Front Hum Neurosci*. 2012;6:145.
358. Bonner-Jackson A, Okonkwo O, Tremont G; Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E  $\epsilon$ 2 and functional decline in amnesic mild cognitive impairment and Alzheimer disease. *Am J Geriatr Psychiatry*. 2012 Jul;20(7):584-93. ADNI
359. Urban NB, Slifstein M, Meda S, Xu X, Ayoub R, Medina O, **Pearlson GD**, Krystal JH, Abi-Dargham A. Imaging human reward processing with positron emission tomography and functional magnetic resonance imaging. *Psychopharmacology (Berl)*. 2012 May;221(1):67-77.
360. Gee DG, Karlsgodt KH, van Erp TG, Bearden CE, Lieberman MD, Belger A, Perkins DO, Olivet DM, Cornblatt BA, Constable T, Woods SW, Addington J, Cadenhead KS, McGlashan TH, Seidman LJ, Tsuang MT, Walker EF, Cannon TD; NAPLS Consortium. Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: a preliminary study. *Schizophr Res*. 2012 Jan;134(1):1-9. NAPLS
361. Calhoun VD, **Pearlson GD**. A selective review of simulated driving studies: Combining naturalistic and hybrid paradigms, analysis approaches, and future directions. *Neuroimage*. 2012 Jan 2;59(1):25-35.
362. Kerestes R, Ladouceur CD, Meda S, Nathan PJ, Blumberg HP, Maloney K, Ruf B, Saricicek A, **Pearlson GD**, Bhagwagar Z, Phillips ML. Abnormal prefrontal activity subserving attentional control of emotion in remitted depressed patients during a working memory task with emotional distracters. *Psychol Med*. 2012 Jan;42(1):29-40.
363. Rasmussen JM, Lakatos A, van Erp TG, Kruggel F, Keator DB, Fallon JT, Macciardi F, Potkin SG; Alzheimer's Disease Neuroimaging Initiative. Empirical derivation of the reference region for computing diagnostic sensitive  $^1$ fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample. *Biochim Biophys Acta*. 2012 Mar;1822(3):457-66. ADNI
364. Xu L, Adali T, Schretlen D, **Pearlson GD**, Calhoun VD. Structural angle and power images reveal interrelated gray and white matter abnormalities in schizophrenia. *Neurol Res Int*. 2012;2012:735249.
365. Ginley MK, Whelan JP, Meyers AW, Relyea GE, **GD Pearlson**. Exploring a multidimensional approach to impulsivity in predicting college student gambling. *Journal of Gambling Studies*. March 2013. In press
366. Jamadar SD, **Pearlson GD**, O'Neil KM, Assaf M. Semantic association fMRI impairments represent a potential schizophrenia biomarker. *Schizophr Res*. 2013 Apr;145(1-3):20-6.
367. Sui J, He H, Liu J, Yu Q, Adali T, **Pearlson GD**, Calhoun VD. Three-way FMRI-DTI-methylation data fusion based on mCCA+jICA and its application to schizophrenia. *Conf Proc IEEE Eng Med Biol Soc*. 2012 Aug;2012:2692-5.



368. Yu Q, Allen EA, Sui J, Arbabshirani MR, **Pearlson GD**, Calhoun VD. Brain connectivity networks in schizophrenia underlying resting state functional magnetic resonance imaging. Curr Top Med Chem. 2012 Nov 1;12(21):2415-25.
369. Cope LM, Shane MS, Segall JM, Nyalakanti PK, Stevens MC, **Pearlson GD**, Calhoun VD, Kiehl KA. Examining the effect of psychopathic traits on gray matter volume in a community substance abuse sample. Psychiatry Res. 2012 Nov 30;204(2-3)
370. Tighe SK, Reading SA, Rivkin P, Caffo B, Schweizer B, **Pearlson GD**, Potash JB, Depaulo JR, Bassett SS. Total white matter hyperintensity volume in bipolar disorder patients and their healthy relatives. Bipolar Disord. 2012 Dec;14(8):888-93.
371. Sui J, He H, **Pearlson GD**, Adali T, Kiehl KA, Yu Q, Clark VP, Castro E, White T, Mueller BA, Ho BC, Andreasen NC, Calhoun VD. Three-way (N-way) fusion of brain imaging data based on mCCA+jICA and its application to discriminating schizophrenia. Neuroimage. 2012 Oct 26;66C:119-132.
372. Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saks JA, D'Souza DC, **Pearlson GD**, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Eur Neuropsychopharmacology. 2013 Aug;23(8):931-40.
373. Balodis IM, Kober H, Worhunsky PD, White MA, Stevens MC, **Pearlson GD**, Sinha R, Grilo CM, Potenza MN. Monetary reward processing in obese individuals with and without binge eating disorder. Biological Psychiatry. 2013 May 1;73(9):877-86.
374. Narayanan B, Stevens MC, Jiantonio RE, Krystal JH, **Pearlson GD**. Effects of memantine on event-related potential, oscillations, and complexity in individuals with and without family histories of alcoholism. J Stud Alcohol Drugs. 2013 Mar;74(2):245-57.
375. Yu Q, Sui J, Liu J, Plis SM, Kiehl KA, **Pearlson GD**, Calhoun VD. Disrupted correlation between low frequency power and connectivity strength of resting state brain networks in schizophrenia. Schizophr Res. 2013 Jan;143(1):165-71.
376. Dager AD, Anderson BM, Stevens MC, Pulido C, Rosen R, Jiantonio-Kelly RE, Sisante JF, Raskin SA, Tennen H, Austad CS, Wood RM, Fallahi CR, **Pearlson GD**. Influence of alcohol use and family history of alcoholism on neural response to alcohol cues in college drinkers. Alcohol Clin Exp Res. 2013 Jan;37 Suppl 1:E161-71.
377. Patel KT, Stevens MC, **Pearlson GD**, Winkler AM, Hawkins KA, Skudlarski P, Bauer LO. Default mode network activity and white matter integrity in healthy middle-aged ApoE4 carriers. Brain Imaging Behav. 2013 Mar;7(1):60-7.
378. Jamadar S, O'Neil KM, **Pearlson GD**, Ansari M, Gill A, Jagannathan K, Assaf M. Impairment in semantic retrieval is associated with symptoms in schizophrenia but not bipolar disorder. Biol Psychiatry. 2013 Mar 15;73(6):555-64.
379. Anticevic A, Brumbaugh MS, Winkler AM, Lombardo LE, Barrett J, Corlett PR, Kober H, Gruber J, Repovs G, Cole MW, Krystal JH, **Pearlson GD**, Glahn DC. Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history. Biol Psychiatry. 2013 Mar 15;73(6):565-73.
380. Jamadar S, Assaf M, Jagannathan K, Anderson K, **Pearlson GD**. Figural memory performance and functional magnetic resonance imaging activity across the adult lifespan. Neurobiol Aging. 2013 Jan;34(1):110-27.
381. *Han SD, Gruhl J, Beckett L, Dodge HH, Stricker NH, Farias S, Mungas D; Alzheimer's Disease Neuroimaging Initiative. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease. Brain Imaging Behav. 2012 Dec;6(4):610-20. ADNI*

382. Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, Curtis SM, Mungas D, Crane PK; Alzheimer's Disease Neuroimaging Initiative. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. *Brain Imaging Behav.* 2012 Dec;6(4):517-27. ADNI
383. Stricker NH, Dodge HH, Dowling NM, Han SD, Erosheva EA, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. *Brain Imaging Behav.* 2012 Dec;6(4):599-609. ADNI
384. Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, Gibbons LE; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. *Brain Imaging Behav.* 2012 Dec;6(4):489-501. ADNI
385. Holland D, Desikan RS, Dale AM, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative. Rates of decline in Alzheimer disease decrease with age. *PLoS One.* 2012;7(8) ADNI
386. Ramanan VK, Kim S, Holohan K, Shen L, Nho K, Risacher SL, Foroud TM, Mukherjee S, Crane PK, Aisen PS, Petersen RC, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI). Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. *Brain Imaging Behav.* 2012 Dec;6(4):634-48. ADNI
387. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoek C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group. Blood-based protein biomarkers for diagnosis of Alzheimer disease. *Arch Neurol.* 2012 Oct;69(10):1318-25. ADNI
388. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HJ, Trojanowski JQ, Shaw LM; Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. *Arch Neurol.* 2012 Oct;69(10):1310-7. ADNI
389. Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D, Weiner M, Mungas D; Alzheimer's Disease Neuroimaging Initiative. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Brain Imaging Behav.* 2012 Dec;6(4):502-16. ADNI
390. Park LQ, Gross AL, McLaren DG, Pa J, Johnson JK, Mitchell M, Manly JJ; Alzheimer's Disease Neuroimaging Initiative. Confirmatory factor analysis of the ADNI Neuropsychological Battery. *Brain Imaging Behav.* 2012 Dec;6(4):528-39. ADNI
391. Domoto-Reilly K, Sapolsky D, Brickhouse M, Dickerson BC; Alzheimer's Disease Neuroimaging Initiative. Naming impairment in Alzheimer's disease is associated with left anterior temporal lobe atrophy. *Neuroimage.* 2012 Oct 15;63(1):348-55. ADNI
392. Gross AL, Manly JJ, Pa J, Johnson JK, Park LQ, Mitchell MB, Melrose RJ, Inouye SK, McLaren DG; Alzheimer's Disease Neuroimaging Initiative. Cortical signatures of cognition and their relationship to Alzheimer's disease. *Brain Imaging Behav.* 2012 Dec;6(4):584-98. ADNI
393. Mukherjee S, Kim S, Gibbons LE, Nho K, Risacher SL, Glymour MM, Habeck C, Lee GJ, Mormino E, Ertekin-Taner N, Montine TJ, Decarli C, Saykin AJ, Crane PK; Alzheimer's Disease Neuroimaging Initiative. Genetic architecture of resilience of executive functioning. *Brain Imaging Behav.* 2012 Dec;6(4):621-33. ADNI

394. Reitz C, Tosto G, Mayeux R, Luchsinger JA; NIA-LOAD/NCRAD Family Study Group; Genetic variants in the Fat and Obesity Associated (FTO) gene and risk of Alzheimer's disease. *Alzheimer's Disease Neuroimaging Initiative. PLoS One.* 2012;7(12) ADNI
395. Swaminathan S, Huentelman MJ, Corneveaux JJ, Myers AJ, Faber KM, Foroud T, Mayeux R, Shen L, Kim S, Turk M, Hardy J, Reiman EM, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative and NIA-LOAD/NCRAD Family Study Group. Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. *PLoS One.* 2012;7(12) ADNI
396. Habeck C, Risacher S, Lee GJ, Glymour MM, Mormino E, Mukherjee S, Kim S, Nho K, DeCarli C, Saykin AJ, Crane PK; Alzheimer's Disease Neuroimaging Initiative. Relationship between baseline brain metabolism measured using PET and memory and executive function in prodromal and early Alzheimer's disease. *Brain Imaging Behav.* 2012 Dec;6(4):568-83. ADNI
397. Mukherjee S, Trittschuh E, Gibbons LE, Mackin RS, Saykin A, Crane PK; Alzheimer's Disease Neuroimaging Initiative. Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI. *Brain Imaging Behav.* 2012 Dec;6(4):649-60. ADNI
398. Casanova R, Hsu FC, Espeland MA; Alzheimer's Disease Neuroimaging Initiative. Classification of structural MRI images in Alzheimer's disease from the perspective of ill-posed problems. *PLoS One.* 2012;7(10). ADNI
399. Nho K, Risacher SL, Crane PK, DeCarli C, Glymour MM, Habeck C, Kim S, Lee GJ, Mormino E, Mukherjee S, Shen L, West JD, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative--ADNI. Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. *Brain Imaging Behav.* 2012 Dec;6(4):551-67. ADNI
400. Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A, Westman E, Pike I, Ward M, Johnston C, Lupton MK, Lunnon K, Soininen H, Kloszewska I, Tsolaki M, Vellas B, Mecocci P, Lovestone S, Newhouse S, Dobson R; Alzheimers Disease Neuroimaging Initiative. Plasma based markers of [11C] PiB-PET brain amyloid burden. *PLoS One.* 2012;7(9) ADNI
401. Lo RY, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Vascular burden and Alzheimer disease pathologic progression. *Neurology.* 2012 Sep 25;79(13):1349-55. ADNI
402. Augustinack JC, Huber KE, Stevens AA, Roy M, Frosch MP, van der Kouwe AJ, Wald LL, Van Leemput K, McKee AC, Fischl B; Alzheimer's Disease Neuroimaging Initiative. Predicting the location of human perirhinal cortex, Brodmann's area 35, from MRI. *Neuroimage.* 2013 Jan 1;64:32-42. ADNI
403. Jamadar S, Powers NR, Meda SA, Calhoun VD, Gelernter J, Gruen JR, **Pearlson GD**. Genetic influences of resting state fMRI activity in language-related brain regions in healthy controls and schizophrenia patients: a pilot study. *Brain Imaging Behav.* 2013 Mar;7(1):15-27.
404. Gray KR, Aljabar P, Heckemann RA, Hammers A, Rueckert D; Alzheimer's Disease Neuroimaging Initiative. Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. *Neuroimage.* 2013 Jan 15. ADNI
405. Eskildsen SF, Coupé P, García-Lorenzo D, Fonov V, Pruessner JC, Collins DL; Alzheimer's Disease Neuroimaging Initiative. Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. *Neuroimage.* 2013 Jan 15;65:511-21. ADNI
406. Rajagopalan P, Toga AW, Jack CR, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative. Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. *Neuroreport.* 2013 Jan 23;24(2):58-62. ADNI

407. Ross DE, Ochs AL, Seabaugh JM, Shrader CR; Alzheimer's Disease Neuroimaging Initiative. Man versus machine: comparison of radiologists' interpretations and NeuroQuant volumetric analyses of brain MRIs in patients with traumatic brain injury. *J Neuropsychiatry Clin Neurosci*. 2013 Winter;25(1):32-9. ADNI
408. Keshavan MS, Clementz BA, **Pearlson GD**, Sweeney JA, Tamminga CA. Reimagining psychoses: An agnostic approach to diagnosis. *Schizophr Res*. 2013 May;146(1-3):10-6.
409. Devito EE, Meda SA, Jiantonio R, Potenza MN, Krystal JH, **Pearlson GD**. Neural correlates of impulsivity in healthy males and females with family histories of alcoholism. *Neuropsychopharmacology*. 2013 Sep;38(10):1854-63.
410. Xu J, Zhang S, Calhoun VD, Monterosso J, Li CS, Worhunsky PD, Stevens M, **Pearlson GD**, Potenza MN. Task-related concurrent but opposite modulations of overlapping functional networks as revealed by spatial ICA. *Neuroimage*. 2013 Apr 21. S1053-8119(13)00385-6.
411. Schretlen DJ, Peña J, Aretouli E, Orue I, Cascella NG, **Pearlson GD**, Ojeda N. Confirmatory factor analysis reveals a latent cognitive structure common to bipolar disorder, schizophrenia, and normal controls. *Bipolar Disord*. 2013 Jun;15(4):422-33.
412. Skudlarski P, Schretlen D, Thaker G, Stevens MC, Keshavan M, Sweeney J, Tamminga C, Clementz B, O'Neil K, **Pearlson GD**. Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. *American Journal of Psychiatry*. 2013 Aug;170(8):886-98.
413. Ahmadi A, **Pearlson GD**, Meda S, Dager A, Potenza M, Rosen R, Austad CS, Raskin SA, Fallahi CR, Tennen H, Wood RM, Stevens MC. Influence of alcohol use on neural response to Go/No-Go task in college drinkers. *Neuropsychopharmacology*. 2013 Oct;38(11):2197-208.
414. Tamminga C, Ivleva E, Keshavan MS, **Pearlson GD**, Clementz BA, Witte B, Morris D, Bishop J, Elliott A, Thaker G, Sweeney J. Clinical phenotypes of psychosis in the bipolar and schizophrenia network on intermediate phenotypes (B-SNIP). *American Journal of Psychiatry*. 2013 Nov;170(11):1263-74.
415. Khadka S, Meda S, Stevens MC, Glahn D, Calhoun V, Sweeney J, Tamminga C, Keshavan M, **Pearlson GD**. Is aberrant functional connectome as psychosis endophenotype? A resting state functional Magnetic Resonance Imaging study. *Biological Psychiatry*. 2013 Sep 15;74(6):458-66.
416. Patel K, Stevens MC, Meda SA, Muska C, Thomas AD, Potenza MN, **Pearlson GD**. Robust changes in reward circuitry during reward loss in current and former cocaine users during performance of a monetary incentive delay task. *Biological Psychiatry*. 2013 Oct 1;74(7):529-37.
417. Jahanshad N, Rajagopalan P, Hua X, Hibar DP, Nir TM, Toga AW, Jack CR Jr, Saykin AJ, Green RC, Weiner MW, Medland SE, Montgomery GW, Hansell NK, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Thompson PM; the Alzheimer's Disease Neuroimaging Initiative. Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. *Proc Natl Acad Sci U S A*. 2013 Mar 19;110(12):4768-73. ADNI
418. Nanda P, Tandon N, Mathew IT, Giakoumatos CI, Abhishekh HA, Clementz BA, **Pearlson GD**, Sweeney J, Tamminga CA, Keshavan MS. Local gyrification index in Probands with psychotic disorders and their first-degree relatives. *Biological Psychiatry*. 2014 Sept 15;76(6):447-55.
419. He BJ, Nolte G, Nagata K, **Pearlson GD** et al. Abstracts of presentations at the International Conference on Basic and Clinical Multimodal Imaging (BaCI), a joint Conference of the International Society for Neuroimaging in Psychiatry (ISNIP), the International Society for Functional Source Imaging (ISFSI), the International Society for Bioelectromagnetism (ISBEM), the International Society for Brain Electromagnetic Topography (ISBET) and the EEG and Clinical Neuroscience Society (ECNS), in Geneva, Switzerland, September 5-8, 2013. *Clinical EEG Neuroscience*. 2013 Dec 24.

420. Dager AD, Anderson BM, Rosen R, Khadka S, Sawyer B, Jiantonio-Kelly RE, Austad CS, Raskin SA, Tennen H, Wood RM, Fallahi CR, **Pearlson GD**. fMRI Response to alcohol pictures predicts subsequent transition to heavy drinking in college students. Addiction. 2014 Apr;109(4):585-95.
421. Assaf M, Hyatt CJ, Wong CG, Johnson MR, Schultz RT, Hendler T, **Pearlson GD**. Mentalizing and motivation neural function during social interactions in autism spectrum disorders. Neuroimage Clinical. 2013 Sep 19;3:321-31.
422. Steele VR, Fink BC, Maurer JM, Arbshirani MR, Wilber CH, Jaffe AJ, Sidz A, **Pearlson GD**, Calhoun VD, Clark VP, Kiehl KA. Brain Potentials measured during a Go/NoGo Task predict completion of substance abuse treatment. Biological Psychiatry. 2014 Jul 1;76(1):75-83.
423. Sprooten E, Brumbaugh MS, Knowles EE, McKay DR, Lewis J, Barrett J, Landau S, Cyr L, Kochunov P, Winkler AM, **Pearlson GD**, Glahn DC. Reduced white matter integrity in sibling pairs discordant for bipolar disorder. American Journal of Psychiatry. 2013 Nov 1;170(11):1317-25.
424. Ivleva EI, Bidesi AS, Keshavan MS, **Pearlson GD**, Meda SA, Dodig D, Moates AF, Lu H, Francis AN, Tandon N, Schretlen DJ, Sweeney JA, Clementz BA, Tamminga CA. Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). American Journal of Psychiatry. 2013 Nov 1;170(11):1285-96.
425. Cavallari M, Moscufo N, Skudlarski P, Meier D, Panzer VP, **Pearlson GD**, White WB, Wolfson L, Guttman CR. Mobility impairment is associated with reduced microstructural integrity of the inferior and superior cerebellar peduncles in elderly with no clinical signs of cerebellar dysfunction. Neuroimage Clinical. 2013 Mar 1;2:332-40.
426. Yu Q, Sui J, Kiehl KA, **Pearlson GD**, Calhoun VD. State-related functional integration and functional segregation brain networks in schizophrenia. Schizophrenia Research. 2013 Nov;150(2-3):450-8.
427. Reilly JL, Frankovich K, Hill S, Gershon ES, Keefe RS, Keshavan MS, **Pearlson GD**, Tamminga CA, Sweeney JA. Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories. Schizophrenia Bulletin. 2014 Sep;40(5):1011-21.
428. Teeters JB, Ginley MK, Whelan JP, Meyers AW, **Pearlson GD**. The moderating effect of gender on the relation between expectancies and gambling frequency among college students. Journal of Gambling Studies. 2015 Mar;31(1):173-82.
429. Holt LJ, Armeli S, Tennen H, Austad CS, Raskin SA, Fallahi CR, Wood R, Rosen RI, Ginley MK, **Pearlson GD**. A person-centered approach to understanding negative reinforcement drinking among first year college students. Addictive Behaviors. 2013 Dec;38(12):2937-44.
430. Fryer SL, Woods SW, Kiehl KA, Calhoun VD, **Pearlson GD**, Roach BJ, Ford JM, Srihari VH, McGlashan TH, Mathalon DH. Deficient suppression of default mode regions during working memory in individuals with early psychosis and at clinical high-risk for psychosis. Frontiers in Psychiatry. 2013 Sep 10;4:92.
431. *Bryant C, Giovanello KS, Ibrahim JG, Chang J, Shen D, Peterson BS, Zhu H; Alzheimer's Disease Neuroimaging Initiative. Mapping the genetic variation of regional brain volumes as explained by all common SNPs from the ADNI study. PLoS One. 2013 Aug 28;8(8). ADNI*
432. Rosenfeld ES, **Pearlson GD**, Sweeney JA, Tamminga CA, Keshavan MS, Nonterah C, Stevens MC. Prolonged hemodynamic response during incidental facial emotion processing in inter-episode bipolar I disorder. Brain Imaging Behaviors. 2014 Mar;8(1):73-86.
433. Ginley MK, Whelan JP, Relyea GE, Meyers AW, **Pearlson GD**. Testing the acquired preparedness model: Predicting college student gambling frequency and symptomatology. J Gambli Stud. 2015 Sep;31(3):907-19.

434. Arbabshirani MR, Kiehl KA, **Pearlson GD**, Calhoun VD. Classification of schizophrenia patients based on resting-state functional network connectivity. Frontiers in Neuroscience. 2013 Jul 30;7:133.
435. Castelluccio BC, Meda SA, Muska CE, Stevens MC, **Pearlson GD**. Error processing in current and former cocaine users. Brain Imaging Behavior. 2014 Mar;8(1):87-96.
436. Dager AD, Jamadar S, Stevens MC, Rosen R, Jiantonio-Kelly RE, Sisante JF, Raskin SA, Tennen H, Austad CS, Wood RM, Fallahi CR, **Pearlson GD**. fMRI response during figural memory task performance in college drinkers. Psychopharmacology (Berl). 2014 Jan;231(1):167-79.
437. Hamm JP, Ethridge LE, Shapiro JR, **Pearlson GD**, Tamminga CA, Sweeney JA, Keshavan MS, Thaker GK, Clementz BA. Family history of psychosis moderates early auditory cortical response abnormalities in non-psychotic bipolar disorder. Bipolar Disorders. 2013 Nov;15(7):774-86.
438. Ginley MK, Whelan JP, Relyea GE, Simmons JL, Meyers AW, **Pearlson GD**. College Student Beliefs About Wagering: An Evaluation of the Adolescent Gambling Expectancies Survey. Journal of Gambling Studies. 2015 Mar;31(1):161-71.
439. Book GA, Anderson BM, Stevens MC, Glahn DC, Assaf M, **Pearlson GD**. Neuroinformatics Database (NiDB)--a modular, portable database for the storage, analysis, and sharing of neuroimaging data. Neuroinformatics. 2013 Oct;11(4):495-505.
440. Giakoumatos CI, Tandon N, Shah J, Mathew IT, Brady RO, Clementz BA, **Pearlson GD**, Thaker GK, Tamminga CA, Sweeney JA, Keshavan MS. Are structural brain abnormalities associated with suicidal behavior in patients with psychotic disorders? Journal Psychiatry Research. 2013 Oct;47(10):1389-95.
441. Tamminga CA, Ivleva EI, Keshavan MS, **Pearlson GD**, Clementz BA, Witte B, Morris DW, Bishop J, Thaker GK, Sweeney JA. Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). American Journal Psychiatry. 2013 Nov 1;170(11):1263-74.
442. Liu CY, Iglesias JE, Tu Z; Alzheimer's Disease Neuroimaging Initiative. Deformable templates guided discriminative models for robust 3D brain MRI segmentation. Neuroinformatics. 2013 Oct;11(4):447-68. ADNI
443. Anticevic A, Cole MW, Repovs G, Murray JD, Brumbaugh MS, Winkler AM, Savic A, Krystal JH, **Pearlson GD**, Glahn DC. Characterizing thalamo-cortical disturbances in schizophrenia and bipolar illness. Cerebral Cortex. 2014 Dec;24(12):3116-30.
444. Unschuld PG, Buchholz AS, Varvaris M, van Zijl PC, Ross CA, Pekar JJ, Hock C, Sweeney JA, Tamminga CA, Keshavan MS, **Pearlson GD**, Thaker GK, Schretlen DJ. Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction. Schizophrenia Bulletin. 2014 May;40(3):653-64.
445. Patel KT, Stevens MC, Meda SA, Muska C, Thomas AD, Potenza MN, **Pearlson GD**. Robust changes in reward circuitry during reward loss in current and former cocaine users during performance of a monetary incentive delay task. Biological Psychiatry. 2013 Oct 1;74(7):529-37.
446. Iglesias JE, Sabuncu MR, Van Leemput K; Alzheimer's Disease Neuroimaging Initiative. Improved inference in Bayesian segmentation using Monte Carlo sampling: application to hippocampal subfield volumetry. Medical Image Analysis. 2013 Oct;17(7):766-78. ADNI
447. Skudlarski P, Schretlen DJ, Thaker GK, Stevens MC, Keshavan MS, Sweeney JA, Tamminga CA, Clementz BA, O'Neil K, **Pearlson GD**. Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. American Journal Psychiatry. 2013 Aug 1;170(8):886-98.

448. Steele VR, Aharoni E, Munro GE, Calhoun VD, Nyalakanti P, Stevens MC, **Pearlson GD**, Kiehl KA. A large scale (N=102) functional neuroimaging study of response inhibition in a Go/NoGo task. Behavioral Brain Research. 2013 Nov 1;256:529-36.
449. Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, Gershon ES, Tamminga CA, **Pearlson GD**, Keshavan MS, Sweeney JA. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. American Journal Psychiatry. 2013 Nov 1;170(11):1275-84.
450. Sui J, He H, Yu Q, Chen J, Rogers J, **Pearlson GD**, Mayer A, Bustillo J, Canive J, Calhoun VD. Combination of resting state fMRI, DTI, and sMRI data to discriminate schizophrenia by N-way MCCA+jICA. Frontiers Human Neuroscience. 2013 May 29;7:235.
451. Chen J, Calhoun VD, **Pearlson GD**, Perrone-Bizzozero N, Sui J, Turner JA, Bustillo JR, Ehrlich S, Sponheim SR, Cañive JM, Ho BC, Liu J. Guided exploration of genomic risk for gray matter abnormalities in schizophrenia using parallel independent component analysis with reference. Neuroimage. 2013 Dec;83:384-96.
452. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboya S, Lee M, Von Korff A; Alzheimer Disease Neuroimaging Initiative, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nature Neuroscience. 2013 Jul;16(7):848-50. ADNI
453. Martínez-Murcia FJ, Górriz JM, Ramírez J, Puntonet CG, Illán IA; Alzheimer's Disease Neuroimaging Initiative. Functional activity maps based on significance measures and Independent Component Analysis. Computer Methods and Programs in Biomedicine. 2013 Jul;111(1):255-68.
454. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB; Alzheimer's Disease Neuroimaging Initiative. Brain changes in older adults at very low risk for Alzheimer's disease. Journal Neuroscience. 2013 May 8;33(19):8237-42. ADNI
455. Dukart J, Kherif F, Mueller K, Adaszewski S, Schroeter ML, Frackowiak RS, Draganski B; Alzheimer's Disease Neuroimaging Initiative. Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease. PLoS Computer Biology. 2013 Apr;9(4). ADNI
456. Dai Y, Wang Y, Wang L, Wu G, Shi F, Shen D; Alzheimer's Disease Neuroimaging Initiative. aBEAT: a toolbox for consistent analysis of longitudinal adult brain MRI. PLoS One. 2013;8(4). ADNI
457. Tong T, Wolz R, Coupé P, Hajnal JV, Rueckert D; Alzheimer's Disease Neuroimaging Initiative. Segmentation of MR images via discriminative dictionary learning and sparse coding: application to hippocampus labeling. Neuroimage. 2013 Aug 1;76:11-23. ADNI
458. Cheng B, Zhang D, Chen S, Kaufer DI, Shen D; Alzheimer's Disease Neuroimaging Initiative. Semi-supervised multimodal relevance vector regression improves cognitive performance estimation from imaging and biological biomarkers. Neuroinformatics. 2013 Jul;11(3):339-53. ADNI
459. Derado G, Bowman FD, Zhang L; Alzheimer's Disease Neuroimaging Initiative Investigators. Predicting brain activity using a Bayesian spatial model. Statistical Methods in Medical Research. 2013 Aug;22(4):382-97. ADNI
460. Ortiz A, Górriz JM, Ramírez J, Martínez-Murcia FJ; Alzheimer's Disease Neuroimaging Initiative. Automatic ROI selection in structural brain MRI using SOM 3D projection. PLoS One. 2014 Apr 11;9(4):e93851. ADNI
461. Mattsson N, Insel P, Tosun D, Zhang J, Jack CR Jr, Galasko D, Weiner M; Alzheimer's Disease Neuroimaging Initiative. Effects of baseline CSF  $\alpha$ -synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. PLoS One. 2013 Dec 31;8(12). ADNI

462. Yang GJ, Murray JD, Repovs G, Cole MW, Savic A, Glasser MF, Pittenger C, Krystal JH, Wang XJ, **Pearlson GD**, Glahn DC, Anticevic A. Altered global brain signal in schizophrenia. Proc Natl Acad Sci U S A. 2014 May 20;111(20):7438-43.
463. Meda SA, Ruaño G, Windemuth A, O'Neil K, Berwise C, Dunn SM, Boccaccio LE, Narayanan B, Kocherla M, Sprooten E, Keshavan MS, Tamminga CA, Sweeney JA, Clementz BA, Calhoun VD, **Pearlson GD**. Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia. Proc Natl Acad Sci U S A. 2014 May 13;111(19).
464. Cetin MS, Christensen F, Abbott CC, Stephen JM, Mayer AR, Cañive JM, Bustillo JR, **Pearlson GD**, Calhoun VD. Thalamus and posterior temporal lobe show greater inter-network connectivity at rest and across sensory paradigms in schizophrenia. Neuroimage. 2014 Aug 15;97:117-26.
465. Balodis IM, Grilo CM, Kober H, Worhunsky PD, White MA, Stevens MC, **Pearlson GD**, Potenza MN. A pilot study linking reduced fronto-striatal recruitment during reward processing to persistent bingeing following treatment for binge-eating disorder. Int J Eat Disord. 2014 May;47(4):376-84.
466. **Pearlson GD**, Ford JM. Distinguishing between schizophrenia and other psychotic disorders. Schizophr Bull. 2014 May;40(3):501-3.
467. Hamm JP, Ethridge LE, Boutros NN, Keshavan MS, Sweeney JA, **Pearlson GD**, Tamminga CA, Clementz BA. Diagnostic specificity and familiarity of early versus late evoked potentials to auditory paired stimuli across the schizophrenia-bipolar psychosis spectrum. Psychophysiology. 2014 Apr;51(4):348-57.
468. *Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain. 2014 May;137(Pt 5):1550-61. ADNI*
469. *Pérez-Palma E, Bustos BI, Villamán CF, Alarcón MA, Avila ME, Ugarte GD, Reyes AE, Opazo C, De Ferrari GV; Alzheimer's Disease Neuroimaging Initiative; NIA-LOAD/NCRAD Family Study Group. Overrepresentation of glutamate signaling in Alzheimer's disease: network-based pathway enrichment using meta-analysis of genome-wide association studies. PLoS One. 2014 Apr 22;9(4):e95413. ADNI*
470. Xu J, Calhoun VD, **Pearlson GD**, Potenza MN. Opposite modulation of brain functional networks implicated at low vs. high demand of attention and working memory. PLoS One. 2014 Jan 31;9(1).
471. *Thompson PM, Stein JL, Medland SE; Alzheimer's Disease Neuroimaging Initiative. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav. 2014 Jun;8(2):153-82. ADNI*
472. *Zhong Y, Huang L, Cai S, Zhang Y, von Deneen KM, Ren A, Ren J; Alzheimer's Disease Neuroimaging Initiative. Altered effective connectivity patterns of the default mode network in Alzheimer's disease: an fMRI study. Neurosci Lett. 2014 Aug 22;578:171-5. ADNI*
473. *Durazzo TC, Mattsson N, Weiner MW, Korecka M, Trojanowski JQ, Shaw LM; Alzheimer's Disease Neuroimaging Initiative. History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. Drug Alcohol Depend. 2014 Sep 1;142:262-8. ADNI*
474. *Paterson RW, Bartlett JW, Blennow K, Fox NC; Alzheimer's Disease Neuroimaging Initiative, Shaw LM, Trojanowski JQ, Zetterberg H, Schott JM. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry. 2014 Jul 29;4:e419. ADNI*
475. Dager AD, Anderson BM, Rosen R, Khadka S, Sawyer B, Jiantonio-Kelly RE, Austad CS, Raskin SA, Tennen H, Wood RM, Fallahi CR, **Pearlson GD**. Functional magnetic resonance imaging



- (fMRI) response to alcohol pictures predicts subsequent transition to heavy drinking in college students. *Addiction*. 2014 Apr;109(4):585-95.
476. Tamminga CA, **Pearlson GD**, Keshavan M, Sweeney J, Clementz B, Thaker G. Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum. *Schizophr Bull*. 2014 Mar;40 Suppl 2:S131-7.
477. Rosenfeld ES, **Pearlson GD**, Sweeney JA, Tamminga CA, Keshavan MS, Nonterah C, Stevens MC. Prolonged hemodynamic response during incidental facial emotion processing in inter-episode bipolar I disorder. *Brain Imaging Behav*. 2014 Mar;8(1):73-86.
478. Zhang Y, Xu Z, Shen X, Pan W; *Alzheimer's Disease Neuroimaging Initiative* Testing for association with multiple traits in generalized estimation equations, with application to neuroimaging data. *Neuroimage*. 2014 Aug 1;96:309-25.ADNI
479. Castelluccio BC, Meda SA, Muska CE, Stevens MC, **Pearlson GD**. Error processing in current and former cocaine users. *Brain Imaging Behav*. 2014 Mar;8(1):87-96.
480. Dager AD, Jamadar S, Stevens MC, Rosen R, Jiantonio-Kelly RE, Sisante JF, Raskin SA, Tennen H, Austad CS, Wood RM, Fallahi CR, **Pearlson GD**. fMRI response during figural memory task performance in college drinkers. *Psychopharmacology (Berl)*. 2014 Jan;231(1):167-79.
481. Unschuld PG, Buchholz AS, Varvaris M, van Zijl PC, Ross CA, Pekar JJ, Hock C, Sweeney JA, Tamminga CA, Keshavan MS, **Pearlson GD**, Thaker GK, Schretlen DJ. Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction. *Schizophr Bull*. 2014 May;40(3):653-64.
482. Ginley MK, Whelan JP, Meyers AW, Relyea GE, **Pearlson GD**. Exploring a multidimensional approach to impulsivity in predicting college student gambling. *J Gambli Stud*. 2014 Jun;30(2):521-36.
483. Ruocco AC, Reilly JL, Rubin LH, Daros AR, Gershon ES, Tamminga CA, **Pearlson GD**, Hill SK, Keshavan MS, Gur RC, Sweeney JA. Emotion recognition deficits in schizophrenia-spectrum disorders and psychotic bipolar disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. *Schizophr Res*. 2014 Sep;158(1-3):105-12.
484. Bridwell DA, Kiehl KA, **Pearlson GD**, Calhoun VD. Patients with schizophrenia demonstrate reduced cortical sensitivity to auditory oddball regularities. *Schizophr Res*. 2014 Sep;158(1-3):189-94.
485. Anticevic A, Yang G, Savic A, Murray JD, Cole MW, Repovs G, **Pearlson GD**, Glahn DC. Mediodorsal and visual thalamic connectivity differ in schizophrenia and bipolar disorder with and without psychosis history. *Schizophr Bull*. 2014 Nov;40(6):1227-43.
486. Damaraju E, Allen EA, Belger A, Ford JM, McEwen S, Mathalon DH, Mueller BA, **Pearlson GD**, Potkin SG, Preda A, Turner JA, Vaidya JG, van Erp TG, Calhoun VD. Dynamic functional connectivity analysis reveals transient states of dysconnectivity in schizophrenia. *Neuroimage Clin*. 2014 Jul 24;5:298-308.
487. Khadka S, Narayanan B, Meda SA, Gelernter J, Han S, Sawyer B, Aslanzadeh F, Stevens MC, Hawkins KA, Anticevic A, Potenza MN, **Pearlson GD**. Genetic association of impulsivity in young adults: a multivariate study. *Transl Psychiatry*. 2014 Sep 30;4.
488. Morean ME, DeMartini KS, Leeman RF, **Pearlson GD**, Anticevic A, Krishnan-Sarin S, Krystal JH, O'Malley SS. Psychometrically improved, abbreviated versions of three classic measures of impulsivity and self-control. *Psychol Assess*. 2014 Sep;26(3):1003-20.
489. Mathew I, Gardin TM, Tandon N, Eack S, Francis AN, Seidman LJ, Clementz B, **Pearlson GD**, Sweeney JA, Tamminga CA, Keshavan MS. Medial temporal lobe structures and hippocampal

- subfields in psychotic disorders: Findings from the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) study. *JAMA Psychiatry*. 2014 Jul 1;71(7):769-77.
490. Cavallari M, Moscufo N, Meier D, Skudlarski P, **Pearlson GD**, White WB, Wolfson L, Guttman CR. Thalamic fractional anisotropy predicts accrual of cerebral white matter damage in older subjects with small-vessel disease. *J Cereb Blood Flow Metab*. 2014 Aug;34(8):1321-7.
491. Narayanan B, O'Neil K, Berwise C, Stevens MC, Calhoun VD, Clementz BA, Tamminga CA, Sweeney JA, Keshavan MS, **Pearlson GD**. Resting state electroencephalogram oscillatory abnormalities in schizophrenia and psychotic bipolar patients and their relatives from the bipolar and schizophrenia network on intermediate phenotypes study. *Biol Psychiatry*. 2014 Sep 15;76(6):456-65.
492. Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Drogos LL, Hill SK, Ruocco AC, Keedy SK, Reilly JL, Keshavan MS, **Pearlson GD**, Tamminga CA, Gershon ES, Sweeney JA. Reduced levels of Vasopressin and reduced behavioral modulation of Oxytocin in psychotic disorders. *Schizophr Bull*. 2014 Nov;40(6):1374-84.
493. Ethridge LE, Soilleux M, Nakonezny PA, Reilly JL, Kristian Hill S, Keefe RS, Gershon ES, **Pearlson GD**, Tamminga CA, Keshavan MS, Sweeney JA. Behavioral response inhibition in psychotic disorders: Diagnostic specificity, familiarity and relation to generalized cognitive deficit. *Schizophr Res*. 2014 Nov;159(2-3):491-8.
494. Pérez-Palma E, Bustos BI, Villamán CF, Alarcón MA, Avila ME, Ugarte GD, Reyes AE, Opazo C, De Ferrari GV; Alzheimer's Disease Neuroimaging Initiative; NIA-LOAD/NCRAD Family Study Group. Overrepresentation of glutamate signaling in Alzheimer's disease: network-based pathway enrichment using meta-analysis of genome-wide association studies. *PLoS One*. 2014 Apr 22;9(4):e95413. ADNI
495. Donohue MC, Jacqmin-Gadda H, Le Goff M, Thomas RG, Raman R, Gamst AC, Beckett LA, Jack CR Jr, Weiner MW, Dartigues JF, Aisen PS; Alzheimer's Disease Neuroimaging Initiative. Estimating long-term multivariate progression from short-term data. *Alzheimers Dement*. 2014 Oct;10(5 Suppl):S400-10. ADNI
496. Armeli S, Dranoff E, Tennen H, Austad CS, Fallahi CR, Raskin S, Wood R, **Pearlson GD**. A longitudinal study of the effects of coping motives, negative affect and drinking level on drinking problems among college students. *Anxiety Stress Coping*. 2014;27(5):527-41.
497. Hahamy A, Calhoun V, **Pearlson GD**, Harel M, Stern N, Attar F, Malach R, Salomon R. Save the global: global signal connectivity as a tool for studying clinical populations with functional magnetic resonance imaging. *Brain Connect*. 2014 Aug;4(6):395-403.
498. Hill SK, Reilly JL, Ragazzino ME, Rubin LH, Bishop JR, Gur RC, Gershon ES, Tamminga CA, **Pearlson GD**, Keshavan MS, Keefe RS, Sweeney JA. Regressing to prior response preference after set switching implicates striatal dysfunction across psychotic disorders: Findings from the B-SNIP study. *Schizophr Bull*. 2015 Jul;41(4):940-50.
499. Rashid B, Damaraju E, **Pearlson GD**, Calhoun VD. Dynamic connectivity states estimated from resting fMRI Identify differences among schizophrenia, bipolar disorder, and healthy control subjects. *Front Hum Neurosci*. 2014 Nov 7;8:897.
500. Sui J, Castro E, He H, Bridwell D, Du Y, **Pearlson GD**, Jiang T, Calhoun VD. Combination of FMRI-SMRI-EEG data improves discrimination of schizophrenia patients by ensemble feature selection. *Conf Proc IEEE Eng Med Biol Soc*. 2014;2014:3889-92.
501. Yuhui Du, Jingyu Liu, Jing Sui, Hao He, **Pearlson GD**, Calhoun VD. Exploring difference and overlap between schizophrenia, schizoaffective and bipolar disorders using resting-state brain functional networks. *Conf Proc IEEE Eng Med Biol Soc*. 2014 Aug;2014:1517-20.

502. Gupta CN, Calhoun VD, Rachakonda S, Chen J, Patel V, Liu J, Segall J, Franke B, Zwiens MP, Arias-Vasquez A, Buitelaar J, Fisher SE, Fernandez G, van Erp TG, Potkin S, Ford J, Mathalon D, McEwen S, Lee HJ, Mueller BA, Greve DN, Andreassen O, Agartz I, Gollub RL, Sponheim SR, Ehrlich S, Wang L, **Pearlson GD**, Glahn DC, Sprooten E, Mayer AR, Stephen J, Jung RE, Canive J, Bustillo J, Turner JA. Patterns of gray matter abnormalities in schizophrenia based on an international mega-analysis. *Schizophr Bull*. 2015 Sep;41(5):1133-42.
503. Iturria-Medina Y, Sotero RC, Toussaint PJ, Evans AC; Alzheimer's Disease Neuroimaging Initiative. Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. *PLoS Comput Biol*. 2014 Nov 20;10(11):e1003956. ADNI
504. Gonen T, Sharon H, **Pearlson GD**, Hendler T. Moods as ups and downs of the motivation pendulum: revisiting reinforcement sensitivity theory (RST) in bipolar disorder. *Front Behav Neurosci*. 2014 Nov 3;8:378.
505. Calhoun VD, Miller R, **Pearlson GD**, Adalı T. The chronnectome: time-varying connectivity networks as the next frontier in fMRI data discovery. *Neuron*. 2014 Oct 22;84(2):262-74.
506. Dager AD, McKay DR, Kent JW Jr, Curran JE, Knowles E, Sprooten E, Göring HH, Dyer TD, **Pearlson GD**, Olvera RL, Fox PT, Lovallo WR, Duggirala R, Almasy L, Blangero J, Glahn DC. Shared genetic factors influence amygdala volumes and risk for alcoholism. *Neuropsychopharmacology*. 2015 Jan;40(2):412-20.
507. Lui S, Yao L, Xiao Y, Keedy SK, Reilly JL, Keefe RS, Tamminga CA, Keshavan MS, **Pearlson GD**, Gong Q, Sweeney JA. Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives. *Psychol Med*. 2015 Jan;45(1):97-108.
508. Ethridge LE, Hamm JP, **Pearlson GD**, Tamminga CA, Sweeney JA, Keshavan MS, Clementz BA. Event-related potential and time-frequency endophenotypes for schizophrenia and psychotic bipolar disorder. *Biol Psychiatry*. 2015 Jan 15;77(2):127-36.
509. Padmanabhan JL, Tandon N, Haller CS, Mathew IT, Eack SM, Clementz BA, **Pearlson GD**, Sweeney JA, Tamminga CA, Keshavan MS. Correlations between brain structure and symptom dimensions of psychosis in schizophrenia, schizoaffective, and psychotic bipolar I disorders. *Schizophr Bull*. 2015 Jan;41(1):154-62.
510. A, Savic A, Repovs G, Yang G, McKay DR, Sprooten E, Knowles EE, Krystal JH, **Pearlson GD**, Glahn DC. Ventral anterior cingulate connectivity distinguished nonpsychotic bipolar illness from psychotic bipolar disorder and schizophrenia. *Schizophr Bull*. 2015 Jan;41(1):133-43.
511. Arnold SJ, Ivleva EI, Gopal TA, Reddy AP, Jeon-Slaughter H, Sacco CB, Francis AN, Tandon N, Bidesi AS, Witte B, Poudyal G, **Pearlson GD**, Sweeney JA, Clementz BA, Keshavan MS, Tamminga CA. Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer). *Schizophr Bull*. 2015 Jan;41(1):233-49.
512. Xu J, Calhoun VD, Worhunsky PD, Xiang H, Li J, Wall JT, **Pearlson GD**, Potenza MN. Functional network overlap as revealed by fMRI using sICA and its potential relationships with functional heterogeneity, balanced excitation and inhibition, and sparseness of neuron activity. *PLoS One*. 2015 Feb 25;10(2).
513. Mattsson N, Insel PS, Aisen PS, Jagust W, Mackin S, Weiner M; Alzheimer's Disease Neuroimaging Initiative. Brain structure and function as mediators of the effects of amyloid on memory. *Neurology*. 2015 Mar 17;84(11):1136-44. ADNI
514. Narayanan B, Ethridge LE, O'Neil K, Dunn S, Mathew I, Tandon N, Calhoun VD, Rúaño G, Kocherla M, Windemuth A, Clementz BA, Tamminga CA, Sweeney JA, Keshavan MS, **Pearlson GD**. Genetic sources of subcomponents of event-related potential in the dimension of psychosis analyzed from the B-SNIP study. *Am J Psychiatry*. 2015 May;172(5):466-78.

515. **Pearlson GD**. Etiologic, Phenomenologic, and Endophenotypic Overlap of Schizophrenia and Bipolar Disorder. Annu Rev Clin Psychol. 2015;11:251-81.
516. Giakoumatos CI, Nanda P, Mathew IT, Tandon N, Shah J, Bishop JR, Clementz BA, **Pearlson GD**, Sweeney JA, Tamminga CA, Keshavan MS. Effects of lithium on cortical thickness and hippocampal subfield volumes in psychotic bipolar disorder. J Psychiatr Res. 2015 Feb;61:180-7.
517. *Leung KK, Malone IM, Ourselin S, Gunter JL, Bernstein MA, Thompson PM, Jack CR Jr, Weiner MW, Fox NC; Alzheimer's Disease Neuroimaging Initiative. Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement. Neuroimage. 2015 Feb 15;107:46-53. ADNI*
518. *Dowling NM, Johnson SC, Gleason CE, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. Neuroimage. 2015 Jan 15;105:357-68. ADNI*
519. *Moradi E, Pepe A, Gaser C, Huttunen H, Tohka J; Alzheimer's Disease Neuroimaging Initiative. Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects. Neuroimage. 2015 Jan 1;104:398-412. ADNI*
520. *Shi J, Stonnington CM, Thompson PM, Chen K, Gutman B, Reschke C, Baxter LC, Reiman EM, Caselli RJ, Wang Y; Alzheimer's Disease Neuroimaging Initiative. Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry. Neuroimage. 2015 Jan 1;104:1-20. ADNI*
521. Dager AD, McKay DR, Kent JW Jr, Curran JE, Knowles E, Sprooten E, Göring HH, Dyer TD, **Pearlson GD**, Olvera RL, Fox PT, Lovallo WR, Duggirala R, Almasy L, Blangero J, Glahn DC. Shared genetic factors influence amygdala volumes and risk for alcoholism. Neuropsychopharmacology. 2015 Jan;40(2):412-20.
522. Lui S, Yao L, Xiao Y, Keedy SK, Reilly JL, Keefe RS, Tamminga CA, Keshavan MS, **Pearlson GD**, Gong Q, Sweeney JA. Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives. Psychol Med. 2015 Jan;45(1):97-108.
523. Ethridge LE, Hamm JP, **Pearlson GD**, Tamminga CA, Sweeney JA, Keshavan MS, Clementz BA. Event-related potential and time-frequency endophenotypes for schizophrenia and psychotic bipolar disorder. Biol Psychiatry. 2015 Jan 15;77(2):127-36.
524. Padmanabhan JL, Tandon N, Haller CS, Mathew IT, Eack SM, Clementz BA, **Pearlson GD**, Sweeney JA, Tamminga CA, Keshavan MS. Correlations between brain structure and symptom dimensions of psychosis in schizophrenia, schizoaffective, and psychotic bipolar I disorders. Schizophr Bull. 2015 Jan;41(1):154-62.
525. Anticevic A, Savic A, Repovs G, Yang G, McKay DR, Sprooten E, Knowles EE, Krystal JH, **Pearlson GD**, Glahn DC. Ventral anterior cingulate connectivity distinguished nonpsychotic bipolar illness from psychotic bipolar disorder and schizophrenia. Schizophr Bull. 2015 Jan;41(1):133-43.
526. Arnold SJ, Ivleva EI, Gopal TA, Reddy AP, Jeon-Slaughter H, Sacco CB, Francis AN, Tandon N, Bidesi AS, Witte B, Poudyal G, **Pearlson GD**, Sweeney JA, Clementz BA, Keshavan MS, Tamminga CA. Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer). Schizophr Bull. 2015 Jan;41(1):233-49.
527. Teeters JB, Ginley MK, Whelan JP, Meyers AW, **Pearlson GD**. The moderating effect of gender on the relation between expectancies and gambling frequency among college students. J Gambli Stud. 2015 Mar;31(1):173-82.
528. Ginley MK, Whelan JP, Relyea GE, Simmons JL, Meyers AW, **Pearlson GD**. College student beliefs about wagering: an evaluation of the adolescent gambling expectancies survey. J Gambli Stud. 2015 Mar;31(1):161-71.

529. Gupta CN, Chen J, Liu J, Damaraju E, Wright C, Perrone-Bizzozero NI, **Pearlson GD**, Luo L, Michael AM, Turner JA, Calhoun VD. Genetic markers of white matter integrity in schizophrenia revealed by parallel ICA. *Front Hum Neurosci*. 2015 Mar 3;9:100.
530. Apostolova LG, Hwang KS, Avila D, Elashoff D, Kohannim O, Teng E, Sokolow S, Jack CR, Jagust WJ, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. *Neurology*. 2015 Feb 17;84(7):729-37. ADNI
531. Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE, Carter SF, Schöll M, Choo IH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. *Neurology*. 2015 Feb 3;84(5):508-15. ADNI
532. Clementz BA, Sweeney J, Keshavan MS, **Pearlson GD**, Tamminga CA. Using biomarker batteries. *Biol Psychiatry*. 2015 Jan 15;77(2):90-2.
533. Yu Q, Erhardt EB, Sui J, Du Y, He H, Hjelm D, Cetin MS, Rachakonda S, Miller RL, **Pearlson GD**, Calhoun VD. Assessing dynamic brain graphs of time-varying connectivity in fMRI data: application to healthy controls and patients with schizophrenia. *Neuroimage*. 2015 Feb 15;107:345-55.
534. Leung KK, Malone IM, Ourselin S, Gunter JL, Bernstein MA, Thompson PM, Jack CR Jr, Weiner MW, Fox NC; Alzheimer's Disease Neuroimaging Initiative. Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement. *Neuroimage*. 2015 Feb 15;107:46-53. ADNI
535. Moradi E, Pepe A, Gaser C, Huttunen H, Tohka J; Alzheimer's Disease Neuroimaging Initiative. Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects. *Neuroimage*. 2015 Jan 1;104:398-412. ADNI
536. Brendel M, Högenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, Rominger A; Alzheimer's Disease Neuroimaging Initiative. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. *Neuroimage*. 2015 Mar;108:450-9. ADNI
537. Li R, Perneczky R, Yakushev I, Förster S, Kurz A, Drzezga A, Kramer S; Alzheimer's Disease Neuroimaging Initiative. Gaussian Mixture Models and Model Selection for [18F] Fluorodeoxyglucose Positron Emission Tomography Classification in Alzheimer's Disease. *PLoS One*. 2015 Apr 28;10(4):e0122731. ADNI
538. Mothi SS, Tandon N, Padmanabhan J, Mathew IT, Clementz B, Tamminga C, **Pearlson GD**, Sweeney J, Keshavan MS. Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders. *Schizophr Res*. 2015 Jun;165(1):103-7.
539. Book GA, Stevens MC, Assaf M, Glahn DC, **Pearlson GD**. Neuroimaging data sharing on the neuroinformatics database platform. *Neuroimage*. 2016 Jan 1;124(Pt B):1089-92.
540. Durazzo TC, Mattsson N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. *Nicotine Tob Res*. 2016 Feb;18(2):204-11. ADNI
541. Sui J, **Pearlson GD**, Du Y, Yu Q, Jones TR, Chen J, Jiang T, Bustillo J, Calhoun VD. In search of multimodal neuroimaging biomarkers of cognitive deficits in schizophrenia. *Biol Psychiatry*. 2015 Dec 1;78(11):794-804.
542. Yarosh HL, Meda SA, de Wit H, Hart AB, **Pearlson GD**. Multivariate analysis of subjective responses to d-amphetamine in healthy volunteers finds novel genetic pathway associations. *Psychopharmacology (Berl)*. 2015 Aug;232(15):2781-94.

543. Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, Jack C Jr, Weiner M, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative Investigators. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18  $\beta$ -Amyloid Measures Across the Spectrum of Alzheimer Disease. *JAMA Neurol.* 2015 May;72(5):571-81. ADNI
544. Fischer CE, Ting WK, Millikin CP, Ismail Z, Schweizer TA; Alzheimer Disease Neuroimaging Initiative.. Gray matter atrophy in patients with mild cognitive impairment/Alzheimer's disease over the course of developing delusions. *Int J Geriatr Psychiatry.* 2016 Jan;31(1):76-82. ADNI
545. Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative. Soluble BACE-1 Activity and sA $\beta$ PP $\beta$  Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort. *J Alzheimers Dis.* 2015;46(2):431-40. ADNI
546. Hohman TJ, Bell SP, Jefferson AL; Alzheimer's Disease Neuroimaging Initiative. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. *JAMA Neurol.* 2015 May;72(5):520-9. ADNI
547. Chen R, Herskovits EH; Alzheimer's Disease Neuroimaging Initiative. Predictive structural dynamic network analysis. *J Neurosci Methods.* 2015 Apr 30;245:58-63. ADNI
548. Cheng B, Liu M, Suk HI, Shen D, Zhang D; Alzheimer's Disease Neuroimaging Initiative.. Multimodal manifold-regularized transfer learning for MCI conversion prediction. *Brain Imaging Behav.* 2015 Dec;9(4):913-26. ADNI
549. Romero K, Ito K, Rogers JA, Polhamus D, Qiu R, Stephenson D, Mohs R, Lalonde R, Sinha V, Wang Y, Brown D, Isaac M, Vamvakas S, Hemmings R, Pani L, Bain LJ, Corrigan B; Alzheimer's Disease Neuroimaging Initiative.; Coalition Against Major Diseases. The future is now: model-based clinical trial design for Alzheimer's disease. *Clin Pharmacol Ther.* 2015 Mar;97(3):210-4. ADNI
550. Hibar DP, Alzheimer's Disease Neuroimaging Initiative, et al. Common genetic variants influence human subcortical brain structures. *Nature.* 2015 Apr 9;520(7546):224-9. ADNI
551. Chiang GC, Cruz Hernandez JC, Kantarci K, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Cerebral Microbleeds, CSF p-Tau, and Cognitive Decline: Significance of Anatomic Distribution. *AJNR Am J Neuroradiol.* 2015 Sep;36(9):1635-41. ADNI
552. Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Tepl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linzasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. *Brain.* 2015 Sep;138(Pt 9):2701-15. ADNI
553. Gifford KA, Phillips JS, Samuels LR, Lane EM, Bell SP, Liu D, Hohman TJ, Romano RR 3rd, Fritzsche LR, Lu Z, Jefferson AL; Alzheimer's Disease Neuroimaging Initiative. Associations between Verbal Learning Slope and Neuroimaging Markers across the Cognitive Aging Spectrum. *J Int Neuropsychol Soc.* 2015 Jul;21(6):455-67. ADNI
554. Du Y, **Pearlson GD**, Liu J, Sui J, Yu Q, He H, Castro E, Calhoun VD. A group ICA based framework for evaluating resting fMRI markers when disease categories are unclear: application to schizophrenia, bipolar, and schizoaffective disorders. *Neuroimage.* 2015 Nov 15;122:272-80.
555. Ziegler G, Penny WD, Ridgway GR, Ourselin S, Friston KJ; Alzheimer's Disease Neuroimaging Initiative. Estimating anatomical trajectories with Bayesian mixed-effects modeling. *Neuroimage.* 2015 Nov 1;121:51-68. ADNI

556. Malpas CB, Saling MM, Velakoulis D, Desmond P, Hicks RJ, O'Brien TJ; Alzheimer Disease Neuroimaging Initiative. Longitudinal Partial Volume Correction in 2-[<sup>18</sup>F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease. *J Comput Assist Tomogr*. 2015 Jul-Aug;39(4):559-64. ADNI
557. Yao Z, Hu B, Zheng J, Zheng W, Chen X, Gao X, Xie Y, Fang L; Alzheimer's Disease Neuroimaging Initiative. A FDG-PET Study of Metabolic Networks in Apolipoprotein E  $\epsilon$ 4 Allele Carriers. *PLoS One*. 2015 Jul 10;10(7):e0132300. ADNI
558. Stevens MC, Gaynor A, Bessette KL, **Pearlson GD**. A preliminary study of the effects of working memory training on brain function. *Brain Imaging Behav*. 2016 Jun;10(2):387-407.
559. Miller RL, Erhardt EB, Agcaoglu O, Allen EA, Michael AM, Turner JA, Bustillo J, Ford JM, Mathalon DH, Van Erp TG, Potkin S, Preda A, **Pearlson GD**, Calhoun VD. Multidimensional frequency domain analysis of full-volume fMRI reveals significant effects of age, gender, and mental illness on the spatiotemporal organization of resting-state brain activity. *Front Neurosci*. 2015 Jun 16;9:203.
560. Samudra N, Ivleva EI, Hubbard NA, Rypma B, Sweeney JA, Clementz BA, Keshavan MS, **Pearlson GD**, Tamminga CA. Alterations in hippocampal connectivity across the psychosis dimension. *Psychiatry Res*. 2015 Aug 30;233(2):148-57.
561. Narayanan B, Soh P, Calhoun VD, Ruaño G, Kocherla M, Windemuth A, Clementz BA, Tamminga CA, Sweeney JA, Keshavan MS, **Pearlson GD**. Multivariate genetic determinants of EEG oscillations in schizophrenia and psychotic bipolar disorder from the BSNIP study. *Transl Psychiatry*. 2015 Jun 23;5:e588.
562. Toledo JB, Bjerke M, Chen K, Rozycki M, Jack CR Jr, Weiner MW, Arnold SE, Reiman EM, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings. *Neurology*. 2015 Jul 14;85(2):144-53. ADNI
563. Daianu M, Jahanshad N, Nir TM, Jack CR Jr, Weiner MW, Bernstein MA, Thompson PM; Alzheimer's Disease Neuroimaging Initiative. Rich club analysis in the Alzheimer's disease connectome reveals a relatively undisturbed structural core network. *Hum Brain Mapp*. 2015 Aug;36(8):3087-103. ADNI
564. Meda SA, Wang Z, Ivleva EI, Poudyal G, Keshavan MS, Tamminga CA, Sweeney JA, Clementz BA, Schretlen DJ, Calhoun VD, Lui S, Damaraju E, **Pearlson GD**. Frequency-specific neural signatures of spontaneous low-frequency resting state fluctuations in psychosis: Evidence from Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Consortium. *Schizophr Bull*. 2015 Nov;41(6):1336-48.
565. Kristian Hill S, Buchholz A, Amsbaugh H, Reilly JL, Rubin LH, Gold JM, Keefe RS, **Pearlson GD**, Keshavan MS, Tamminga CA, Sweeney JA. Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment. *Schizophr Res*. 2015 Aug;166(1-3):310-5.
566. Ayton S, Faux NG, Bush AI; Alzheimer's Disease Neuroimaging Initiative. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. *Nat Commun*. 2015 May 19;6:6760. ADNI
567. Lorenzi M, Ayache N, Pennec X; Alzheimer's Disease Neuroimaging Initiative (ADNI). Regional flux analysis for discovering and quantifying anatomical changes: An application to the brain morphometry in Alzheimer's disease. *Neuroimage*. 2015 Jul 15;115:224-34. ADNI
568. Hyatt CJ, Calhoun VD, **Pearlson GD**, Assaf M. Specific default mode subnetworks support mentalizing as revealed through opposing network recruitment by social and semantic fMRI tasks. *Hum Brain Mapp*. 2015 Aug;36(8):3047-63.

569. Iglesias JE, Augustinack JC, Nguyen K, Player CM, Player A, Wright M, Roy N, Frosch MP, McKee AC, Wald LL, Fischl B, Van Leemput K; Alzheimer's Disease Neuroimaging Initiative. A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRI. *Neuroimage*. 2015 Jul 15;115:117-37. ADNI
570. David ND, Lin F, Porsteinsson AP; Alzheimer's Disease Neuroimaging Initiative. Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment. *Am J Geriatr Psychiatry*. 2016 Jan;24(1):70-80. ADNI
571. Zetterberg H, Skillbäck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, Weiner MW, Blennow K; Alzheimer's Disease Neuroimaging Initiative. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. *JAMA Neurol*. 2016 Jan;73(1):60-7. ADNI
572. Worhunsky PD, Dager AD, Meda SA, Khadka S, Stevens MC, Austad CS, Raskin SA, Tennen H, Wood RM, Fallahi CR, Potenza MN, **Pearlson GD**. A preliminary prospective study of an escalation in 'maximum daily drinks', fronto-parietal circuitry and impulsivity-related domains in young adult drinkers. *Neuropsychopharmacology*. 2016 May;41(6):1637-47.
573. Lencer R, Sprenger A, Reilly JL, McDowell JE, Rubin LH, Badner JA, Keshavan MS, **Pearlson GD**, Tamminga CA, Gershon ES, Clementz BA, Sweeney JA. Pursuit eye movements as an intermediate phenotype across psychotic disorders: Evidence from the B-SNIP study. *Schizophr Res*. 2015 Dec;169(1-3):326-33.
574. Mokhtari M, Narayanan B, Hamm JP, Soh P, Calhoun VD, Ruaño G, Kocherla M, Windemuth A, Clementz BA, Tamminga CA, Sweeney JA, Keshavan MS, **Pearlson GD**. Multivariate genetic correlates of the auditory paired stimuli-based P2 event-related potential in the psychosis dimension From the BSNIP study. *Schizophr Bull*. 2016 May;42(3):851-62.
575. **Pearlson GD**, Liu J, Calhoun VD. An introductory review of parallel independent component analysis (p-ICA) and a guide to applying p-ICA to genetic data and imaging phenotypes to identify disease-associated biological pathways and systems in common complex disorders. *Front Genet*. 2015 Sep 7;6:276.
576. Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN, Yushkevich PA, Wolk DA; Alzheimer's Disease Neuroimaging Initiative. Suspected non-AD pathology in mild cognitive impairment. *Neurobiol Aging*. 2015 Dec;36(12):3152-62. ADNI
577. Jiang J, Duan H, Huang Z, Yu Z; Alzheimer's Disease Neuroimaging Initiative. Study of amyloid- $\beta$  peptide functional brain networks in AD, MCI and HC. *Biomed Mater Eng*. 2015;26 Suppl 1:S2197-205. ADNI
578. Wang C, Tan L, Wang HF, Yu WJ, Liu Y, Jiang T, Tan MS, Hao XK, Zhang DQ, Yu JT; Alzheimer's Disease Neuroimaging Initiative. Common variants in *PLD3* and correlation to amyloid-related phenotypes in Alzheimer's disease. *J Alzheimers Dis*. 2015;46(2):491-5. ADNI
579. Zhan Y, Chen K, Wu X, Zhang D, Zhang J, Yao L, Guo X; Alzheimer's Disease Neuroimaging Initiative. Identification of conversion from normal elderly cognition to Alzheimer's disease using multimodal support vector machine. *J Alzheimers Dis*. 2015;47(4):1057-67. ADNI
580. Malpas CB, Saling MM, Velakoulis D, Desmond P, O'Brien TJ; Alzheimer's Disease Neuroimaging Initiative. Tau and amyloid- $\beta$  cerebrospinal fluid biomarkers have differential relationships with cognition in mild cognitive impairment. *J Alzheimers Dis*. 2015;47(4):965-75. ADNI
581. Klöppel S, Peter J, Ludl A, Pilatus A, Maier S, Mader I, Heimbach B, Frings L, Egger K, Dukart J, Schroeter ML, Perneczky R, Häussermann P, Vach W, Urbach H, Teipel S, Hüll M, Abdulkadir A; Alzheimer's Disease Neuroimaging Initiative. Applying automated MR-based diagnostic methods to the memory clinic: A Prospective Study. *J Alzheimers Dis*. 2015;47(4):939-54. ADNI



582. Michaud TL, Kane RL, McCarten JR, Gaugler JE, Nyman JA, Kuntz KM; Alzheimer's Disease Neuroimaging Initiative . Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis. *J Alzheimers Dis*. 2015;47(3):729-40. ADNI
583. Chung JK, Plitman E, Nakajima S, Chakravarty MM, Caravaggio F, Gerretsen P, Iwata Y, Graff-Guerrero A; Alzheimer's Disease Neuroimaging Initiative. Cortical Amyloid  $\beta$  Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment. *J Geriatr Psychiatry Neurol*. 2016 May;29(3):149-59. ADNI
584. García Barrado L, Coart E, Burzykowski T; Alzheimer's Disease Neuroimaging Initiative. Development of a diagnostic test based on multiple continuous biomarkers with an imperfect reference test. *Stat Med*. 2016 Feb 20;35(4):595-608. ADNI
585. Corbin WR, Papova A, Morean ME, O'Malley SS, Krishnan-Sarin S, Abi-Dargham A, Anticevic A, **Pearlson GD**, Petrakis I, Pittman BP, Krystal JH. Integrating acquired preparedness and dual process models of risk for heavy drinking and related problems. *Psychol Addict Behav*. 2015 Dec;29(4):864-74.
586. Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative. Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. *BMC Geriatr*. 2015 Sep 7;15:107. ADNI
587. van Erp TG, .....**Pearlson GD**, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Mol Psychiatry*. 2016 Apr;21(4):585.
588. Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Comparison of visual and quantitative Florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes. *JAMA Neurol*. 2015 Oct;72(10):1183-90. ADNI
589. Zhang DF, Li J, Wu H, Cui Y, Bi R, Zhou HJ, Wang HZ, Zhang C, Wang D; Alzheimer's Disease Neuroimaging Initiative (ADNI)., Kong QP, Li T, Fang Y, Jiang T, Yao YG. CFH variants affect structural and functional brain changes and genetic risk of Alzheimer's disease. *Neuropsychopharmacology*. 2016 Mar;41(4):1034-45. ADNI
590. Steele VR, Anderson NE, Claus ED, Bernat EM, Rao V, Assaf M, **Pearlson GD**, Calhoun VD, Kiehl KA. Neuroimaging measures of error-processing: Extracting reliable signals from event-related potentials and functional magnetic resonance imaging. *Neuroimage*. 2016 May 15;132:247-60.
591. Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. *Alzheimers Res Ther*. 2016 Feb 12;8:8. ADNI
592. Hibar DP, .....**Pearlson GD**, et al. Subcortical volumetric abnormalities in bipolar disorder. *Mol Psychiatry*. 2016 Dec;21(12):1710-1716.
593. Treisman GJ, Jayaram G, Margolis RL, **Pearlson GD**, Schmidt CW, Mihelish GL, Kennedy A, Howson A, Rasulnia M, Misiuta IE. Perspectives on the use of eHealth in the management of patients with schizophrenia. *J Nerv Ment Dis*. 2016 Aug;204(8):620-9.
594. Mackey S, Kan KJ, Chararani B, Alia-Klein N, Batalla A, Brooks S, Cousijn J, Dagher A, de Ruitter M, Desrivieres S, Feldstein Ewing SW, Goldstein RZ, Goudriaan AE, Heitzeg MM, Hutchison K, Li CS, London ED, Lorenzetti V, Luijten M, Martin-Santos R, Morales AM, Paulus MP, Paus T, **Pearlson GD**, Schluter R, Momenan R, Schmaal L, Schumann G, Sinha R, Sjoerds Z, Stein DJ, Stein EA, Solowij N, Tapert S, Uhlmann A, Veltman D, van Holst R, Walter H, Wright MJ, Yucel M, Yurgelun-Todd D, Hibar DP, Jahanshad N, Thompson PM, Glahn DC, Garavan H, Conrod P. Genetic

- imaging consortium for addiction medicine: From neuroimaging to genes. Prog Brain Res. 2016;224:203-23.
595. Balodis IM, Kober H, Worhunsky PD, Stevens MC, **Pearlson GD**, Carroll KM, Potenza MN. Neurofunctional reward processing changes in cocaine dependence during recovery. Neuropsychopharmacology. 2016 Jul;41(8):2112-21.
596. Glahn DC, Knowles EE, **Pearlson GD**. Genetics of cognitive control: Implications for NIMH's research domain criteria initiative. Am J Med Genet B Neuropsychiatr Genet. 2016 Jan;171B(1):111-20.
597. *Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP; Alzheimer's Disease Neuroimaging Initiative. Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimers Res Ther. 2016 Jan 15;8:2. ADNI*
598. *Marnane M, Al-Jawadi OO, Mortazavi S, Pogorzelec KJ, Wang BW, Feldman HH, Hsiung GY; Alzheimer's Disease Neuroimaging Initiative. Periventricular hyperintensities are associated with elevated cerebral amyloid. Neurology. 2016 Feb 9;86(6):535-43. ADNI*
599. *Kim J, Pan W; Alzheimer's Disease Neuroimaging Initiative. Highly adaptive tests for group differences in brain functional connectivity. Neuroimage Clin. 2015 Oct 22;9:625-39. ADNI*
600. Wang Z, Meda SA, Keshavan MS, Tamminga CA, Sweeney JA, Clementz BA, Schretlen DJ, Calhoun VD, Lui S, **Pearlson GD**. Large-scale fusion of gray matter and resting-state functional MRI reveals common and distinct biological markers across the psychosis spectrum in the B-SNIP cohort. Front Psychiatry. 2015 Dec 21;6:174.
601. Nanda P, Tandon N, Mathew IT, Padmanabhan JL, Clementz BA, **Pearlson GD**, Sweeney JA, Tamminga CA, Keshavan MS. Impulsivity across the psychosis spectrum: Correlates of cortical volume, suicidal history, and social and global function. Schizophr Res. 2016 Jan;170(1):80-6.
602. Yang GJ, Murray JD, Wang XJ, Glahn DC, **Pearlson GD**, Repovs G, Krystal JH, Anticevic A. Functional hierarchy underlies preferential connectivity disturbances in schizophrenia. Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E219-28.
603. Du Y, **Pearlson GD**, Yu Q, He H, Lin D, Sui J, Wu L, Calhoun VD. Interaction among subsystems within default mode network diminished in schizophrenia patients: A dynamic connectivity approach. Schizophr Res. 2016 Jan;170(1):55-65.
604. Clementz BA, Sweeney JA, Hamm JP, Ivleva EI, Ethridge LE, **Pearlson GD**, Keshavan MS, Tamminga CA. Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry. 2016 Apr 1;173(4):373-84.
605. Hochberger WC, Hill SK, Nelson CL, Reilly JL, Keefe RS, **Pearlson GD**, Keshavan MS, Tamminga CA, Clementz BA, Sweeney JA. Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. Schizophr Res. 2016 Jan;170(1):156-61.
606. Soh P, Narayanan B, Khadka S, Calhoun VD, Keshavan MS, Tamminga CA, Sweeney JA, Clementz BA, **Pearlson GD**. Joint coupling of awake EEG frequency activity and MRI gray matter volumes in the psychosis dimension: A BSNIP Study. Front Psychiatry. 2015 Nov 9;6:162.
607. *Teipel S, Grothe MJ; Alzheimer's Disease Neuroimaging Initiative. Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease? Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):526-36. ADNI*
608. *Hua X, Ching CR, Mezher A, Gutman BA, Hibar DP, Bhatt P, Leow AD, Jack CR Jr, Bernstein MA, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative. MRI-based brain atrophy*

rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. *Neurobiol Aging*. 2016 Jan;37:26-37. ADNI

609. Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, Kauwe J, Goate A, Cruchaga C; Alzheimer's Disease Neuroimaging Initiative. A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. *Neurobiol Aging*. 2016 Jan;37:208.e1-9. ADNI
610. Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC; Alzheimer's Disease Neuroimaging Initiative. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. *Nat Commun*. 2016 Jun 21;7:11934. ADNI
611. Hodgson K, Almasy L, Knowles EE, Kent JW, Curran JE, Dyer TD, Göring HH, Olvera RL, Fox PT, **Pearlson GD**, Krystal JH, Duggirala R, Blangero J, Glahn DC. Genome-wide significant loci for addiction and anxiety. *Eur Psychiatry*. 2016 Aug;36:47-54.
612. Otto MW, Pollack MH, Dowd SM, Hofmann SG, **Pearlson GD**, Szuhany KL, Gueorguieva R, Krystal JH, Simon NM, Tolin DF. Randomized trial of D-cycloserine enhancement of cognitive-behavioral therapy for panic disorder. *Depress Anxiety*. 2016 Aug;33(8):737-45.
613. Reilly JL, Hill SK, Gold JM, Keefe RS, Clementz BA, Gershon E, Keshavan MS, **Pearlson GD**, Tamminga CA, Sweeney JA. Impaired context processing is attributable to global neuropsychological impairment in schizophrenia and psychotic bipolar disorder. *Schizophr Bull*. 2017 Mar 1;43(2):397-406.
614. Liu H, Zhou X, Jiang H, He H, Liu X; Alzheimer's Disease Neuroimaging Initiative. A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease. *Sci Rep*. 2016 Jun 7;6:26712. ADNI
615. Chen J, Calhoun VD, Perrone-Bizzozero NI, **Pearlson GD**, Sui J, Du Y, Liu J. A pilot study on commonality and specificity of copy number variants in schizophrenia and bipolar disorder. *Transl Psychiatry*. 2016 May 31;6(5):e824.
616. Tan L, Wang HF, Tan MS, Tan CC, Zhu XC, Miao D, Yu WJ, Jiang T, Tan L, Yu JT; Alzheimer's Disease Neuroimaging Initiative. Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. *Sci Rep*. 2016 May 27;6:26027. ADNI
617. **Pearlson GD**, Clementz BA, Sweeney JA, Keshavan MS, Tamminga CA. Does biology transcend the symptom-based boundaries of psychosis? *Psychiatr Clin North Am*. 2016 Jun;39(2):165-74.
618. Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Accelerating rates of cognitive decline and imaging markers associated with  $\beta$ -amyloid pathology. *Neurology*. 2016 May 17;86(20):1887-96. ADNI
619. Rashid B, Arbabshirani MR, Damaraju E, Cetin MS, Miller R, **Pearlson GD**, Calhoun VD. Classification of schizophrenia and bipolar patients using static and dynamic resting-state fMRI brain connectivity. *Neuroimage*. 2016 Jul 1;134:645-57.
620. Xu W, Wang HF, Tan L, Tan MS, Tan CC, Zhu XC, Miao D, Yu WJ, Jiang T, Tan L, Yu JT; Alzheimer's Disease Neuroimaging Initiative Group. The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum. *Sci Rep*. 2016 Apr 27;6:24480. ADNI
621. Hanna RC, Shalvoy A, Cullum CM, Ivleva EI, Keshavan M, **Pearlson GD**, Hill SK, Sweeney JA, Tamminga CA, Ghose S. Cognitive function in individuals with psychosis: Moderation by adolescent cannabis use. *Schizophr Bull*. 2016 Nov;42(6):1496-1503.

622. Sundermann EE, Biegon A, Rubin LH, Lipton RB, Mowrey W, Landau S, Maki PM; Alzheimer's Disease Neuroimaging Initiative. Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. *Neurology*. 2016 Apr 12;86(15):1368-76. ADNI
623. Miller RL, Yaesoubi M, Turner JA, MATHALON D, Preda A, **Pearlson GD**, Adali T, Calhoun VD. Higher Dimensional meta-state analysis reveals reduced resting fMRI connectivity dynamism in schizophrenia patients. *PLoS One*. 2016 Mar 16;11(3).
624. Padmanabhan JL, Nanda P, Tandon N, Mothi SS, Bolo N, McCarroll S, Clementz BA, Gershon ES, **Pearlson GD**, Sweeney JA, Tamminga CA, Keshavan MS. Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives. *J Psychiatr Res*. 2016 Jun;77:52-8.
625. Rubin LH, Connelly JJ, Reilly JL, Carter CS, Drogos LL, Pournajafi-Nazarloo H, Ruocco AC, Keedy SK, Matthew I, Tandon N, **Pearlson GD**, Clementz BA, Tamminga CA, Gershon ES, Keshavan MS, Bishop JR, Sweeney JA. Sex and diagnosis specific associations between DNA methylation of the oxytocin receptor gene with emotion processing and temporal-limbic and prefrontal brain volumes in psychotic disorders. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2016 Mar 1;1(2):141-151.
626. Lupton MK, Strike L, Hansell NK, Wen W, Mather KA, Armstrong NJ, Thalamuthu A, McMahon KL, de Zubicaray GI, Assareh AA, Simmons A, Proitsi P, Powell JF, Montgomery GW, Hibar DP, Westman E, Tsolaki M, Kloszewska I, Soininen H, Mecocci P, Velas B, Lovestone S; Alzheimer's Disease Neuroimaging Initiative., Brodaty H, Ames D, Trollor JN, Martin NG, Thompson PM, Sachdev PS, Wright MJ. The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. *Neurobiol Aging*. 2016 Apr;40:68-77. ADNI
627. Landau SM, Horng A, Fero A, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. *Neurology*. 2016 Apr 12;86(15):1377-85. ADNI
628. Francis AN, Mothi SS, Mathew IT, Tandon N, Clementz B, **Pearlson GD**, Sweeney JA, Tamminga CA, Keshavan MS. Callosal abnormalities across the psychosis dimension: Bipolar schizophrenia network on intermediate phenotypes. *Biol Psychiatry*. 2016 Oct 15;80(8):627-35.
629. Bridwell DA, Rachakonda S, Silva RF, **Pearlson GD**, Calhoun VD. Spatiospectral decomposition of multi-subject EEG: Evaluating blind source separation algorithms on real and realistic simulated data. *Brain Topogr*. 2018 Jan;31(1):47-61.
630. Huang M, Yang W, Feng Q, Chen W; Alzheimer's Disease Neuroimaging Initiative. Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer's disease. *Sci Rep*. 2017 Jan 12;7:39880. ADNI
631. Grothe MJ, Villeneuve S, Dyrba M, Bartrés-Faz D, Wirth M; Alzheimer's Disease Neuroimaging Initiative. Multimodal characterization of older Hochberger2 carriers reveals selective reduction of amyloid load. *Neurology*. 2017 Feb 7;88(6):569-576. ADNI
632. Rubin LH, Yao L, Keedy SK, Reilly JL, Bishop JR, Carter CS, Pournajafi-Nazarloo H, Drogos LL, Tamminga CA, **Pearlson GD**, Keshavan MS, Clementz BA, Hill SK, Liao W, Ji GJ, Lui S, Sweeney JA. Sex differences in associations of arginine vasopressin and oxytocin with resting-state functional brain connectivity. *J Neurosci Res*. 2017 Jan 2;95(1-2):576-586.
633. Zamroziewicz M, Raskin SA, Tennen H, Austad CS, Wood RM, Fallahi CR, Dager AD, Sawyer B, Leen S, **Pearlson GD**. Effects of drinking patterns on prospective memory performance in college students. *Neuropsychology*. 2017 Feb;31(2):191-199.
634. Ivleva EI, Clementz BA, Dutcher AM, Arnold SJ, Jeon-Slaughter H, Aslan S, Witte B, Poudyal G, Lu H, Meda SA, **Pearlson GD**, Sweeney JA, Keshavan MS, Tamminga CA. Brain structure biomarkers in the psychosis biotypes: Findings from the Bipolar-Schizophrenia Network for Intermediate Phenotypes. *Biol Psychiatry*. 2017 Jul 1;82(1):26-39.

635. Hager B, Yang AC, Brady R, Meda S, Clementz B, **Pearlson GD**, Sweeney JA, Tamminga C, Keshavan M. Neural complexity as a potential translational biomarker for psychosis. J Affect Disord. 2017 Jul;216:89-99.
636. Yu Q, Wu L, Bridwell DA, Erhardt EB, Du Y, He H, Chen J, Liu P, Sui J, **Pearlson GD**, Calhoun VD. Building an EEG-fMRI Multi-Modal Brain Graph: A concurrent EEG-fMRI study. Front Hum Neurosci. 2016 Sep 28;10:476.
637. Yang GJ, Murray JD, Glasser M, **Pearlson GD**, Krystal JH, Schleifer C, Repovs G, Anticevic A. Altered global signal topography in schizophrenia. Cereb Cortex. 2017 Nov 1;27(11):5156-5169.
638. Ruf BM, Bessette KL, **Pearlson GD**, Stevens MC. Effect of trait anxiety on cognitive test performance in adolescents with and without attention-deficit/hyperactivity disorder. J Clin Exp Neuropsychol. 2017 Jun;39(5):434-448.
639. Chen J, Calhoun VD, **Pearlson GD**, Perrone-Bizzozero NI, Turner JA, Ehrlich S, Ho BC, Liu J. Independent component analysis of SNPs reflects polygenic risk scores for schizophrenia. Schizophr Res. 2017 Mar;181:83-85.
640. *Sabuncu MR, Ge T, Holmes AJ, Smoller JW, Buckner RL, Fischl B; Alzheimer's Disease Neuroimaging Initiative. Morphometricity as a measure of the neuroanatomical signature of a trait. Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):E5749-56. ADNI*
641. Choi J, Corcoran CM, Fiszdon JM, Stevens M, Javitt DC, Deasy M, Haber LC, Dewberry MJ, **Pearlson GD**. Pupillometer-based neurofeedback cognitive training to improve processing speed and Social Functioning in Individuals at Clinical High Risk for Psychosis. Psychiatr Rehabil J. 2017 Mar;40(1):33-42.
642. Polimanti R, Wang Q, Meda SA, Patel KT, **Pearlson GD**, Zhao H, Farrer LA, Kranzler HR, Gelernter J. The Interplay between risky sexual behaviors and alcohol dependence: Genome-wide association and neuroimaging support for LHPP as a risk gene. Neuropsychopharmacology. 2017 Feb;42(3):598-605.
643. Khadka S, **Pearlson GD**, Calhoun VD, Liu J, Gelernter J, Bessette KL, Stevens MC. Multivariate imaging genetics study of MRI gray matter volume and SNPs reveals biological pathways correlated with brain structural differences in Attention Deficit Hyperactivity Disorder. Front Psychiatry. 2016 Jul 25;7:128.
644. *Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR; Alzheimer's Disease Neuroimaging Initiative. Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology. 2016 Aug 2;87(5):481-8. ADNI*
645. Krystal JH, **Pearlson GD**, et al. Constance E. Lieber, Theodore R. Stanley, and the enduring impact of philanthropy on psychiatry research. Biol Psychiatry. 2016 Jul 15;80(2):84-6.
646. *Schmitz TW, Nathan Spreng R; Alzheimer's Disease Neuroimaging Initiative. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun. 2016 Nov 4;7:13249. ADNI*
647. Tandon N, Nanda P, Padmanabhan JL, Mathew IT, Eack SM, Narayanan B, Meda SA, Bergen SE, Ruaño G, Windemuth A, Kocherla M, Petryshen TL, Clementz B, Sweeney J, Tamminga C, **Pearlson GD**, Keshavan MS. Novel gene-brain structure relationships in psychotic disorder revealed using parallel independent component analyses. Schizophr Res. 2017 Apr;182:74-83.
648. *Zhang X, Mormino EC, Sun N, Sperling RA, Sabuncu MR, Yeo BT; Alzheimer's Disease Neuroimaging Initiative. Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6535-E6544. ADNI*

649. Xu J, Potenza MN, Calhoun VD, Zhang R, Yip SW, Wall JT, **Pearlson GD**, Worhunsky PD, Garrison KA, Moran JM. Large-scale functional network overlap is a general property of brain functional organization: Reconciling inconsistent fMRI findings from general-linear-model-based analyses. *Neurosci Biobehav Rev*. 2016 Dec;71:83-100.
650. Hochberger WC, Combs T, Reilly JL, Bishop JR, Keefe RSE, Clementz BA, Keshavan MS, **Pearlson GD**, Tamminga CA, Hill SK, Sweeney JA. Deviation from expected cognitive ability across psychotic disorders. *Schizophr Res*. 2018 Feb;192:300-307.
651. Yao N, Winkler AM, Barrett J, Book GA, Beetham T, Horseman R, Leach O, Hodgson K, Knowles EE, Mathias S, Stevens MC, Assaf M, van Erp TGM, **Pearlson GD**, Glahn DC. Inferring pathobiology from structural MRI in schizophrenia and bipolar disorder: Modeling head motion and neuroanatomical specificity. *Hum Brain Mapp*. 2017 Aug;38(8):3757-3770.
652. Sheffield JM, Kandala S, Tamminga CA, **Pearlson GD**, Keshavan MS, Sweeney JA, Clementz BA, Lerman-Sinkoff DB, Hill SK, Barch DM. Transdiagnostic associations between functional brain network integrity and cognition. *JAMA Psychiatry*. 2017 Jun 1;74(6):605-613.
653. Hibar DP, Westlye LT, **Pearlson GD**, Thompson PM, Andreassen OA, et al. Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. *Mol Psychiatry*. 2018 Apr;23(4):932-942.
654. Steffens DC, Wang L, Manning KJ, **Pearlson GD**. Negative Affectivity, aging, and depression: Results from the neurobiology of late-life depression (NBOLD) study. *Am J Geriatr Psychiatry*. 2017 Oct;25(10):1135-1149.
655. Hudgens-Haney ME, Ethridge LE, Knight JB, McDowell JE, Keedy SK, **Pearlson GD**, Tamminga CA, Keshavan MS, Sweeney JA, Clementz BA. Intrinsic neural activity differences among psychotic illnesses. *Psychophysiology*. 2017 Aug;54(8):1223-1238.
656. Polimanti R, Meda SA, **Pearlson GD**, Zhao H, Sherva R, Farrer LA, Kranzler HR, Gelernter J. S100A10 identified in a genome-wide gene x cannabis dependence interaction analysis of risky sexual behaviours. *J Psychiatry Neurosci*. 2017 Jun;42(4):252-261.
657. Eum S, Hill SK, Rubin LH, Carnahan RM, Reilly JL, Ivleva EI, Keedy SK, Tamminga CA, **Pearlson GD**, Clementz BA, Gershon ES, Keshavan MS, Keefe RS, Sweeney JA, Bishop JR. Cognitive burden of anticholinergic medications in psychotic disorders. *Schizophr Res*. 2017 Dec;190:129-135.
658. Du Y, **Pearlson GD**, Lin D, Sui J, Chen J, Salman M, Tamminga CA, Ivleva EI, Sweeney JA, Keshavan MS, Clementz BA, Bustillo J, Calhoun VD. Identifying dynamic functional connectivity biomarkers using GIG-ICA: Application to schizophrenia, schizoaffective disorder, and psychotic bipolar disorder. *Hum Brain Mapp*. 2017 May;38(5):2683-2708.
659. Khadka S, Stevens MC, Aslanzadeh F, Narayanan B, Hawkins KA, Austad CS, Raskin SA, Tennen H, Wood RM, Fallahi C, Potenza MN, **Pearlson GD**. Composite impulsivity-related domains in college students. *J Psychiatr Res*. 2017 Jul;90:118-125.
660. Meda SA, Gueorguieva RV, Pittman B, Rosen RR, Aslanzadeh F, Tennen H, Leen S, Hawkins K, Raskin S, Wood RM, Austad CS, Dager A, Fallahi C, **Pearlson GD**. Longitudinal influence of alcohol and marijuana use on academic performance in college students. *PLoS One*. 2017 Mar 8;12(3).
661. Hawkins KA, Emadi N, **Pearlson GD**, Winkler AM, Taylor B, Dulipsingh L, King D, Pittman B, Blank K. Hyperinsulinemia and elevated systolic blood pressure independently predict white matter hyperintensities with associated cognitive decrement in the middle-aged offspring of dementia patients. *Metab Brain Dis*. 2017 Jun;32(3):849-857.

662. Krystal JH, Petrakis IL, O'Malley S, Krishnan-Sarin S, **Pearlson GD**, Yoon G. NMDA glutamate receptor antagonism and the heritable risk for alcoholism: new insights from a study of nitrous oxide. *Int J Neuropsychopharmacol*. 2017 Apr 1;20(4):351-353.
663. Klinger RY, James OG, Borges-Neto S, Bisanar T, Li YJ, Qi W, Berger M, Terrando N, Newman MF, Doraiswamy PM, Mathew JP; Alzheimer's Disease Neuroimaging Initiative (ADNI) Study Group; Neurologic Outcomes Research Group (NORG). 18F-florbetapir positron emission tomography-determined cerebral  $\beta$ -amyloid deposition and neurocognitive performance after cardiac surgery. *Anesthesiology*. 2018 Apr;128(4):728-744. ADNI
664. Zhou HH, Singh V, Johnson SC, Wahba G; Alzheimer's Disease Neuroimaging Initiative. Statistical tests and identifiability conditions for pooling and analyzing multisite datasets. *Proc Natl Acad Sci USA*. 2018 Jan 31. 2018 Feb 13;115(7):1481-1486. ADNI
665. Fryer SL, Roach BJ, Ford JM, Donaldson KR, Calhoun VD, **Pearlson GD**, Kiehl KA, Srihari VH, McGlashan TH, Woods SW, Mathalon DH. Should I stay or should I go? fMRI study of response inhibition in early illness schizophrenia and risk for psychosis. *Schizophr Bull*. 2019 Jan 1;45(1):158-168.
666. Du L, Liu K, Yao X, Yan J, Risacher SL, Han J, Guo L, Saykin AJ, Shen L; Alzheimer's Disease Neuroimaging Initiative. Pattern discovery in brain imaging genetics via SCCA modeling with a generic non-convex penalty. *Sci Rep*. 2017 Oct 25;7(1):14052. ADNI
667. Risacher SL, Anderson WH, Charil A, Castelluccio PF, Shcherbinin S, Saykin AJ, Schwarz AJ; Alzheimer's Disease Neuroimaging Initiative. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. *Neurology*. 2017 Nov 21;89(21):2176-2186. ADNI
668. Lencer R, Mills LJ, Alliey-Rodriguez N, Shafee R, Lee AM, Reilly JL, Sprenger A, McDowell JE, McCarroll SA, Keshavan MS, **Pearlson GD**, Tamminga CA, Clementz BA, Gershon ES, Sweeney JA, Bishop JR. Genome-wide association studies of smooth pursuit and antisaccade eye movements in psychotic disorders: findings from the B-SNIP study. *Transl Psychiatry*. 2017 Oct 24;7(10):e1249.
669. Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ; Alzheimer's Disease Neuroimaging Initiative. In vivo staging of regional amyloid deposition. *Neurology*. 2017 Nov 14;89(20):2031-2038. ADNI
670. Meda SA, Dager AD, Hawkins KA, Tennen H, Raskin S, Wood RM, Austad CS, Fallahi CR, **Pearlson GD**. Heavy drinking in college students is associated with accelerated gray matter volumetric decline over a 2 year period. *Front Behav Neurosci*. 2017 Sep 29;11:176.
671. Choi J, Lysaker PH, Bell MD, Dixon L, Margolies P, Gold M, Golden-Roose E, Thime W, Haber LC, Dewberry MJ, Stevens M, **Pearlson GD**, Fiszdon JM. Decisional informatics for psychosocial rehabilitation: A feasibility pilot on tailored and fluid treatment algorithms for serious mental illness. *J Nerv Ment Dis*. 2017 Nov;205(11):867-872.
672. **Pearlson GD**. Applications of resting state functional MR imaging to neuropsychiatric diseases. *Neuroimaging Clin N Am*. 2017 Nov;27(4):709-723.
673. Fu Z, Tu Y, Di X, Du Y, **Pearlson GD**, Turner JA, Biswal BB, Zhang Z, Calhoun VD. Characterizing dynamic amplitude of low-frequency fluctuation and its relationship with dynamic functional connectivity: An application to schizophrenia. *Neuroimage*. 2018 Oct 15;180(Pt B):619-631.
674. Guo S, Lai C, Wu C, Cen G; Alzheimer's Disease Neuroimaging Initiative. Corrigendum: Conversion discriminative analysis on mild cognitive impairment using multiple cortical features from MR images. *Front Aging Neurosci*. 2017 Sep 5;9:293. ADNI
675. Hudgens-Haney ME, Ethridge LE, McDowell JE, Keedy SK, **Pearlson GD**, Tamminga CA, Keshavan MS, Sweeney JA, Clementz BA. Psychosis subgroups differ in intrinsic neural activity but not task-specific processing. *Schizophr Res*. 2018 May;195:222-230.

676. Lim YY, Mormino EC; Alzheimer's Disease Neuroimaging Initiative. APOE genotype and early  $\beta$ -amyloid accumulation in older adults without dementia. *Neurology*. 2017 Sep 5;89(10):1028-1034. ADNI
677. Russo MJ, Campos J, Vázquez S, Sevlever G, Allegri RF; Alzheimer's Disease Neuroimaging Initiative. Adding recognition discriminability index to the delayed recall is useful to predict conversion from mild cognitive impairment to Alzheimer's disease in the Alzheimer's disease neuroimaging initiative. *Front Aging Neurosci*. 2017 Mar 10;9:46. ADNI
678. Munilla J, Ortiz A, Górriz JM, Ramírez J; Alzheimer's Disease Neuroimaging Initiative. Construction and analysis of weighted brain networks from SICE for the study of Alzheimer's disease. *Front Neuroinform*. 2017 Mar 10;11:19. ADNI
679. Hao X, Li C, Du L, Yao X, Yan J, Risacher SL, Saykin AJ, Shen L, Zhang D; Alzheimer's Disease Neuroimaging Initiative. Mining outcome-relevant brain imaging genetic associations via three-way sparse canonical correlation analysis in Alzheimer's disease. *Sci Rep*. 2017 Mar 14;7:44272. ADNI
680. Park JY, Na HK, Kim S, Kim H, Kim HJ, Seo SW, Na DL, Han CE, Seong JK; Alzheimer's Disease Neuroimaging Initiative. Robust identification of alzheimer's disease subtypes based on cortical atrophy patterns. *Sci Rep*. 2017 Mar 9;7:43270. ADNI
681. Rodrigue AL, McDowell JE, Tandon N, Keshavan MS, Tamminga CA, **Pearlson GD**, Sweeney JA, Gibbons RD, Clementz BA. Multivariate Relationships between cognition and brain anatomy across the psychosis spectrum. *Biol Psychiatry, Cogn Neurosci Neuroimaging*. 2018 Dec;3(12):992-1002.
682. Dager AD, Tice MR, Book GA, Tennen H, Raskin SA, Austad CS, Wood RM, Fallahi CR, Hawkins KA, **Pearlson GD**. Relationship between fMRI response during a nonverbal memory task and marijuana use in college students. *Drug Alcohol Depend*. 2018 Jul 1;188:71-78.
683. Meda SA, Hawkins KA, Dager AD, Tennen H, Khadka S, Austad CS, Wood RM, Raskin S, Fallahi CR, **Pearlson GD**. Longitudinal effects of alcohol consumption on the hippocampus and parahippocampus in college students. *Biol Psychiatry, Cogn Neurosci Neuroimaging*. 2018 Jul;3(7):610-617.
684. Ellingson JM, Potenza MN, **Pearlson GD**. Methodological factors as a potential source of discordance between self-report and behavioral measures of impulsivity and related constructs. *Addict Behav*. 2018 Sep;84:126-130.
685. Shafee R, Nanda P, Padmanabhan JL, Tandon N, Alliey-Rodriguez N, Kalapurakkel S, Weiner DJ, Gur RE, Keefe RSE, Hill SK, Bishop JR, Clementz BA, Tamminga CA, Gershon ES, **Pearlson GD**, Keshavan MS, Sweeney JA, McCarroll SA, Robinson EB. Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. *Transl Psychiatry*. 2018 Apr 12;8(1):78.
686. Abush H, Ghose S, Van Enkevort EA, Clementz BA, **Pearlson GD**, Sweeney JA, Keshavan MS, Tamminga CA, Ivleva EI. Associations between adolescent cannabis use and brain structure in psychosis. *Psychiatry Res Neuroimaging*. 2018 Jun 30;276:53-64.
687. Ji L, **Pearlson GD**, Hawkins KA, Steffens DC, Guo H, Wang L. A new measure for neural compensation is positively correlated with working memory and gait speed. *Front Aging Neurosci*. 2018 Mar 19;10:71.
688. Taylor BA, Dager AD, Panza GA, Zaleski AL, Meda S, Book G, Stevens MC, Tartar S, White CM, Polk DM, **Pearlson GD**, Thompson PD. The effect of high-dose atorvastatin on neural activity and cognitive function. *Am Heart J*. 2018 Mar;197:166-174.
689. Zhou X, Chen Y, Mok KY, Zhao Q, Chen K, Chen Y, Hardy J, Li Y, Fu AKY, Guo Q, Ip NY; Alzheimer's Disease Neuroimaging Initiative. Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer's disease pathogenesis. *Proc Natl Acad Sci USA*. 2018 Feb 20;115(8):1697-1706. ADNI



690. van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, **Pearlson GD**, Et Al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium. Biol Psychiatry. 2018 Nov 1;84(9):644-654.
691. Kelly S, Jahanshad N, **Pearlson GD**, Et al. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI working group. Mol Psychiatry. 2018 May;23(5):1261-1269.
692. Shagan S, Shagan D, Shagan B, Fiszdon JM, Thime W, Haber LC, **Pearlson GD**, Choi J. How music impacts visual attention training in schizophrenia: A pilot study. J Nerv Ment Dis. 2018 Dec;206(12):968-970.
693. Stevens MC, **Pearlson GD**, Calhoun VD, Bessette KL. Functional neuroimaging evidence for distinct neurobiological pathways in attention-deficit/hyperactivity disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Aug;3(8):675-685.
694. *Lu D, Popuri K, Ding GW, Balachandar R, Beg MF; Alzheimer's Disease Neuroimaging Initiative. Multimodal and multiscale deep neural networks for the early diagnosis of Alzheimer's disease using structural MR and FDG-PET images. Sci Rep. 2018 Apr 9;8(1):5697. ADNI*
695. Rubin LH, Li S, Yao L, Keedy SK, Reilly JL, Hill SK, Bishop JR, Sue Carter C, Pournajafi-Nazarloo H, Drogos LL, Gershon E, **Pearlson GD**, Tamminga CA, Clementz BA, Keshavan MS, Lui S, Sweeney JA. Peripheral oxytocin and vasopressin modulates regional brain activity differently in men and women with schizophrenia. Schizophr Res. 2018 Dec;202:173-179.
696. *Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, Cash DM, Thomas DL, Dick KM, Cardoso J, van Swieten J, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, de Mendonça A, Sorbi S, Warren JD, Crutch S, Fox NC, Ourselin S, Schott JM, Rohrer JD, Alexander DC; Genetic FTD Initiative (GENFI); Alzheimer's Disease Neuroimaging Initiative (ADNI). Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference. Nat Commun. 2018 Oct 15;9(1):4273. ADNI*
697. Gershon ES, **Pearlson GD**, Keshavan MS, Tamminga C, Clementz B, Buckley PF, Alliey-Rodriguez N, Liu C, Sweeney JA, Keedy S, Meda SA, Tandon N, Shafee R, Bishop JR, Ivleva EI. Genetic analysis of deep phenotyping projects in common disorders. Schizophr Res. 2018 May;195:51-57.
698. **Pearlson GD**. Resting state brain patterns, cognitive ability, and meritocracy. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Oct;3(10):824-825.
699. Hawkins KA, Emadi N, **Pearlson GD**, Taylor B, Khadka S, King D, Blank K. The effect of age and smoking on the hippocampus and memory in late middle age. Hippocampus. 2018 Nov;28(11):846-849.
700. Yu Q, Du Y, Chen J, Sui J, Adali T, **Pearlson GD**, Calhoun VD. Application of graph theory to assess static and dynamic brain connectivity: Approaches for building brain graphs. Proc IEEE Inst Electr Electron Eng. 2018 May;106(5):886-906.
701. Lizano P, Lutz O, Ling G, Padmanabhan J, Tandon N, Sweeney J, Tamminga C, **Pearlson GD**, Ruaño G, Kocherla M, Windemuth A, Clementz B, Gershon E, Keshavan M. VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders: a B-SNIP study. Transl Psychiatry. 2018 Oct 11;8(1):215.
702. Ji L, **Pearlson GD**, Zhang X, Steffens DC, Ji X, Guo H, Wang L. Physical exercise increases involvement of motor networks as a compensatory mechanism during a cognitively challenging task. Int J Geriatr Psychiatry. 2018 Aug;33(8):1153-1159.

703. Arbabshirani MR, Preda A, Vaidya JG, Potkin SG, **Pearlson GD**, Voyvodic J, Mathalon D, van Erp T, Michael A, Kiehl KA, Turner JA, Calhoun VD. Autoconnectivity: A new perspective on human brain function. *J Neurosci Methods*. 2019 Jul 15;323:68-76.
704. Ji JL, Diehl C, Schleifer C, Tamminga CA, Keshavan MS, Sweeney JA, Clementz BA, Hill SK, **Pearlson GD**, Yang G, Creatura G, Krystal JH, Repovs G, Murray J, Winkler A, Anticevic A. Schizophrenia exhibits bi-directional brain-wide alterations in cortico-striato-cerebellar circuits. *Cereb Cortex*. 2019 Dec 17;29(11):4463-4487.
705. Lizano P, Lutz O, Ling G, Lee AM, Eum S, Bishop JR, Kelly S, Pasternak O, Clementz B, **Pearlson GD**, Sweeney JA, Gershon E, Tamminga C, Keshavan M. Association of choroid plexus enlargement with cognitive, inflammatory, and structural phenotypes across the psychosis spectrum. *Am J Psychiatry*. 2019 Jul 1;176(7):564-572.
706. *Kundu S, Lukemire J, Wang Y, Guo Y; Alzheimer's Disease Neuroimaging Initiative. A novel joint brain network analysis using longitudinal Alzheimer's disease data. Sci Rep. 2019 Dec 20;9(1):19589. ADNI*
707. Cetin-Karayumak S, Di Biase MA, Chunga N, Reid B, Somes N, Lyall AE, Kelly S, Solgun B, Pasternak O, Vangel M, **Pearlson GD**, Tamminga C, Sweeney JA, Clementz B, Schretlen D, Viher PV, Stegmayer K, Walther S, Lee J, Crow T, James A, Voineskos A, Buchanan RW, Szeszko PR, Malhotra AK, Hegde R, McCarley R, Keshavan M, Shenton M, Rathi Y, Kubicki M. White matter abnormalities across the lifespan of schizophrenia: a harmonized multi-site diffusion MRI study. *Mol Psychiatry*. 2020 Dec;25(12):3208-3219.
708. Chye Y, Mackey S, Gutman BA, Ching CRK, Batalla A, Blaine S, Brooks S, Caparelli EC, Cousijn J, Dagher A, Foxe JJ, Goudriaan AE, Hester R, Hutchison K, Jahanshad N, Kaag AM, Korucuoglu O, Li CR, London ED, Lorenzetti V, Luijten M, Martin-Santos R, Meda SA, Momenan R, Morales A, Orr C, Paulus MP, **Pearlson GD**, Reneman L, Schmaal L, Sinha R, Solowij N, Stein DJ, Stein EA, Tang D, Uhlmann A, van Holst R, Veltman DJ, Verdejo-Garcia A, Wiers RW, Yücel M, Thompson PM, Conrod P, Garavan H. Subcortical surface morphometry in substance dependence: An ENIGMA addiction working group study. *Addict Biol*. 2020 Nov;25(6):e12830.
709. Choi J, Taylor B, Fiszdon JM, Kurtz MM, Tek C, Dewberry MJ, Haber LC, Shagan D, Assaf M, **Pearlson GD**. The synergistic benefits of physical and cognitive exercise in schizophrenia: Promoting motivation to enhance community effectiveness. *Schizophr Res Cogn*. 2019 Apr 25;19:100147.
710. Chen J, Calhoun VD, Lin D, Perrone-Bizzozero NI, Bustillo JR, **Pearlson GD**, et al. Shared genetic risk of schizophrenia and gray matter reduction in 6p22. *Schizophr Bull*. 2019 Jan 1;45(1):222-232.
711. Rabany L, Brocke S, Calhoun VD, Pittman B, Corbera S, Wexler BE, Bell MD, Pelphrey K, **Pearlson GD**, Assaf M. Corrigendum to "Dynamic functional connectivity in schizophrenia and autism spectrum disorder: Convergence, divergence and classification" *Neuroimage Clin*. 2019;24:102012.
712. Spreng RN, DuPre E, Ji JL, Yang G, Diehl C, Murray JD, **Pearlson GD**, Anticevic A. Structural covariance reveals alterations in control and salience network integrity in chronic schizophrenia. *Cereb Cortex*. 2019 Dec 17;29(12):5269-5284.
713. Steffens DC, Wang L, **Pearlson GD**. Functional connectivity predictors of acute depression treatment outcome. *Int Psychogeriatr*. 2019 Dec;31(12):1831-1835.
714. Chung YS, Poppe A, Novotny S, Epperson CN, Kober H, Granger DA, Blumberg HP, Ochsner K, Gross JJ, **Pearlson GD**, Stevens MC. A preliminary study of association between adolescent estradiol level and dorsolateral prefrontal cortex activity during emotion regulation. *Psychoneuroendocrinology*. 2019 Nov;109:104398.
715. Rabany L, Brocke S, Calhoun VD, Pittman B, Corbera S, Wexler BE, Bell MD, Pelphrey K, **Pearlson GD**, Assaf M. Corrigendum to "Dynamic functional connectivity in schizophrenia and

autism spectrum disorder: Convergence, divergence and classification" Neuroimage Clin. 2019;24:102012.

716. Kundu S, Lukemire J, Wang Y, Guo Y; Alzheimer's Disease Neuroimaging Initiative. A novel joint brain network analysis using longitudinal Alzheimer's disease data. Sci Rep. 2019 Dec 20;9(1):19589. ADNI
717. Gupta Y, Lama RK, Kwon GR; Alzheimer's Disease Neuroimaging Initiative. Prediction and classification of Alzheimer's disease based on combined features from apolipoprotein-E genotype, cerebrospinal fluid, MR, and FDG-PET imaging biomarkers. Front Comput Neurosci. 2019 Oct 16;13:72. ADNI
718. Horgusluoglu-Moloch E, Risacher SL, Crane PK, Hibar D, Thompson PM, Saykin AJ, Nho K; Alzheimer's Disease Neuroimaging Initiative (ADNI). Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways. Sci Rep. 2019 Oct 10;9(1):14498. ADNI
719. Yu Q, Chen J, Du Y, Sui J, Damaraju E, Turner JA, van Erp TGM, Macciardi F, Belger A, Ford JM, McEwen S, Mathalon DH, Mueller BA, Preda A, Vaidya J, **Pearlson GD**, Calhoun VD. A method for building a genome-connectome bipartite graph model. J Neurosci Methods. 2019 May 15;320:64-71.
720. Emam H, Steffens DC, **Pearlson GD**, Wang L. Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late-life depression. Int J Geriatr Psychiatry. 2019 May;34(5):730-737.
721. Iraj A, Fu Z, Damaraju E, DeRamus TP, Lewis N, Bustillo JR, Lenroot RK, Belger A, Ford JM, McEwen S, Mathalon DH, Mueller BA, **Pearlson GD**, Potkin SG, Preda A, Turner JA, Vaidya JG, van Erp TGM, Calhoun VD. Spatial dynamics within and between brain functional domains: A hierarchical approach to study time-varying brain function. Hum Brain Mapp. 2019 Apr 15;40(6):1969-1986.
722. van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, **Pearlson GD**, Yao N, Fukunaga M, Hashimoto R, Okada N, Yamamori H, Clark VP, Mueller BA, de Zwarte SMC, Ophoff RA, van Haren NEM, Andreassen OA, Gurholt TP, Gruber O, Kraemer B, Richter A, Calhoun VD, Crespo-Facorro B, Roiz-Santiañez R, Tordesillas-Gutiérrez D, Loughland C, Catts S, Fullerton JM, Green MJ, Henskens F, Jablensky A, Mowry BJ, Pantelis C, Quidé Y, Schall U, Scott RJ, Cairns MJ, Seal M, Tooney PA, Rasser PE. Reply to: New meta- and mega-analyses of magnetic Resonance Imaging Findings in Schizophrenia: Do they really increase our knowledge about the nature of the disease process? Biol Psychiatry. 2019 Apr 1;85(7):e35-e39.
723. Zhao Q, Liu M, Ha L, Zhou Y; Alzheimer's Disease Neuroimaging Initiative. Quantitative 18F-AV1451 brain tau PET imaging in cognitively normal older adults, mild cognitive impairment, and Alzheimer's disease patients. Front Neuroi. 2019 May 15;10:486. ADNI
724. Franzmeier N, Rubinski A, Neitzel J, Ewers M; Alzheimer's Disease Neuroimaging Initiative (ADNI). The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. Nat Commun. 2019 Apr 16;10(1):1766. ADNI
725. Alliey-Rodriguez N, Grey TA, Shafee R, Asif H, Lutz O, Bolo NR, Padmanabhan J, Tandon N, Klinger M, Reis K, Spring J, Coppes L, Zeng V, Hegde RR, Hoang DT, Bannai D, Nawaz U, Henson P, Liu S, Gage D, McCarroll S, Bishop JR, Hill S, Reilly JL, Lencer R, Clementz BA, Buckley P, Glahn DC, Meda SA, Narayanan B, **Pearlson GD**, Keshavan MS, Ivleva EI, Tamminga C, Sweeney JA, Curtis D, Badner JA, Keedy S, Rapoport J, Liu C, Gershon ES. NRXN1 is associated with enlargement of the temporal horns of the lateral ventricles in psychosis. Transl Psychiatry. 2019 Sep 17;9(1):230.
726. Banz BC, Worhunsky PD, Pittman BP, Astur RS, Tennen HA, Raskin SA, Austad CS, Wood RM, Fallahi CR, Potenza MN, **Pearlson GD**. Relationships between drinking quantity and frequency and

- behavioral and hippocampal BOLD responses during working memory performance involving allocentric spatial navigation in college students. Drug Alcohol Depend. 2019 Aug 1;201:236-243.
727. Hett K, Ta VT, Catheline G, Tourdias T, Manjón JV, Coupé P; Alzheimer's Disease Neuroimaging Initiative. Multimodal hippocampal subfield grading for Alzheimer's disease classification. Sci Rep. 2019 Sep 25;9(1):13845. ADNI
728. Iraj A, Deramus TP, Lewis N, Yaesoubi M, Stephen JM, Erhardt E, Belger A, Ford JM, McEwen S, Mathalon DH, Mueller BA, **Pearlson GD**, Potkin SG, Preda A, Turner JA, Vaidya JG, van Erp TGM, Calhoun VD. The spatial chronnectome reveals a dynamic interplay between functional segregation and integration. Hum Brain Mapp. 2019 Jul;40(10):3058-3077.
729. Li Y, Yao Z, Yu Y, Fu Y, Zou Y, Hu B; Alzheimer's Disease Neuroimaging Initiative. The influence of cerebrospinal fluid abnormalities and APOE 4 on PHF-Tau protein: Evidence from voxel analysis and graph theory. Front Aging Neurosci. 2019 Aug 8;11:208. ADNI
730. Liu J, Zhang B, Wilson G, Kong J; Alzheimer's Disease Neuroimaging Initiative. New perspective for non-invasive brain stimulation site selection in mild cognitive impairment: Based on meta- and functional connectivity analyses. Front Aging Neurosci. 2019 Aug 27;11:228. ADNI
731. Meda SA, Narayanan B, Chorlian D, Meyers JL, Gelernter J, Hesselbrock V, Bauer L, Calhoun VD, Porjesz B, **Pearlson GD**. Multivariate analyses reveal biological components related to neuronal signaling and immunity mediating electroencephalograms abnormalities in alcohol-dependent individuals from the collaborative study on the genetics of alcoholism cohort. Alcohol Clin Exp Res. 2019 Jul;43(7):1462-1477.
732. Parker DA, Hamm JP, McDowell JE, Keedy SK, Gershon ES, Ivleva EI, **Pearlson GD**, Keshavan MS, Tamminga CA, Sweeney JA, Clementz BA. Auditory steady-state EEG response across the schizo-bipolar spectrum. Schizophr Res. 2019 Jul;209:218-226.
733. Schilling LP, Pascoal TA, Zimmer ER, Mathotaarachchi S, Shin M, de Mello Rieder CR, Gauthier S, Palmieri A, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative. Regional amyloid- $\beta$  load and white matter abnormalities contribute to hypometabolism in Alzheimer's dementia. Mol Neurobiol. 2019 Jul;56(7):4916-4924. ADNI (Q4) ADNI
734. Yang Z, Zhuang X, Bird C, Sreenivasan K, Mishra V, Banks S, Cordes D; Alzheimer's Disease Neuroimaging Initiative. Performing sparse regularization and dimension reduction simultaneously in multimodal data fusion. Front Neurosci. 2019 Jul 3;13:642. ADNI
735. Zhou X, Chen Y, Mok KY, Kwok TCY, Mok VCT, Guo Q, Ip FC, Chen Y, Mullapudi N; Alzheimer's Disease Neuroimaging Initiative, Giusti-Rodríguez P, Sullivan PF, Hardy J, Fu AKY, Li Y, Ip NY. Non-coding variability at the APOE locus contributes to the Alzheimer's risk. Nat Commun. 2019 Jul 25;10(1):3310. ADNI
736. Chen J, Calhoun VD, Lin D, Perrone-Bizzozero NI, Bustillo JR, **Pearlson GD**, Potkin SG, van Erp TGM, Macciardi F, Ehrlich S, Ho BC, Sponheim SR, Wang L, Stephen JM, Mayer AR, Hanlon FM, Jung RE, Clementz BA, Keshavan MS, Gershon ES, Sweeney JA, Tamminga CA, Andreassen OA, Agartz I, Westlye LT, Sui J, Du Y, Turner JA, Liu J. Shared genetic risk of schizophrenia and gray matter reduction in 6p22.1. Schizophr Bull. 2019 Jan 1;45(1):222-232.
737. Emam H, Steffens DC, **Pearlson GD**, Wang L. Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late-life depression. Int J Geriatr Psychiatry. 2019 May;34(5):730-737.
738. Fryer SL, Roach BJ, Ford JM, Donaldson KR, Calhoun VD, **Pearlson GD**, Kiehl KA, Srihari VH, McGlashan TH, Woods SW, Mathalon DH. Should I stay or should I go? fMRI study of response inhibition in early illness schizophrenia and risk for psychosis. Schizophr Bull. 2019 Jan 1;45(1):158-168.

739. Goudey B, Fung BJ, Schieber C, Faux NG; Alzheimer's Disease Metabolomics Consortium; Alzheimer's Disease Neuroimaging Initiative. A blood-based signature of cerebrospinal fluid A $\beta$ 1-42 status. *Sci Rep*. 2019 Mar 11;9(1):4163. ADNI
740. Lee G, Nho K, Kang B, Sohn KA, Kim D; for Alzheimer's Disease Neuroimaging Initiative. Predicting Alzheimer's disease progression using multi-modal deep learning approach. *Sci Rep*. 2019 Feb 13;9(1):1952. ADNI
741. Lencer R, Yao L, Reilly JL, Keedy SK, McDowell JE, Keshavan MS, **Pearlson GD**, Tamminga CA, Gershon ES, Clementz BA, Lui S, Sweeney JA. Alterations in intrinsic fronto-thalamo-parietal connectivity are associated with cognitive control deficits in psychotic disorders. *Hum Brain Mapp*. 2019 Jan;40(1):163-174.
742. Mackey S, Allgaier N, Chaarani B, Spechler P, Orr C, Bunn J, Allen NB, Alia-Klein N, Batalla A, Blaine S, Brooks S, Caparelli E, Chye YY, Cousijn J, Dagher A, Desrivieres S, Feldstein-Ewing S, Foxe JJ, Goldstein RZ, Goudriaan AE, Heitzeg MM, Hester R, Hutchison K, Korucuoglu O, Li CR, London E, Lorenzetti V, Luijten M, Martin-Santos R, May A, Momenan R, Morales A, Paulus MP, **Pearlson GD**, Rousseau ME, Salmeron BJ, Schluter R, Schmaal L, Schumann G, Sjoerds Z, Stein DJ, Stein EA, Sinha R, Solowij N, Tapert S, Uhlmann A, Veltman D, van Holst R, Whittle S, Wright MJ, Yücel M, Zhang S, Yurgelun-Todd D, Hibar DP, Jahanshad N, Evans A, Thompson PM, Glahn DC, Conrod P, Garavan H; ENIGMA Addiction Working Group. Mega-analysis of gray matter volume in substance dependence: General and substance-specific regional effects. *Am J Psychiatry*. 2019 Feb 1;176(2):119-128.
743. Moran C, Beare R, Wang W, Callisaya M, Srikanth V; Alzheimer's Disease Neuroimaging Initiative. Type 2 diabetes mellitus, brain atrophy, and cognitive decline. *Neurology*. 2019 Feb 19;92(8):e823-e830. ADNI
744. Pushkarskaya H, Sobowale K, Henick D, Tolin DF, Anticevic A, **Pearlson GD**, Levy I, Harpaz-Rotem I, Pittenger C. Contrasting contributions of anhedonia to obsessive-compulsive, hoarding, and post-traumatic stress disorders. *J Psychiatr Res*. 2019 Feb;109:202-213.
745. Rashid B, Chen J, Rashid I, Damaraju E, Liu J, Miller R, Agcaoglu O, van Erp TGM, Lim KO, Turner JA, Mathalon DH, Ford JM, Voyvodic J, Mueller BA, Belger A, McEwen S, Potkin SG, Preda A, Bustillo JR, **Pearlson GD**, Calhoun VD. A framework for linking resting-state connectome/genome features in schizophrenia: A pilot study. *Neuroimage*. 2019 Jan 1;184:843-854.
746. Reininghaus U, Böhnke JR, Chavez-Baldini U, Gibbons R, Ivleva E, Clementz BA, **Pearlson GD**, Keshavan MS, Sweeney JA, Tamminga CA. Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). *World Psychiatry*. 2019 Feb;18(1):67-76.
747. Varatharajah Y, Ramanan VK, Iyer R, Vemuri P; Alzheimer's Disease Neuroimaging Initiative. Predicting Short-term MCI-to-AD Progression using imaging, CSF, genetic factors, cognitive resilience, and demographics. *Sci Rep*. 2019 Feb 19;9(1):2235. ADNI
748. Yu Q, Chen J, Du Y, Sui J, Damaraju E, Turner JA, van Erp TGM, MacCiaridi F, Belger A, Ford JM, McEwen S, Mathalon DH, Mueller BA, Preda A, Vaidya J, **Pearlson GD**, Calhoun VD. A method for building a genome-connectome bipartite graph model. *J Neurosci Methods*. 2019 May 15;320:64-71.
749. Stan AD, Tamminga CA, Han K, Kim JB, Padmanabhan J, Tandon N, Hudgens-Haney ME, Keshavan MS, Clementz BA, **Pearlson GD**, Sweeney JA, Gibbons RD. Associating psychotic symptoms with altered brain anatomy in psychotic disorders using multidimensional item response theory models. *Cereb Cortex*. 2020 May 14;30(5):2939-2947.
750. DeRamus TP, Silva RF, Iraj A, Damaraju E, Belger A, Ford JM, McEwen SC, Mathalon DH, Mueller BA, **Pearlson GD**, Potkin SG, Preda A, Turner JA, Vaidya JG, van Erp TGM, Calhoun VD. Covarying structural alterations in laterality of the temporal lobe in schizophrenia: A case for source-based laterality. *NMR Biomed*. 2020 Jun;33(6):e4294.

751. Alexander-Bloch AF, Raznahan A, Vandekar SN, Seidlitz J, Lu Z, Matthias SR, Knowles E, Mollon J, Rodrigue A, Curran JE, Görring HHH, Satterthwaite TD, Gur RE, Bassett DS, Hoftman GD, **Pearlson GD**, Shinohara RT, Liu S, Fox PT, Almasy L, Blangero J, Glahn DC. Imaging local genetic influences on cortical folding. *Proc Natl Acad Sci U S A*. 2020 Mar 31;117(13):7430-7436.
752. Bannai D, Lizano P, Kasetty M, Lutz O, Zeng V, Sarvode S, Kim LA, Hill S, Tamminga C, Clementz B, Gershon E, **Pearlson GD**, Miller JB, Keshavan M. Retinal layer abnormalities and their association with clinical and brain measures in psychotic disorders: A preliminary study. *Psychiatry Res Neuroimaging*. 2020 May 30;299:111061.
753. Blackburn KM, Ivleva EI, Weir RA, Kim M, Hopkins SC, Hudgens-Haney ME, Keedy SK, Gershon ES, Sweeney JA, Keshavan MS, **Pearlson GD**, Clementz BA, Tamminga CA, Vernino S. NMDA receptor antibody seropositivity in psychosis: A pilot study from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP). *Schizophr Res*. 2020 Apr;218:318-320.
754. Dai W, Chen M, Duan W, Zhao L, Bolo NR, Tamminga C, Clementz BA, **Pearlson GD**, Alsop DC, Keshavan M. Abnormal perfusion fluctuation and perfusion connectivity in bipolar disorder measured by dynamic arterial spin labeling. *Bipolar Disord*. 2020 Jun;22(4):401-410.
755. Hett K, Ta VT, Catheline G, Tourdias T, Manjón JV, Coupé P; Alzheimer's Disease Neuroimaging Initiative. Author Correction: Multimodal hippocampal subfield grading for Alzheimer's disease classification. *Sci Rep*. 2020 Jun 30;10(1):10969. ADNI
756. Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, Hansson O; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFinder Study. Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. *Nat Commun*. 2020 May 26;11(1):2612. ADNI
757. Grasby KL, Walton E, Wang M, Alzheimer's Disease Neuroimaging Initiative; CHARGE Consortium; EPIGEN Consortium; IMAGEN Consortium; SYS Consortium; Parkinson's Progression Markers Initiative, Alvim MKM, Glahn DC, Medland SE, Et al. Enhancing neuroimaging genetics through meta-analysis consortium (ENIGMA)—genetics working group. The genetic architecture of the human cerebral cortex. *Science*. 2020 Mar 20;367(6484). ADNI
758. Chang YC, Wu JT, Hong MY, Tung YA, Hsieh PH, Yee SW, Giacomini KM, Oyang YJ, Chen CY; Alzheimer's Disease Neuroimaging Initiative. GenEpi: gene-based epistasis discovery using machine learning. *BMC Bioinformatics*. 2020 Feb 24;21(1):68. ADNI
759. Shen X, Ma S, Vemuri P, Simon G; Alzheimer's Disease Neuroimaging Initiative. Challenges and opportunities with causal discovery algorithms: Application to Alzheimer's pathophysiology. *Sci Rep*. 2020 Feb 19;10(1):2975. ADNI
760. Yan T, Liang J, Gao J, Wang L, Fujioka H; Alzheimer Disease Neuroimaging Initiative, Zhu X, Wang X. FAM222A encodes a protein which accumulates in plaques in Alzheimer's disease. *Nat Commun*. 2020 Jan 21;11(1):411. ADNI
761. Franzmeier N, Neitzel J, Rubinski A, Smith R, Strandberg O, Ossenkoppele R, Hansson O, Ewers M; Alzheimer's Disease Neuroimaging Initiative (ADNI). Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. *Nat Commun*. 2020 Jan 17;11(1):347. ADNI
762. Haeny AM, Gueorguieva R, Morean ME, Krishnan-Sarin S, DeMartini KS, **Pearlson GD**, Anticevic A, Krystal JH, O'Malley SS. The association of impulsivity and family history of alcohol use disorder on alcohol use and consequences. *Alcohol Clin Exp Res*. 2020 Jan;44(1):159-167.
763. Trotti RL, Parker DA, Sabatinelli D, Tamminga CA, Gershon ES, Keedy SK, Keshavan MS, **Pearlson GD**, Sweeney JA, McDowell JE, Clementz BA. Electrophysiological correlates of emotional scene processing in bipolar disorder. *J Psychiatr Res*. 2020 Jan;120:83-90.

764. Zhang W, Lei D, Keedy SK, Ivleva EI, Eum S, Yao L, Tamminga CA, Clementz BA, Keshavan MS, **Pearlson GD**, Gershon ES, Bishop JR, Gong Q, Lui S, Sweeney JA. Brain gray matter network organization in psychotic disorders. Neuropsychopharmacology. 2020 Mar;45(4):666-674.
765. Haeny AM, Gueorguieva R, Morean ME, Krishnan-Sarin S, DeMartini KS, **Pearlson GD**, Anticevic A, Krystal JH, O'Malley SS. The association of impulsivity and family history of alcohol use disorder on alcohol use and consequences. Alcohol Clin Exp Res. 2020 Jan;44(1):159-167.
766. Ji L, Meda SA, Tamminga CA, Clementz BA, Keshavan MS, Sweeney JA, Gershon ES, **Pearlson GD**. Characterizing functional regional homogeneity (ReHo) as a B-SNIP psychosis biomarker using traditional and machine learning approaches. Schizophr Res. 2020 Jan;215:430-438.
767. Mollon J, Mathias SR, Knowles EEM, Rodrigue A, Koenis MMG, **Pearlson GD**, Reichenberg A, Barrett J, Denbow D, Aberizk K, Zatony M, Poldrack RA, Blangero J, Glahn DC. Cognitive impairment from early to middle adulthood in patients with affective and nonaffective psychotic disorders. Psychol Med. 2020 Jan;50(1):48-57.
768. **Pearlson GD**. Binges, brains, birthdays, and BACs. Alcohol Clin Exp Res. 2021 Jan;45(1):54-55.
769. Zeng V, Lizano P, Bolo NR, Lutz O, Brady R Jr, Ivleva EI, Dai W, Clementz B, Tamminga C, **Pearlson GD**, Keshavan M. Altered cerebral perfusion in bipolar disorder: A pCASL MRI study. Bipolar Disord. 2021 Mar;23(2):130-140.
770. *Franzmeier N, Suárez-Calvet M, Frontzkowski L, Moore A, Hohman TJ, Morenas-Rodriguez E, Nuscher B, Shaw L, Trojanowski JQ, Dichgans M, Kleinberger G, Haass C, Ewers M; Alzheimer's Disease Neuroimaging Initiative (ADNI). Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Mol Neurodegener. 2020 Oct 8;15(1):57.*
771. Tamminga CA, Clementz BA, **Pearlson GD**, Keshavan M, Gershon ES, Ivleva EI, McDowell J, Meda SA, Keedy S, Calhoun VD, Lizano P, Bishop JR, Hudgens-Haney M, Alliey-Rodriguez N, Asif H, Gibbons R. Biotyping in psychosis: using multiple computational approaches with one data set. Neuropsychopharmacology. 2021 Jan;46(1):143-155.
772. Vergara VM, Damaraju E, Turner JA, **Pearlson GD**, Belger A, Mathalon DH, Potkin SG, Preda A, Vaidya JG, van Erp TGM, McEwen S, Calhoun VD. Altered domain functional network connectivity strength and randomness in schizophrenia. Front Psychiatry. 2019 Jul 23;10:499.
773. Fu Z, Iraj A, Turner JA, Sui J, Miller R, **Pearlson GD**, Calhoun VD. Dynamic state with covarying brain activity-connectivity: On the pathophysiology of schizophrenia. Neuroimage. 2021 Jan 1;224:117385.
774. Iraj A, Deramus TP, Lewis N, Yaesoubi M, Stephen JM, Erhardt E, Belger A, Ford JM, McEwen S, Mathalon DH, Mueller BA, **Pearlson GD**, Potkin SG, Preda A, Turner JA, Vaidya JG, van Erp TGM, Calhoun VD. The spatial chronnectome reveals a dynamic interplay between functional segregation and integration. Hum Brain Mapp. 2019 Jul;40(10):3058-3077.
775. Gertler J, Novotny S, Poppe A, Chung YS, Gross JJ, **Pearlson GD**, Stevens MC. Neural correlates of non-specific skin conductance responses during resting state fMRI. Neuroimage. 2020 Jul 1;214:116721.
776. Fu Z, Sui J, Turner JA, Du Y, Assaf M, **Pearlson GD**, Calhoun VD. Dynamic functional network reconfiguration underlying the pathophysiology of schizophrenia and autism spectrum disorder. Hum Brain Mapp. 2021 Jan;42(1):80-94.
777. *Fotiadis P, Reijmer YD, Van Veluw SJ, Martinez-Ramirez S, Karahanoglu FI, Gokcal E, Schwab KM; Alzheimer's Disease Neuroimaging Initiative study group, Goldstein JN, Rosand J, Viswanathan A, Greenberg SM, Gurol ME. White matter atrophy in cerebral amyloid angiopathy. Neurology. 2020 Aug 4;95(5):e554-e562.*

778. Woods SW, Bearden CE, Sabb FW, Stone WS, Torous J, Cornblatt BA, Perkins DO, Cadenhead KS, Addington J, Powers AR 3rd, Mathalon DH, Calkins ME, Wolf DH, Corcoran CM, Horton LE, Mittal VA, Schiffman J, Ellman LM, Strauss GP, Mamah D, Choi J, **Pearlson GD**, Shah JL, Fusar-Poli P, Arango C, Perez J, Koutsouleris N, Wang J, Kwon JS, Walsh BC, McGlashan TH, Hyman SE, Gur RE, Cannon TD, Kane JM, Anticevic A. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. Schizophr Res. 2021 Jan;227:10-17.
779. Koenis MMG, Durnez J, Rodrigue AL, Mathias SR, Alexander-Bloch AF, Barrett JA, Doucet GE, Frangou S, Knowles EEM, Mollon J, Denbow D, Aberizk K, Zatony M, Janssen RJ, Curran JE, Blangero J, Poldrack RA, **Pearlson GD**, Glahn DC. Associations of cannabis use disorder with cognition, brain structure, and brain function in African Americans. Hum Brain Mapp. 2021 Apr 15;42(6):1727-1741.
780. Asif H, Alliey-Rodriguez N, Keedy S, Tamminga CA, Sweeney JA, **Pearlson GD**, Clementz BA, Keshavan MS, Buckley P, Liu C, Neale B, Gershon ES. GWAS significance thresholds for deep phenotyping studies can depend upon minor allele frequencies and sample size. Mol Psychiatry. 2021 Jun;26(6):2048-2055.
781. Clementz BA, Trotti RL, **Pearlson GD**, Keshavan MS, Gershon ES, Keedy SK, Ivleva EI, McDowell JE, Tamminga CA. Testing psychosis phenotypes from bipolar-schizophrenia network for intermediate phenotypes for clinical application: Biotype characteristics and targets. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Aug;5(8):808-818.
782. Lizano P, Lutz O, Xu Y, Rubin LH, Paskowitz L, Lee AM, Eum S, Keedy SK, Hill SK, Reilly JL, Wu B, Tamminga CA, Clementz BA, **Pearlson GD**, Gershon ES, Keshavan MS, Sweeney JA, Bishop JR. Multivariate relationships between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis. Mol Psychiatry. 2021 Jul;26(7):3430-3443.
783. Hudgens-Haney ME, Clementz BA, Ivleva EI, Keshavan MS, **Pearlson GD**, Gershon ES, Keedy SK, Sweeney JA, Gaudoux F, Bunouf P, Canolle B, Tonner F, Gatti-McArthur S, Tamminga CA. Cognitive impairment and diminished neural responses constitute a biomarker signature of negative symptoms in psychosis. Schizophr Bull. 2020 Feb 11;46(5):1269-81. Online ahead of print.
784. Hyatt CJ, Calhoun VD, Pittman B, Corbera S, Bell MD, Rabany L, Pelphrey K, **Pearlson GD**, Assaf M. Default mode network modulation by mentalizing in young adults with autism spectrum disorder or schizophrenia. Neuroimage Clin. 2020;27:102343.
785. Du Y, Hao H, Wang S, **Pearlson GD**, Calhoun VD. Identifying commonality and specificity across psychosis sub-groups via classification based on features from dynamic connectivity analysis. Neuroimage Clin. 2020;27:102284.
786. Kelly S, Guimond S, Pasternak O, Lutz O, Lizano P, Cetin-Karayumak S, Sweeney JA, **Pearlson GD**, Clementz BA, McDowell JE, Tamminga CA, Shenton ME, Keshavan MS. White matter microstructure across brain-based biotypes for psychosis - findings from the bipolar-schizophrenia network for intermediate phenotypes. Psychiatry Res Neuroimaging. 2021 Feb 28;308:111234.
787. Luo N, Sui J, Abrol A, Chen J, Turner JA, Damaraju E, Fu Z, Fan L, Lin D, Zhuo C, Xu Y, Glahn DC, Rodrigue AL, Banich MT, **Pearlson GD**, Calhoun VD. Structural brain architectures match intrinsic functional networks and vary across domains: A Study from 15,000+ Individuals. Cereb Cortex. 2020 Sep 3;30(10):5460-5470.
788. Okuneye VT, Meda S, **Pearlson GD**, Clementz BA, Keshavan MS, Tamminga CA, Ivleva E, Sweeney JA, Gershon ES, Keedy SK. Resting state auditory-language cortex connectivity is associated with hallucinations in clinical and biological subtypes of psychotic disorders. Neuroimage Clin. 2020;27:102358.
789. Herms EN, Bishop JR, Okuneye VT, Tamminga CA, Keshavan MS, **Pearlson GD**, Clementz BA, McDowell JE, Ivleva EI, Gershon ES, Sweeney JA, Keedy SK. No connectivity alterations for striatum, default mode, or salience network in association with self-reported antipsychotic medication dose in a large chronic patient group. Schizophr Res. 2020 Sep;223:359-360.



790. Rabin RA, Mackey S, Parvaz MA, Cousijn J, Li CS, **Pearlson GD**, Schmaal L, Sinha R, Stein E, Veltman D, Thompson PM, Conrod P, Garavan H, Alia-Klein N, Goldstein RZ. Common and gender-specific associations with cocaine use on gray matter volume: Data from the ENIGMA addiction working group. *Hum Brain Mapp*. 2022 Jan;43(1):543-554.
791. Brakemeier S, Sprenger A, Meyhöfer I, McDowell JE, Rubin LH, Hill SK, Keshavan MS, **Pearlson GD**, Tamminga CA, Gershon ES, Keedy SS, Sweeney JA, Clementz BA, Lencer R. Smooth pursuit eye movement deficits as a biomarker for psychotic features in bipolar disorder-Findings from the PARDIP study. *Bipolar Disord*. 2020 Sep;22(6):602-611.
792. Lutz O, Lizano P, Mothi SS, Zeng V, Hegde RR, Hoang DT, Henson P, Brady R, Tamminga CA, **Pearlson GD**, Clementz BA, Sweeney JA, Keshavan MS. Do neurobiological differences exist between paranoid and non-paranoid schizophrenia? Findings from the bipolar schizophrenia network on intermediate phenotypes study. *Schizophr Res*. 2020 Sep;223:96-104.
793. Massa N, Owens AV, Harmon W, Bhattacharya A, Ivleva EI, Keedy S, Sweeney JA, **Pearlson GD**, Keshavan MS, Tamminga CA, Clementz BA, Duncan E. Relationship of prolonged acoustic startle latency to diagnosis and biotype in the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) cohort. *Schizophr Res*. 2020 Feb;216:357-366.
794. Miller RL, **Pearlson GD**, Calhoun VD. Whole brain polarity regime dynamics are significantly disrupted in schizophrenia and correlate strongly with network connectivity measures. *PLoS One*. 2019 Dec 11;14(12):e0224744.
795. *Teipel SJ, Fritz HC, Grothe MJ; Alzheimer's Disease Neuroimaging Initiative. Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease. Neurology. 2020 Sep 8;95(10):e1301-e1311.*
796. Gotra MY, Hill SK, Gershon ES, Tamminga CA, Ivleva EI, **Pearlson GD**, Keshavan MS, Clementz BA, McDowell JE, Buckley PF, Sweeney JA, Keedy SK. Distinguishing patterns of impairment on inhibitory control and general cognitive ability among bipolar with and without psychosis, schizophrenia, and schizoaffective disorder. *Schizophr Res*. 2020 Sep;223:148-157.
797. Hochberger WC, Eskridge CLM, Bishop JR, Reilly JL, Rubin LH, Keedy S, Gershon ES, Tamminga CA, **Pearlson GD**, Ragozzino M, Keshavan MS, Sweeney JA, Hill SK. Catechol-O-methyltransferase genotype differentially contributes to the flexibility and stability of cognitive sets in patients with psychotic disorders and their first-degree relatives. *Schizophr Res*. 2020 Sep;223:236-241.
798. Faghiri A, Iraj A, Damaraju E, Belger A, Ford J, Mathalon D, Mcewen S, Mueller B, **Pearlson GD**, Preda A, Turner J, Vaidya JG, Van Erp TGM, Calhoun VD. Weighted average of shared trajectory: A new estimator for dynamic functional connectivity efficiently estimates both rapid and slow changes over time. *J Neurosci Methods*. 2020 Jan 21;334:108600. Online ahead of print.
799. Rokham H, **Pearlson GD**, Abrol A, Falakshahi H, Plis S, Calhoun VD. Addressing inaccurate nosology in mental health: A multilabel data cleansing approach for detecting label noise from structural magnetic resonance imaging data in mood and psychosis disorders. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2020 Aug;5(8):819-832.
800. *Kundu S, Lukemire J, Wang Y, Guo Y; Alzheimer's Disease Neuroimaging Initiative. A novel joint brain network analysis using longitudinal Alzheimer's disease data. Sci Rep. 2019 Dec 20;9(1):19589.*
801. Rodrigue AL, Mastrovito D, Esteban O, Durnez J, Koenis MMG, Janssen R, Alexander-Bloch A, Knowles EM, Mathias SR, Mollon J, **Pearlson GD**, Frangou S, Blangero J, Poldrack RA, Glahn DC. Searching for imaging biomarkers of psychotic dysconnectivity. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2021 Dec;6(12):1135-1144.
802. Radua J, Vieta E, Shinohara R, Kochunov P, Quidé Y, Green MJ, Weickert CS, Weickert T, Bruggemann J, Kircher T, Nenadić I, Et al; ENIGMA Consortium collaborators. Increased power by

harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. *Neuroimage*. 2020 Sep;218:116956. ENIGMA

803. Mothi SS, Sudarshan M, Tandon N, Tamminga C, **Pearlson GD**, Sweeney J, Clementz B, Keshavan MS. Machine learning improved classification of psychoses using clinical and biological stratification: Update from the bipolar-schizophrenia network for intermediate phenotypes (B-SNIP). *Schizophr Res*. 2019 Dec;214:60-69.
804. Squillario M, Abate G, Tomasi F, Tozzo V, Barla A, Uberti D; Alzheimer's Disease Neuroimaging Initiative. A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensemble and on multivariate algorithms, to characterize late onset Alzheimer's disease. *Sci Rep*. 2020 Jul 21;10(1):12063. ADNI
805. Knowles EEM, Mathias SR, **Pearlson GD**, Barrett J, Mollon J, Denbow D, Aberzik K, Zatony M, Glahn DC. Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence. *Schizophr Res*. 2019 Apr;206:333-346.
806. Sendi MSE, **Pearlson GD**, Mathalon DH, Ford JM, Preda A, van Erp TGM, Calhoun VD. Multiple overlapping dynamic patterns of the visual sensory network in schizophrenia. *Schizophr Res*. 2021 Feb;228:103-111.
807. Seitz J, Cetin-Karayumak S, Lyall A, Pasternak O, Baxi M, Vangel M, **Pearlson GD**, Tamminga C, Sweeney J, Clementz B, Schretlen D, Viher PV, Stegmayer K, Walther S, Lee J, Crow T, James A, Voineskos A, Buchanan RW, Szeszko PR, Malhotra A, Keshavan M, Koerte IK, Shenton ME, Rathi Y, Kubicki M. Investigating sexual dimorphism of human white matter in a harmonized, multisite diffusion magnetic resonance imaging study. *Cereb Cortex*. 2021 Jan 1;31(1):201-212.
808. Seitz-Holland J, Cetin-Karayumak S, Wojcik JD, Lyall A, Levitt J, Shenton ME, Pasternak O, Westin CF, Baxi M, Kelly S, Meshulam-Gately R, Vangel M, **Pearlson GD**, Tamminga CA, Sweeney JA, Clementz BA, Schretlen D, Viher PV, Stegmayer K, Walther S, Lee J, Crow T, James A, Voineskos A, Buchanan RW, Szeszko PR, Malhotra AK, Rathi Y, Keshavan M, Kubicki M. Elucidating the relationship between white matter structure, demographic, and clinical variables in schizophrenia-a multicenter harmonized diffusion tensor imaging study. *Mol Psychiatry*. 2021 Sep;26(9):5357-5370.
809. Book GA, Meda SA, Janssen R, Dager AD, Poppe A, Stevens MC, Assaf M, Glahn D, **Pearlson GD**. Effects of weather and season on human brain volume. *PLoS One*. 2021 Mar 24;16(3):e0236303.
810. DeMartini KS, Gueorguieva R, **Pearlson GD**, Krishnan-Sarin S, Anticevic A, Ji LJ, Krystal JH, O'Malley SS. Mapping data-driven individualized neurobehavioral phenotypes in heavy alcohol drinkers. *Alcohol Clin Exp Res*. 2021 Apr;45(4):841-853.
811. Frässle S, Harrison SJ, Heinzle J, Clementz BA, Tamminga CA, Sweeney JA, Gershon ES, Keshavan MS, **Pearlson GD**, Powers A, Stephan KE. Regression dynamic causal modeling for resting-state fMRI. *Hum Brain Mapp*. 2021 May;42(7):2159-2180.
812. Trotti RL, Abdelmageed S, Parker DA, Sabatinelli D, Tamminga CA, Gershon ES, Keedy SK, Keshavan MS, **Pearlson GD**, Sweeney JA, McDowell JE, Clementz BA. Neural processing of repeated emotional scenes in schizophrenia, schizoaffective disorder, and bipolar disorder. *Schizophr Bull*. 2021 Aug 21;47(5):1473-1481.
813. Yan W, Zhao M, Fu Z, **Pearlson GD**, Sui J, Calhoun VD. Mapping relationships among schizophrenia, bipolar and schizoaffective disorders: A deep classification and clustering framework using fMRI time series. *Schizophr Res*. 2022 Jul;245:141-150.
814. Brown JA, Jackson BS, Burton CR, Hoy JE, Sweeney JA, **Pearlson GD**, Keshavan MS, Keedy SS, Gershon ES, Tamminga CA, Clementz BA, McDowell JE. Reduced white matter microstructure in bipolar disorder with and without psychosis. *Bipolar Disord*. 2021 Dec;23(8):801-809.

815. Huang LY, Jackson BS, Rodrigue AL, Tamminga CA, Gershon ES, **Pearlson GD**, Keshavan MS, Keedy SS, Hill SK, Sweeney JA, Clementz BA, McDowell JE. Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophrenia network for intermediate phenotypes 2 (B-SNIP2). *Psychol Med*. 2022 Oct;52(13):2692-2701.
816. Türközer HB, Ivleva EI, Palka J, Clementz BA, Shafee R, **Pearlson GD**, Sweeney JA, Keshavan MS, Gershon ES, Tamminga CA. Biomarker profiles in psychosis risk groups within unaffected relatives based on familiarity and age. *Schizophr Bull*. 2021 Jul 8;47(4):1058-1067.
817. Fu Z, Iraj A, Turner JA, Sui J, Miller R, **Pearlson GD**, Calhoun VD. Dynamic state with covarying brain activity-connectivity: On the pathophysiology of schizophrenia. *Neuroimage*. 2021 Jan 1;224:117385.
818. Frässle S, Harrison SJ, Heinzle J, Clementz BA, Tamminga CA, Sweeney JA, Gershon ES, Keshavan MS, **Pearlson GD**, Powers A, Stephan KE. Regression dynamic causal modeling for resting-state fMRI. *Hum Brain Mapp*. 2021 May;42(7):2159-2180.
819. Sendi MSE, **Pearlson GD**, Mathalon DH, Ford JM, Preda A, van Erp TGM, Calhoun VD. Multiple overlapping dynamic patterns of the visual sensory network in schizophrenia. *Schizophr Res*. 2021 Feb;228:103-111.
820. Woods SW, Bearden CE, Sabb FW, Stone WS, Torous J, Cornblatt BA, Perkins DO, Cadenhead KS, Addington J, Powers AR 3rd, Mathalon DH, Calkins ME, Wolf DH, Corcoran CM, Horton LE, Mittal VA, Schiffman J, Ellman LM, Strauss GP, Mamah D, Choi J, **Pearlson GD**, Shah JL, Fusar-Poli P, Arango C, Perez J, Koutsouleris N, Wang J, Kwon JS, Walsh BC, McGlashan TH, Hyman SE, Gur RE, Cannon TD, Kane JM, Anticevic A. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. *Schizophr Res*. 2021 Jan;227:10-17.
821. Fu Z, Sui J, Turner JA, Du Y, Assaf M, **Pearlson GD**, Calhoun VD. Dynamic functional network reconfiguration underlying the pathophysiology of schizophrenia and autism spectrum disorder. *Hum Brain Mapp*. 2021 Jan;42(1):80-94.
822. Sendi MSE, Zendeherouh E, Ellis CA, Liang Z, Fu Z, Mathalon DH, Ford JM, Preda A, van Erp TGM, Miller RL, **Pearlson GD**, Turner JA, Calhoun VD. Aberrant dynamic functional connectivity of default mode network in schizophrenia and links to symptom severity. *Front Neural Circuits*. 2021 Mar 18;15:649417.
823. Huang LY, Jackson BS, Rodrigue AL, Tamminga CA, Gershon ES, **Pearlson GD**, Keshavan MS, Keedy SS, Hill SK, Sweeney JA, Clementz BA, McDowell JE. Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophrenia network for intermediate phenotypes 2 (B-SNIP2). *Psychol Med*. 2022 Oct;52(13):2692-2701.
824. Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkopppele R, Strandberg OT, La Joie R, Aksman LM, Grothe MJ, Iturria-Medina Y; Alzheimer's Disease Neuroimaging Initiative, Pontecorvo MJ, Devous MD, Rabinovici GD, Alexander DC, Lyoo CH, Evans AC, Hansson O. Four distinct trajectories of tau deposition identified in Alzheimer's disease. *Nat Med*. 2021 May;27(5):871-881. ADNI
825. **Pearlson GD**, Stevens MC, D'Souza DC. Cannabis and driving. *Front Psychiatry*. 2021 Sep 24;12:689444.
826. Frässle S, Harrison SJ, Heinzle J, Clementz BA, Tamminga CA, Sweeney JA, Gershon ES, Keshavan MS, **Pearlson GD**, Powers A, Stephan KE. Regression dynamic causal modeling for resting-state fMRI. *Hum Brain Mapp*. 2021 May;42(7):2159-2180.
827. Rodrigue AL, Mastrovito D, Esteban O, Durnez J, Koenis MMG, Janssen R, Alexander-Bloch A, Knowles EM, Mathias SR, Mollon J, **Pearlson GD**, Frangou S, Blangero J, Poldrack RA, Glahn DC. Searching for imaging biomarkers of psychotic dysconnectivity. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2021 Dec;6(12):1135-1144.

828. *Gonneaud J, Baria AT, Pichet Binette A, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, Salloway S, Farlow M, Gauthier S, Benzinger TLS, Morris JC, Bateman RJ, Breitner JCS, Poirier J, Vachon-Preseau E, Villeneuve S; Alzheimer's Disease Neuroimaging Initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN) Study Group; Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) Research Group. Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. Nat Commun. 2021 Sep 9;12(1):5346. ADNI*
829. *Das SR, Lyu X, Duong MT, Xie L, McCollum L, de Flores R, DiCalogero M, Irwin DJ, Dickerson BC, Nasrallah IM, Yushkevich PA, Wolk DA; Alzheimer's Disease Neuroimaging Initiative. Tau-atrophy variability reveals phenotypic heterogeneity in Alzheimer's disease. Ann Neurol. 2021 Nov;90(5):751-762. ADNI*
830. Brown JA, Jackson BS, Burton CR, Hoy JE, Sweeney JA, **Pearlson GD**, Keshavan MS, Keedy SS, Gershon ES, Tamminga CA, Clementz BA, McDowell JE. Reduced white matter microstructure in bipolar disorder with and without psychosis. Bipolar Disord. 2021 Dec;23(8):801-809.
831. Calhoun VD, **Pearlson GD**, Sui J. Data-driven approaches to neuroimaging biomarkers for neurological and psychiatric disorders: emerging approaches and examples. Curr Opin Neurol. 2021 Aug 1;34(4):469-479.
832. Rubin LH, Han J, Coughlin JM, Hill SK, Bishop JR, Tamminga CA, Clementz BA, **Pearlson GD**, Keshavan MS, Gershon ES, Heilman KJ, Porges SW, Sweeney JA, Keedy S. Real-time facial emotion recognition deficits across the psychosis spectrum: A B-SNIP Study. Schizophr Res. 2022 May;243:489-499.
833. Jiang W, Rootes-Murdy K, Chen J, Bizzozero NIP, Calhoun VD, van Erp TGM, Ehrlich S, Agartz I, Jönsson EG, Andreassen OA, Wang L, **Pearlson GD**, Glahn DC, Hong E, Liu J, Turner JA. Multivariate alterations in insula-medial prefrontal cortex linked to genetics in 12q24 in schizophrenia. Psychiatry Res. 2021 Dec;306:114237.
834. Parker DA, Trotti RL, McDowell JE, Keedy SK, Hill SK, Gershon ES, Ivleva EI, **Pearlson GD**, Keshavan MS, Tamminga CA, Clementz BA. Auditory oddball responses across the schizophrenia-bipolar spectrum and their relationship to cognitive and clinical features. Am J Psychiatry. 2021 Oct 1;178(10):952-964.
835. Trotti RL, Abdelmageed S, Parker DA, Sabatinelli D, Tamminga CA, Gershon ES, Keedy SK, Keshavan MS, **Pearlson GD**, Sweeney JA, McDowell JE, Clementz BA. Neural processing of repeated emotional scenes in schizophrenia, schizoaffective disorder, and bipolar disorder. Schizophr Bull. 2021 Aug 21;47(5):1473-1481.
836. Eum S, Hill SK, Alliey-Rodriguez N, Stevenson JM, Rubin LH, Lee AM, Mills LJ, Reilly JL, Lencer R, Keedy SK, Ivleva E, Keefe RSE, **Pearlson GD**, Clementz BA, Tamminga CA, Keshavan MS, Gershon ES, Sweeney JA, Bishop JR. Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. Neuropsychopharmacology. 2021 Sep;46(10):1802-1810.
837. Türközer HB, Ivleva EI, Palka J, Clementz BA, Shafee R, **Pearlson GD**, Sweeney JA, Keshavan MS, Gershon ES, Tamminga CA. Biomarker profiles in psychosis risk groups within unaffected relatives based on familiarity and age. Schizophr Bull. 2021 Jul 8;47(4):1058-1067.
838. Elad D, Cetin-Karayumak S, Zhang F, Cho KIK, Lyall AE, Seitz-Holland J, Ben-Ari R, **Pearlson GD**, Tamminga CA, Sweeney JA, Clementz BA, Schretlen DJ, Viher PV, Stegmayer K, Walther S, Lee J, Crow TJ, James A, Voineskos AN, Buchanan RW, Szeszko PR, Malhotra AK, Keshavan MS, Shenton ME, Rathi Y, Bouix S, Sochen N, Kubicki MR, Pasternak O. Improving the predictive potential of diffusion MRI in schizophrenia using normative models-Towards subject-level classification. Hum Brain Mapp. 2021 Oct 1;42(14):4658-4670.
839. Hyatt CJ, Wexler BE, Pittman B, Nicholson A, **Pearlson GD**, Corbera S, Bell MD, Pelphrey K, Calhoun VD, Assaf M. Atypical dynamic functional network connectivity state engagement during

- social-emotional processing in schizophrenia and autism. *Cereb Cortex*. 2022 Aug 3;32(16):3406-3422.
840. Koenis MMG, Durnez J, Rodrigue AL, Mathias SR, Alexander-Bloch AF, Barrett JA, Doucet GE, Frangou S, Knowles EEM, Mollon J, Denbow D, Aberizk K, Zatony M, Janssen RJ, Curran JE, Blangero J, Poldrack RA, **Pearlson GD**, Glahn DC. Associations of cannabis use disorder with cognition, brain structure, and brain function in African Americans. *Hum Brain Mapp*. 2021 Apr 15;42(6):1727-1741.
841. Lizano P, Lutz O, Xu Y, Rubin LH, Paskowitz L, Lee AM, Eum S, Keedy SK, Hill SK, Reilly JL, Wu B, Tamminga CA, Clementz BA, **Pearlson GD**, Gershon ES, Keshavan MS, Sweeney JA, Bishop JR. Multivariate relationships between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis. *Mol Psychiatry*. 2021 Jul;26(7):3430-3443.
842. *Chung Y, Lee H; the Alzheimer's Disease Neuroimaging Initiative (ADNI). Correlation between Alzheimer's disease and type 2 diabetes using non-negative matrix factorization. Sci Rep. 2021 Jul 27;11(1):15265. ADNI*
843. *Hu WT, Ozturk T, Kollhoff A, Wharton W, Christina Howell J; Alzheimer's Disease Neuroimaging Initiative (ADNI). Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease. Nat Commun. 2021 Jun 28;12(1):4001. ADNI*
844. *Yang Z, Nasrallah IM, Shou H, Wen J, Doshi J, Habes M, Erus G, Abdulkadir A, Resnick SM, Albert MS, Maruff P, Fripp J, Morris JC, Wolk DA, Davatzikos C; iSTAGING Consortium; Baltimore Longitudinal Study of Aging (BLSA); Alzheimer's Disease Neuroimaging Initiative (ADNI). A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. Nat Commun. 2021 Dec 3;12(1):7065. ADNI*
845. *Chen SD, Lu JY, Li HQ, Yang YX, Jiang JH, Cui M, Zuo CT, Tan L, Dong Q, Yu JT; Alzheimer's Disease Neuroimaging Initiative (ADNI). Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. Transl Psychiatry. 2021 Sep 18;11(1):483. ADNI*
846. Haeny AM, Gueorguieva R, Jackson A, Morean ME, Krishnan-Sarin S, DeMartini KS, **Pearlson GD**, Anticevic A, Krystal JH, O'Malley SS. Individual differences in the associations between risk factors for alcohol use disorder and alcohol use-related outcomes. *Psychol Addict Behav*. 2021 Aug;35(5):501-513.
847. Koenis MMG, Papasavas PK, Janssen RJ, Tishler DS, **Pearlson GD**. Brain responses to anticipatory cues and milkshake taste in obesity, and their relationship to bariatric surgery outcome. *Neuroimage*. 2021 Dec 15;245:118623.
848. *Shen XN, Huang YY, Chen SD, Guo Y, Tan L, Dong Q, Yu JT; Alzheimer's Disease Neuroimaging Initiative. Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. Transl Psychiatry. 2021 Nov 13;11(1):585. ADNI*
849. Eskridge CLM, Hochberger WC, Kaseda ET, Lencer R, Reilly JL, Keedy SK, Keefe RSE, **Pearlson GD**, Keshavan MS, Tamminga CA, Sweeney JA, Hill SK. Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. *Schizophr Res*. 2021 Oct;236:54-60.
850. Yan W, Zhao M, Fu Z, **Pearlson GD**, Sui J, Calhoun VD. Mapping relationships among schizophrenia, bipolar and schizoaffective disorders: A deep classification and clustering framework using fMRI time series. *Schizophr Res*. 2022 Jul;245:141-150.
851. *Neitzel J, Franzmeier N, Rubinski A, Dichgans M, Brendel M; Alzheimer's Disease Neuroimaging Initiative (ADNI), Malik R, Ewers M. KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. Nat Commun. 2021 Jun 22;12(1):3825. ADNI*

852. Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, Hansson O; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFinder Study. Author Correction: Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. *Nat Commun*. 2021 Aug 5;12(1):4862. ADNI
853. Clementz BA, Parker DA, Trotti RL, McDowell JE, Keedy SK, Keshavan MS, **Pearlson GD**, Gershon ES, Ivleva EI, Huang LY, Hill SK, Sweeney JA, Thomas O, Hudgens-Haney M, Gibbons RD, Tamminga CA. Psychosis biotypes: Replication and validation from the B-SNIP consortium. *Schizophr Bull*. 2022 Jan 21;48(1):56-68.
854. Xiao Y, Liao W, Long Z, Tao B, Zhao Q, Luo C, Tamminga CA, Keshavan MS, **Pearlson GD**, Clementz BA, Gershon ES, Ivleva EI, Keedy SK, Biswal BB, Mechelli A, Lencer R, Sweeney JA, Lui S, Gong Q. Subtyping schizophrenia patients based on patterns of structural brain alterations. *Schizophr Bull*. 2022 Jan 21;48(1):241-250.
855. D'Souza DC, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, **Pearlson GD**, Ranganathan M, Selloni A, Solowij N, Spinazzola E. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. *World J Biol Psychiatry*. 2022 Dec;23(10):719-742.
856. Zhang L, Lizano P, Guo B, Xu Y, Rubin LH, Hill SK, Alliey-Rodriguez N, Lee AM, Wu B, Keedy SK, Tamminga CA, **Pearlson GD**, Clementz BA, Keshavan MS, Gershon ES, Sweeney JA, Bishop JR. Inflammation subtypes in psychosis and their relationships with genetic risk for psychiatric and cardiometabolic disorders. *Brain Behav Immun Health*. 2022 Apr 8;22:100459.
857. Zhao Q, Cao H, Zhang W, Li S, Xiao Y, Tamminga CA, Keshavan MS, **Pearlson GD**, Clementz BA, Gershon ES, Hill SK, Keedy SK, Ivleva EI, Lencer R, Sweeney JA, Gong Q, Lui S. A subtype of institutionalized patients with schizophrenia characterized by pronounced subcortical and cognitive deficits. *Neuropsychopharmacology*. 2022 Nov;47(12):2024-2032.
858. Johnstone S, Sorkhou M, Al-Saghir N, Lowe DJE, Steele VR, **Pearlson GD**, Castle DJ, George TP. Neuromodulation to treat substance use disorders in people with schizophrenia and other psychoses: A systematic review. *Front Psychiatry*. 2022 Feb 14;13:793938.
859. Iraj A, Faghiri A, Fu Z, Kochunov P, Adhikari BM, Belger A, Ford JM, McEwen S, Mathalon DH, **Pearlson GD**, Potkin SG, Preda A, Turner JA, Van Erp TGM, Chang C, Calhoun VD. Moving beyond the 'CAP' of the Iceberg: Intrinsic connectivity networks in fMRI are continuously engaging and overlapping. *Neuroimage*. 2022 May 1;251:119013.
860. Duong MT, Das SR, Lyu X, Xie L, Richardson H, Xie SX, Yushkevich PA; Alzheimer's Disease Neuroimaging Initiative (ADNI), Wolk DA, Nasrallah IM. Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. *Nat Commun*. 2022 Mar 21;13(1):1495. ADNI
861. Zhang L, Hill SK, Guo B, Wu B, Alliey-Rodriguez N, Eum S, Lizano P, Ivleva EI, Reilly JL, Keefe RSE, Keedy SK, Tamminga CA, **Pearlson GD**, Clementz BA, Keshavan MS, Gershon ES, Sweeney JA, Bishop JR. Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2022 Mar 8;113:110464.
862. Wen J, Fu CHY, Tosun D, Veturi Y, Yang Z, Abdulkadir A, Mamourian E, Srinivasan D, Skampardon I, Singh A, Nawani H, Bao J, Erus G, Shou H, Habes M, Doshi J, Varol E, Mackin RS, Sotiras A, Fan Y, Saykin AJ, Sheline YI, Shen L, Ritchie MD, Wolk DA, Albert M, Resnick SM, Davatzikos C; iSTAGING consortium, ADNI, BIOCARD, and BLSA. Characterizing heterogeneity in neuroimaging, cognition, clinical symptoms, and genetics among patients with late-life depression. *JAMA Psychiatry*. 2022 May 1;79(5):464-474. ADNI
863. Patel KT, Stevens MC, Dunlap A, Gallagher A, O'Malley SS, DeMartini K, Potenza MN, Krystal JH, **Pearlson GD**. Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or

- negative for alcohol use disorder. A pilot randomised trial. *Neuropsychopharmacology*. 2022 Mar;47(4):840-846.
864. Milicic L, Vacher M, Porter T, Doré V, Burnham SC, Bourgeat P, Shishegar R, Doecke J, Armstrong NJ, Tankard R, Maruff P, Masters CL, Rowe CC, Villemagne VL, Laws SM; Alzheimer's Disease Neuroimaging Initiative (ADNI); Australian Imaging Biomarkers and Lifestyle (AIBL) Study. Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. *Geroscience*. 2022 Jun;44(3):1807-1823. ADNI
865. Yang Z, Caldwell JZK, Cummings JL, Ritter A, Kinney JW, Cordes D; Alzheimer's Disease Neuroimaging Initiative (ADNI). Sex modulates the pathological aging effect on caudate functional connectivity in mild cognitive impairment. *Front Psychiatry*. 2022 Apr 5;13:804168. ADNI
866. Miller RL, Vergara VM, **Pearlson GD**, Calhoun VD. Multiframe evolving dynamic functional connectivity (EVOdFNC): A method for constructing and investigating functional brain motifs. *Front Neurosci*. 2022 Apr 19;16:770468.
867. Qi S; Sui J; **Pearlson GD**; Bustillo J; Perrone-Bizzozero NI; Kochunov P; Turner JA; Fu Z; Shao W; Jiang R; Yang X; Liu J; Du Y; Chen J; Zhang D; Calhoun VD. Derivation and utility of schizophrenia polygenic risk associated multimodal MRI frontotemporal network. *Nat Commun*. 2022 Aug 22;13(1):4929.
868. Du Y; He X; Kochunov P; **Pearlson GD**; Hong LE; van Erp TG; Belger A; Calhoun VD. A new multimodality fusion classification approach to explore the uniqueness of schizophrenia and autism spectrum disorder. *Hum Brain Mapp*. 2022 Aug 15;43(12):3887-3903.
869. Grella ON; Dunlap A; Nicholson AM; Stevens K; Pittman B; Corbera S; Diefenbach G; **Pearlson GD**; Assaf M. Personality as a mediator of autistic traits and internalizing symptoms in two community samples. *BMC Psychol*. 2022 Mar 28;10(1):81.
870. Motlaghian SM; Belger A; Bustillo JR; Ford JM; Iraj A; Lim K; Mathalon DH; Mueller BA; O'Leary D; **Pearlson GD**; Potkin SG; Preda A; van Erp TG; Calhoun VD. Nonlinear functional network connectivity in resting functional magnetic resonance imaging data. *Hum Brain Mapp*. 2022 Oct 15;43(15):4556-4566.
871. Seitz-Holland J; Wojcik JD; Cetin-Karayumak S; Lyall AE; Pasternak O; Rathi Y; Vangel M; **Pearlson GD**; Tamminga C; Sweeney JA; Clementz BA; Schretlen DA; Viher PV; Stegmayer K; Walther S; Lee J; Crow T; James A; Voineskos A; Buchanan RW; Szeszko PR; Malhotra AK; Kelly S; Shenton ME; Keshavan MS; Meshulam-Gately RI; Kubicki M. Cognitive deficits, clinical variables, and white matter microstructure in schizophrenia: a multisite harmonization study. *Mol Psychiatry*. 2022 Sep;27(9):3719-3730.
872. DeRamus TP; Wu L; Qi S; Iraj A; Silva R; Du Y; **Pearlson GD**; Mayer A; Bustillo JR; Stromberg SF; Calhoun VD. Multimodal data fusion of cortical-subcortical morphology and functional network connectivity in psychotic spectrum disorder. *Neuroimage Clin*. 2022;35:103056.
873. Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D; Alzheimer's Disease Neuroimaging Initiative; Strandberg O, Janelidze S, Palmqvist S, Mattsson-Carlgren N, Smith R, Stomrud E, Ossenkoppele R, Hansson O. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. *Nat Commun*. 2022 Nov 4;13(1):6635. ADNI
874. D'Souza DC, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, **Pearlson GD**, Ranganathan M, Selloni A, Solowij N, Spinazzola E. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. *World J Biol Psychiatry*. 2022 Dec;23(10):719-742.
875. Zalzal A, Fiszdon JM, Moritz S, Wardwell P, Petrik T, Mathews L, Shagan D, Bracken D, Bell MD, **Pearlson GD**, Choi J. Metacognitive training to improve insight and work outcome in schizophrenia. *J Nerv Ment Dis*. 2022 Sep 1;210(9):655-658.

876. Chen J, Fu Z, Bustillo JR, Perrone-Bizzozero NI, Lin D, Canive J, **Pearlson GD**, Stephen JM, Mayer AR, Potkin SG, van Erp TGM, Kochunov P, Elliot Hong L, Adhikari BM, Andreassen OA, Agartz I, Westlye LT, Sui J, Du Y, Macciardi F, Hanlon FM, Jung RE, Turner JA, Liu J, Calhoun VD. Genome-transcriptome-functional connectivity-cognition link differentiates schizophrenia from bipolar disorder. *Schizophr Bull.* 2022 Nov 18;48(6):1306-1317.
877. Iraj A, Faghiri A, Fu Z, Rachakonda S, Kochunov P, Belger A, Ford JM, McEwen S, Mathalon DH, Mueller BA, **Pearlson GD**, Potkin SG, Preda A, Turner JA, van Erp TGM, Calhoun VD. Multi-spatial-scale dynamic interactions between functional sources reveal sex-specific changes in schizophrenia. *Netw Neurosci.* 2022 Jun 1;6(2):357-381.
878. Koenis MMG, Ng J, Anderson B, Stevens MC, Tishler DS, Papasavas PK, Stone A, McLaughlin T, Verhaak A, Domakonda MJ, **Pearlson GD**. Food cue reactivity in successful laparoscopic gastric banding: A sham-deflation-controlled pilot study. *Front Hum Neurosci.* 2022 Aug 25;16:902192.
879. Yan T, Liang J, Gao J, Wang L, Fujioka H; Alzheimer Disease Neuroimaging Initiative; Zhu X, Wang X. Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer's disease. *Nat Commun.* 2022 Jul 11;13(1):4006. ADNI
880. Inglese M, Patel N, Linton-Reid K, Loreto F, Win Z, Perry RJ, Carswell C, Grech-Sollars M, Crum WR, Lu H, Malhotra PA; Alzheimer's Disease Neuroimaging Initiative; Aboagye EO. A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer's disease. *Commun Med (Lond).* 2022 Jun 20;2:70. ADNI
881. Rubin LH, Han J, Coughlin JM, Hill SK, Bishop JR, Tamminga CA, Clementz BA, **Pearlson GD**, Keshavan MS, Gershon ES, Heilman KJ, Porges SW, Sweeney JA, Keedy S. Real-time facial emotion recognition deficits across the psychosis spectrum: A B-SNIP Study. *Schizophr Res.* 2022 May;243:489-499.
882. Fathian A, Jamali Y, Raoufy MR; Alzheimer's Disease Neuroimaging Initiative. The trend of disruption in the functional brain network topology of Alzheimer's disease. *Sci Rep.* 2022 Sep 2;12(1):14998. ADNI
883. Türközer HB, Lizano P, Adhan I, Ivleva EI, Lutz O, Zeng V, Zeng A, Raymond N, Bannai D, Lee A, Bishop JR, Clementz BA, **Pearlson GD**, Sweeney JA, Gershon ES, Keshavan MS, Tamminga CA. Regional and sex-specific alterations in the visual cortex of individuals with psychosis spectrum disorders. *Biol Psychiatry.* 2022 Sep 1;92(5):396-406.
884. Hyatt CJ, Wexler BE, Pittman B, Nicholson A, **Pearlson GD**, Corbera S, Bell MD, Pelphrey K, Calhoun VD, Assaf M. Atypical dynamic functional network connectivity state engagement during social-emotional processing in schizophrenia and autism. *Cereb Cortex.* 2022 Aug 3;32(16):3406-3422.
885. Rootes-Murdy K, Edmond JT, Jiang W, Rahaman MA, Chen J, Perrone-Bizzozero NI, Calhoun VD, van Erp TGM, Ehrlich S, Agartz I, Jönsson EG, Andreassen OA, Westlye LT, Wang L, **Pearlson GD**, Glahn DC, Hong E, Buchanan RW, Kochunov P, Voineskos A, Malhotra A, Tamminga CA, Liu J, Turner JA. Clinical and cortical similarities identified between bipolar disorder I and schizophrenia: A multivariate approach. *Front Hum Neurosci.* 2022 Nov 10;16:1001692.
886. Huang LY, Jackson BS, Rodrigue AL, Tamminga CA, Gershon ES, **Pearlson GD**, Keshavan MS, Keedy SS, Hill SK, Sweeney JA, Clementz BA, McDowell JE. Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophrenia network for intermediate phenotypes 2 (B-SNIP2). *Psychol Med.* 2022 Oct;52(13):2692-2701.
887. Karpouzian-Rogers T, Sweeney JA, Rubin LH, McDowell J, Clementz BA, Gershon E, Keshavan MS, **Pearlson GD**, Tamminga CA, Reilly JL. Reduced task-evoked pupillary response in preparation for an executive cognitive control response among individuals across the psychosis spectrum. *Schizophr Res.* 2022 Oct;248:79-88.



888. Yan W, Zhao M, Fu Z, **Pearlson GD**, Sui J, Calhoun VD. Mapping relationships among schizophrenia, bipolar and schizoaffective disorders: A deep classification and clustering framework using fMRI time series. *Schizophr Res*. 2022 Jul; 245:141-150.
889. Jiang J, Sheng C, Chen G, Liu C, Jin S, Li L, Jiang X, Han Y; Alzheimer's Disease Neuroimaging Initiative. Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment. *Geroscience*. 2022 Aug;44(4):2319-2336. ADNI
890. Öhrfelt A, Benedet AL, Ashton NJ, Kvartsberg H, Vandijck M, Weiner MW, Trojanowski JQ, Shaw LM, Zetterberg H, Blennow K; Alzheimer's Disease Neuroimaging Initiative. Association of CSF GAP-43 with the rate of cognitive decline and progression to dementia in amyloid-positive individuals. *Neurology*. 2023 Jan 17;100(3):e275-e285. ADNI
891. Zhang L, Lizano P, Xu Y, Rubin LH, Lee AM, Lencer R, Reilly JL, Keefe RSE, Keedy SK, **Pearlson GD**, Clementz BA, Keshavan MS, Gershon ES, Tamminga CA, Sweeney JA, Hill SK, Bishop JR. Peripheral inflammation is associated with impairments of inhibitory behavioral control and visual sensorimotor function in psychotic disorders. *Schizophr Res*. 2023 Mar 23;255:69-78.
892. Rokham H, Falakshahi H, Fu Z, **Pearlson GD**, Calhoun VD. Evaluation of boundaries between mood and psychosis disorder using dynamic functional network connectivity (dFNC) via deep learning classification. *Hum Brain Mapp*. 2023 Jun 1;44(8):3180-3195.
893. Vasconcelos Da Silva M, Melendez-Torres GJ, Ismail Z, Testad I, Ballard C, Creese B; Alzheimer's Disease Neuroimaging Initiative. A data-driven examination of apathy and depressive symptoms in dementia with independent replication. *Alzheimers Dement (Amst)*. 2023 Feb 5;15(1):e12398. ADNI
894. Uscătescu LC; Kronbichler M; Said-Yürekli S; Kronbichler L; Calhoun V; Corbera S; Bell M; Pelphrey K; **Pearlson GD**; Assaf M. Intrinsic neural timescales in autism spectrum disorder and schizophrenia. A replication and direct comparison study. *Schizophrenia (Heidelb)*. 2023 Mar 30;9(1):18.
895. Liang C; **Pearlson GD**; Bustillo J; Kochunov P; Turner JA; Wen X; Jiang R; Fu Z; Zhang X; Li K; Xu X; Zhang D; Qi S; Calhoun VD. Psychotic symptom, mood, and cognition-associated multimodal MRI reveal shared links to the salience network within the psychosis spectrum disorders. *Schizophr Bull*. 2023 Jan 3;49(1):172-184.
896. Meng X, Iraj A, Fu Z, Kochunov P, Belger A, Ford JM, McEwen S, Mathalon DH, Mueller BA, **Pearlson GD**, Potkin SG, Preda A, Turner J, van Erp TGM, Sui J, Calhoun VD. Multi-model order spatially constrained ICA reveals highly replicable group differences and consistent predictive results from resting data: A large N fMRI schizophrenia study. *Neuroimage Clin*. 2023;38:103434.
897. Vasconcelos Da Silva M, Melendez-Torres GJ, Ismail Z, Testad I, Ballard C, Creese B; Alzheimer's Disease Neuroimaging Initiative. A data-driven examination of apathy and depressive symptoms in dementia with independent replication. *Alzheimers Dement (Amst)*. 2023 Feb 5;15(1):e12398.
898. Zhou X, Chen Y, Ip FCF, Jiang Y, Cao H, Lv G, Zhong H, Chen J, Ye T, Chen Y, Zhang Y, Ma S, Lo RMN, Tong EPS; Alzheimer's Disease Neuroimaging Initiative; Mok VCT, Kwok TCY, Guo Q, Mok KY, Shoai M, Hardy J, Chen L, Fu AKY, Ip NY. Deep learning-based polygenic risk analysis for Alzheimer's disease prediction. *Commun Med (Lond)*. 2023 Apr 6;3(1):49.
899. Del Re EC, Yassin W, Zeng V, Keedy S, Alliey-Rodriguez N, Ivleva E, Hill S, Rychagov N, McDowell JE, Bishop JR, Mesholam-Gately R, Merola G, Lizano P, Gershon E, **Pearlson GD**, Sweeney JA, Clementz B, Tamminga C, Keshavan M. Characterization of childhood trauma, hippocampal mediation and cannabis use in a large dataset of psychosis and non-psychosis individuals. *Schizophr Res*. 2023 May;255:102-109.
900. Cetin-Karayumak S, Lyall AE, Di Biase MA, Seitz-Holland J, Zhang F, Kelly S, Elad D, **Pearlson GD**, Tamminga CA, Sweeney JA, Clementz BA, Schretlen D, Stegmayer K, Walther S, Lee J, Crow T, James A, Voineskos A, Buchanan RW, Szeszko PR, Malhotra AK, Keshavan M, Shenton ME, Rathi Y, Pasternak O, Kubicki M. Characterization of the extracellular free water signal in

- schizophrenia using multi-site diffusion MRI harmonization. *Mol Psychiatry*. 2023 May;28(5):2030-2038.
901. Trotti RL, Parker DA, Sabatinelli D, Keshavan MS, Keedy SK, Gershon ES, **Pearlson GD**, Hill SK, Tamminga CA, McDowell JE, Clementz BA. Emotional scene processing in biotypes of psychosis. *Psychiatry Res*. 2023 Jun;324:115227.
902. Cannizzaro A, Ronat L, El Haffaf LM, Hanganu A; ADNI. Associations between neuropsychiatric symptoms of affective and vegetative domains and brain morphology in aging people with mild cognitive impairment and Alzheimer's disease. *Int J Geriatr Psychiatry*. 2023 Jun;38(6):e5952.
903. McLachlan E, Ocal D, Burgess N, Reeves S, Howard R; Alzheimer's Disease Neuroimaging Initiative. Association Between False Memories and Delusions in Alzheimer Disease. *JAMA Psychiatry*. 2023 Jul 1;80(7):700-709.
904. Duda M, Faghiri A, Belger A, Bustillo JR, Ford JM, Mathalon DH, Mueller BA, **Pearlson GD**, Potkin SG, Preda A, Sui J, Van Erp TGM, Calhoun VD. Alterations in grey matter structure linked to frequency-specific cortico-subcortical connectivity in schizophrenia via multimodal data fusion. *bioRxiv* [Preprint]. 2023 Jul 6.
905. Iraj A, Chen J, Lewis N, Faghiri A, Fu Z, Agcaoglu O, Kochunov P, Adhikari BM, Mathalon DH, **Pearlson GD**, Macciardi F, Preda A, van Erp TGM, Bustillo JR, Díaz-Caneja CM, Andrés-Camazón P, Dhamala M, Adali T, Calhoun VD. Spatial dynamic subspaces encode sex-specific schizophrenia disruptions in transient network overlap and its links to genetic risk. *bioRxiv* [Preprint]. 2023 Jul 19.
906. Azevedo T, Bethlehem RAI, Whiteside DJ, Swaddiwudhipong N, Rowe JB, Lió P, Rittman T; Alzheimer's Disease Neuroimaging Initiative. Identifying healthy individuals with Alzheimer's disease neuroimaging phenotypes in the UK Biobank. *Commun Med (Lond)*. 2023 Jul 20;3(1):100.
907. Erickson P, Simrén J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, Langhough R, Jonaitis EM, Van Hulle CA, Betthausen TJ, Carlsson CM, Asthana S, Ashton NJ, Johnson SC, Shaw LM, Blennow K, Andreasson U, Bendlin BB, Zetterberg H; ADNI Cohort. Prevalence and clinical Implications of a  $\beta$ -Amyloid-Negative, Tau-positive cerebrospinal fluid biomarker profile in Alzheimer disease. *JAMA Neurol*. 2023 Jul 31;80(9):969-79. Online ahead of print.
908. Tuena C, Maestri S, Serino S, Pedroli E, Stramba-Badiale M, Riva G; Alzheimer's Disease Neuroimaging Initiative. Prognostic relevance of gait-related cognitive functions for dementia conversion in amnesic mild cognitive impairment. *BMC Geriatr*. 2023 Jul 31;23(1):462.
909. Lee G, Nho K, Kang B, Sohn KA, Kim D; Alzheimer's Disease Neuroimaging Initiative. Author Correction: Predicting Alzheimer's disease progression using multi-modal deep learning approach. *Sci Rep*. 2023 Aug 1;13(1):12466.
910. Koen JD, Lewis L, Rugg MD, Clementz BA, Keshavan MS, **Pearlson GD**, Sweeney JA, Tamminga CA, Ivleva EI. Supervised machine learning classification of psychosis biotypes based on brain structure: findings from the Bipolar-Schizophrenia network for intermediate phenotypes (B-SNIP). *Sci Rep*. 2023 Aug 10;13(1):12980.
911. Bocancea DI, Svenningsson AL, van Loenhoud AC, Groot C, Barkhof F, Strandberg O, Smith R; Alzheimer's Disease Neuroimaging Initiative; La Joie R, Rosen HJ, Pontecorvo MJ, Rabinovici GD, van der Flier WM, Hansson O, Ossenkoppele R. Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis. *Brain*. 2023 Sep 1;146(9):3719-3734.
912. Pusuluri K, Fu Z, Miller R, **Pearlson GD**, Kochunov P, Van Erp TGM, Iraj A, Calhoun VD. 4D dynamic spatial brain networks at rest linked to cognition show atypical variability and coupling in schizophrenia. *bioRxiv* [Preprint]. 2023 Sep 18.
913. Clementz BA, Chattopadhyay I, Trotti RL, Parker DA, Gershon ES, Hill SK, Ivleva EI, Keedy SK, Keshavan MS, McDowell JE, **Pearlson GD**, Tamminga CA, Gibbons RD. Clinical characterization

and differentiation of B-SNIP psychosis Biotypes: Algorithmic Diagnostics for Efficient Prescription of Treatments (ADEPT)-1. *Schizophr Res*. 2023 Oct;260:143-151.

914. Jiang Y, Luo C, Wang J, Palaniyappan L, Chang X, Xiang S, Zhang J, Duan M, Huang H, Gaser C, Nemoto K, Miura K, Hashimoto R, Westlye LT, Richard G, Fernandez-Cabello S, Parker N, Andreassen OA, Kircher T, Nenadić I, Stein F, Thomas-Odenthal F, Teutenberg L, Usemann P, Dannlowski U, Hahn T, Grotegerd D, Meinert S, Lencer R, Tang Y, Zhang T, Li C, Yue W, Zhang Y, Yu X, Zhou E, Lin CP, Tsai SJ, Rodrigue AL, Glahn D, **Pearlson GD**, Blangero J, Karuk A, Pomarol-Clotet E, Salvador R, Fuentes-Claramonte P, Garcia-León MÁ, Spalletta G, Piras F, Vecchio D, Banaj N, Cheng J, Liu Z, Yang J, Gonul AS, Uslu O, Burhanoglu BB, Demir AU, Rotes-Murdy K, Calhoun VD, Sim K, Green M, Quidé Y, Chung YC, Kim WS, Sponheim SR, Demro C, Ramsay IS, Iasevoli F, de Bartolomeis A, Barone A, Ciccarelli M, Brunetti A, Coccozza S, Pontillo G, Tranfa M, Park MTM, Kirschner M, Georgiadis F, Kaiser S, Rheenen TEV, Rossell SL, Hughes M, Woods W, Carruthers SP, Sumner P, Ringin E, Spaniel F, Skoch A, Tomecek D, Homan P, Homan S, Omlor W, Cecere G, Nguyen DD, Preda A, Thomopoulos S, Jahanshad N, Cui LB, Yao D, Thompson PM, Turner JA, van Erp TGM, Cheng W; ENIGMA Schizophrenia Consortium; ZIB Consortium; Feng J. Two neurostructural subtypes: results of machine learning on brain images from 4,291 individuals with schizophrenia. *medRxiv* [Preprint]. 2023 Oct 12:2023.10.11.23296862.
915. Lizano P, Kiely C, Mijalkov M, Meda SA, Keedy S, Hoang D, Zeng V, Lutz O, Pereira JB, Ivleva EI, Volpe G, Xu Y, Lee AM, Rubin LH, Hill SK, Clementz BA, Tamminga CA, **Pearlson GD**, Sweeney JA, Gershon ES, Keshavan MS, Bishop JR. Peripheral inflammatory subgroup differences in anterior Default Mode network and multiplex functional network topology are associated with cognition in psychosis. *Brain Behav Immun*. 2023 Nov;114:3-15.
916. Yip SW, Lichenstein SD, Liang Q, Chaarani B, Dager A, **Pearlson GD**, Banaschewski T, Bokde ALW, Desrivieres S, Flor H, Grigis A, Gowland P, Heinz A, Brühl R, Martinot JL, Martinot MP, Artiges E, Nees F, Orfanos DP, Paus T, Poustka L, Hohmann S, Millenet S, Fröhner JH, Smolka MN, Vaidya N, Walter H, Whelan R, Schumann G, Garavan H. Brain networks and adolescent alcohol use. *JAMA Psychiatry*. 2023 Nov 1;80(11):1131-1141.
917. Huang LY, Parker DA, Ethridge LE, Hamm JP, Keedy SS, Tamminga CA, **Pearlson GD**, Keshavan MS, Hill SK, Sweeney JA, McDowell JE, Clementz BA. Double dissociation between P300 components and task switch error type in healthy but not psychosis participants. *Schizophr Res*. 2023 Nov;261:161-169.
918. Jo T, Kim J, Bice P, Huynh K, Wang T, Arnold M, Meikle PJ, Giles C, Kaddurah-Daouk R, Saykin AJ, Nho K; Alzheimer's Disease Metabolomics Consortium (ADMC); Alzheimer's Disease Neuroimaging Initiative (ADNI). Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data. *EBioMedicine*. 2023 Nov;97:104820.
919. Omlor W, Rabe F, Fuchs S, Cecere G, Homan S, Surbeck W, Kallen N, Georgiadis F, Spiller T, Seifritz E, Weickert T, Bruggemann J, Weickert C, Potkin S, Hashimoto R, Sim K, Rotes-Murdy K, Quidé Y, Houenou J, Banaj N, Vecchio D, Piras F, Piras F, Spalletta G, Salvador R, Karuk A, Pomarol-Clotet E, Rodrigue A, **Pearlson GD**, Glahn D, Tomecek D, Spaniel F, Skoch A, Kirschner M, Kaiser S, Kochunov P, Fan FM, Andreassen OA, Westlye LT, Berthet P, Calhoun VD, Howells F, Uhlmann A, Scheffler F, Stein D, Iasevoli F, Cairns MJ, Carr VJ, Catts SV, Di Biase MA, Jablensky A, Green MJ, Henskens FA, Klauser P, Loughland C, Michie PT, Mowry B, Pantelis C, Rasser PE, Schall U, Scott R, Zalesky A, de Bartolomeis A, Barone A, Ciccarelli M, Brunetti A, Coccozza S, Pontillo G, Tranfa M, Di Giorgio A, Thomopoulos SI, Jahanshad N, Thompson PM, van Erp T, Turner J, Homan P. Estimating multimodal brain variability in schizophrenia spectrum disorders: A worldwide ENIGMA study. *bioRxiv* [Preprint]. 2023 Nov 2.
920. Iraj A, Fu Z, Faghiri A, Duda M, Chen J, Rachakonda S, DeRamus T, Kochunov P, Adhikari BM, Belger A, Ford JM, Mathalon DH, **Pearlson GD**, Potkin SG, Preda A, Turner JA, van Erp TGM, Bustillo JR, Yang K, Ishizuka K, Faria A, Sawa A, Hutchison K, Osuch EA, Theberge J, Abbott C, Mueller BA, Zhi D, Zhuo C, Liu S, Xu Y, Salman M, Liu J, Du Y, Sui J, Adali T, Calhoun VD. Identifying canonical and replicable multi-scale intrinsic connectivity networks in 100k+ resting-state fMRI datasets. *Hum Brain Mapp*. 2023 Dec 1;44(17):5729-5748.

921. Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR Jr, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TLS, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP; Dominantly Inherited Alzheimer Network and the Alzheimer's Disease Neuroimaging Initiative. Etiology of white matter hyperintensities in autosomal dominant and sporadic Alzheimer disease. *JAMA Neurol.* 2023 Dec 1;80(12):1353-1363.
922. Anderson J, Calhoun VD, **Pearlson GD**, Hawkins KA, Stevens MC. Age-related, multivariate associations between white matter microstructure and behavioral performance in three executive function domains. *Dev Cogn Neurosci.* 2023 Dec;64:101318.
923. Harikumar A, Solovyeva KP, Misiura M, Iraj A, Plis SM, **Pearlson GD**, Turner JA, Calhoun VD. Revisiting functional dysconnectivity: a review of three model frameworks in schizophrenia. *Curr Neurol Neurosci Rep.* 2023 Dec;23(12):937-946.
924. Iraj A, Chen J, Lewis N, Faghiri A, Fu Z, Agcaoglu O, Kochunov P, Adhikari BM, Mathalon DH, **Pearlson GD**, Macciardi F, Preda A, van Erp TGM, Bustillo JR, Díaz-Caneja CM, Andrés-Camazón P, Dhamala M, Adali T, Calhoun VD. Spatial dynamic subspaces encode sex-specific schizophrenia disruptions in transient network overlap and their links to genetic risk. *Biol Psychiatry.* 2023 Dec 7. Online ahead of print.
925. Lin D, Fu Z, Liu J, Perrone-Bizzozero N, Hutchison KE, Bustillo J, Du Y, **Pearlson GD**, Calhoun VD. Association between the oral microbiome and brain resting state connectivity in schizophrenia. *bioRxiv* [Preprint]. 2023 Dec 26. Preprint.
926. Sullivan AJ, Chung YS, Novotny S, Epperson CN, Kober H, Blumberg HP, Gross JJ, Ochsner KN, **Pearlson GD**, Stevens MC. Estradiol effects on an emotional interference task in adolescents with current and remitted depression. *Horm Behav.* 2024 Jan;157:105450.
927. Parker D, Trotti R, McDowell J, Keedy S, Keshavan M, **Pearlson GD**, Gershon E, Ivleva E, Huang LY, Sauer K, Hill S, Sweeny J, Tamminga C, Clementz B. Differentiating biomarker features and familial characteristics of B-SNIP psychosis biotypes. *Res Sq* [Preprint]. 2024 Jan 5.
928. Zhang Q, Fan C, Wang L, Li T, Wang M, Han Y, Jiang J; and for the Alzheimer's Disease Neuroimaging Initiative. Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer's disease: an exploratory study of 18F-FDG-PET. *Geroscience.* 2024 Feb;46(1):1407-1420.
929. Ji Y, **Pearlson GD**, Bustillo J, Kochunov P, Turner JA, Jiang R, Shao W, Zhang X, Fu Z, Li K, Liu Z, Xu X, Zhang D, Qi S, Calhoun VD. Identifying psychosis subtypes use individualized covariance structural differential networks and multi-site clustering. *Schizophr Res.* 2024 Feb;264:130-139.
930. Lamsma J, Raine A, Kia SM, Cahn W, Arold D, Banaj N, Barone A, Brosch K, Brouwer R, Brunetti A, Calhoun VD, Chew QH, Choi S, Chung YC, Ciccarelli M, Cobia D, Cocozza S, Dannlowski U, Dazzan P, de Bartolomeis A, Di Forti M, Dumais A, Edmond JT, Ehrlich S, Evermann U, Flinkenflügel K, Georgiadis F, Glahn DC, Goltermann J, Green MJ, Grotegerd D, Guerrero-Pedraza A, Ha M, Hong EL, Hulshoff Pol H, Iasevoli F, Kaiser S, Kaleda V, Karuk A, Kim M, Kircher T, Kirschner M, Kochunov P, Kwon JS, Lebedeva I, Lencer R, Marques TR, Meinert S, Murray R, Nenadić I, Nguyen D, **Pearlson GD**, Piras F, Pomarol-Clotet E, Pontillo G, Potvin S, Preda A, Quidé Y, Rodrigue A, Rootes-Murdy K, Salvador R, Skoch A, Sim K, Spalletta G, Spaniel F, Stein F, Thomas-Odenthal F, Tikász A, Tomecek D, Tomyshev A, Tranfa M, Tsogt U, Turner JA, van Erp TGM, van Haren NEM, van Os J, Vecchio D, Wang L, Wroblewski A, Nickl-Jockschat T. Structural brain abnormalities and aggressive behaviour in schizophrenia: Mega-analysis of data from 2095 patients and 2861 healthy controls via the ENIGMA consortium. *medRxiv* [Preprint]. 2024 Feb.

931. Guimond S, Alftieh A, Devenyi GA, Mike L, Chakravarty MM, Shah JL, Parker DA, Sweeney JA, **Pearlson GD**, Clementz BA, Tamminga CA, Keshavan M. Enlarged pituitary gland volume: a possible state rather than trait marker of psychotic disorders. *Psychol Med*. 2024 Feb 15;1-9. Online ahead of print.
932. Kikuchi M, Miyashita A, Hara N, Kasuga K, Saito Y, Murayama S, Kakita A, Akatsu H, Ozaki K, Niida S, Kuwano R, Iwatsubo T, Nakaya A, Ikeuchi T; Alzheimer's Disease Neuroimaging Initiative; Japanese Alzheimer's Disease Neuroimaging Initiative. Polygenic effects on the risk of Alzheimer's disease in the Japanese population. *Alzheimers Res Ther*. 2024 Feb 27;16(1):45.
933. Zhang Y, Xue L, Zhang S, Yang J, Zhang Q, Wang M, Wang L, Zhang M, Jiang J, Li Y; Alzheimer's Disease Neuroimaging Initiative. A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer's disease. *Alzheimers Res Ther*. 2024 Mar 14;16(1):60.
934. Xing Y, van Erp TGM, **Pearlson GD**, Kochunov P, Calhoun VD, Du Y. More reliable biomarkers and more accurate prediction for mental disorders using a label-noise filtering-based dimensional prediction method. *iScience*. 2024 Feb 23;27(3):109319.
935. Mehta DD, Siddiqui S, Ward HB, Steele VR, **Pearlson GD**, George TP. Functional and structural effects of repetitive transcranial magnetic stimulation (rTMS) for the treatment of auditory verbal hallucinations in schizophrenia: A systematic review. *Schizophr Res*. 2024 Mar 25;267:86-98. Online ahead of print.
936. Woods SW, Parker S, Kerr MJ, Walsh BC, Wijtenburg SA, Prunier N, Nunez AR, Buccilli K, Mourgues-Codern C, Brummitt K, Kinney KS, Trankler C, Szacilo J, Colton BL, Ali M, Haidar A, Billah T, Huynh K, Ahmed U, Adery LL, Marcy PJ, Allott K, Amminger P, Arango C, Broome MR, Cadenhead KS, Chen EYH, Choi J, Conus P, Cornblatt BA, Glenthøj LB, Horton LE, Kambeitz J, Kapur T, Keshavan MS, Koutsouleris N, Langbein K, Lavoie S, Diaz-Caneja CM, Mathalon DH, Mittal VA, Nordentoft M, Pasternak O, **Pearlson GD**, Gaspar PA, Shah JL, Smesny S, Stone WS, Strauss GP, Wang J, Corcoran CM, Perkins DO, Schiffman J, Perez J, Mamah D, Ellman LM, Powers AR 3rd, Coleman MJ, Anticevic A, Fusar-Poli P, Kane JM, Kahn RS, McGorry PD, Bearden CE, Shenton ME, Nelson B, Calkins ME, Hendricks L, Bouix S, Addington J, McGlashan TH, Yung AR; Accelerating Medicines Partnership Schizophrenia. Development of the PSYCHS: Positive symptoms and diagnostic criteria for the CAARMS harmonized with the SIPS. *Early Interv Psychiatry*. 2024 Apr;18(4):255-272.
937. Yan W, **Pearlson GD**, Fu Z, Li X, Irajai A, Chen J, Sui J, Volkow ND, Calhoun VD. A brainwide risk score for psychiatric disorder evaluated in a large adolescent population reveals increased divergence among higher-risk groups relative to control participants. *Biol Psychiatry*. 2024 Apr 1;95(7):699-708.
938. Kohler R, Lichenstein SD, Cheng A, Holmes A, Bzdok D, **Pearlson GD**, Yip SW. Identification of a composite latent dimension of reward and impulsivity across clinical, behavioral, and neurobiological domains among youth. *Biol Psychiat Cog Neurosci Neuroimg*. 2024 Apr;9(4):407-416.
939. Starkey B, **Pearlson GD**, Bond D, Glaser C, Bhargava A, Grosberg BM, Verhaak A. Characterizing cannabis use and perceived benefit in a tertiary headache center patient sample. *Neurol Clin Pract*. 2024 Apr;14(2).
940. Oka T, Matsuzawa Y, Tsuneyoshi M, Nakamura Y, Aoshima K, Tsugawa H; Alzheimer's Disease Metabolomics Consortium. Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort. *Sci Rep*. 2024 Apr 2;14(1):6797.
941. Wang YT, Theriault J, Servaes S, Tissot C, Rahmouni N, Macedo AC, Fernandez-Arias J, Mathotaarachchi SS, Benedet AL, Stevenson J, Ashton NJ, Lussier FZ, Pascoal TA, Zetterberg H, Rajah MN, Blennow K, Gauthier S, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative. Sex-

specific modulation of amyloid- $\beta$  on tau phosphorylation underlies faster tangle accumulation in females. *Brain*. 2024 Apr 4;147(4):1497-1510.

942. Williamson JN, James SA, Mullen SP, Sutton BP, Wszalek T, Mulyana B, Mukli P, Yabluchanskiy A; Alzheimer's Disease Neuroimaging Initiative Consortium; Yang Y. Sex differences in interacting genetic and functional connectivity biomarkers in Alzheimer's disease. *Geroscience*. 2024 Apr 10. Online ahead of print.
943. Wannan CMJ, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker JT, Bearden CE, Billah T, Bouix S, Broome MR, Buccilli K, Cadenhead KS, Calkins ME, Cannon TD, Cecci G, Chen EYH, Cho KIK, Choi J, Clark SR, Coleman MJ, Conus P, Corcoran CM, Cornblatt BA, Diaz-Caneja CM, Dwyer D, Ebdrup BH, Ellman LM, Fusar-Poli P, Galindo L, Gaspar PA, Gerber C, Glenthøj LB, Glynn R, Harms MP, Horton LE, Kahn RS, Kambeitz J, Kambeitz-Ilankovic L, Kane JM, Kapur T, Keshavan MS, Kim SW, Koutsouleris N, Kubicki M, Kwon JS, Langbein K, Lewandowski KE, Light GA, Mamah D, Marcy PJ, Mathalon DH, McGorry PD, Mittal VA, Nordentoft M, Nunez A, Pasternak O, **Pearlson GD**, Et al Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and study design of the largest global prospective cohort study of clinical high risk for psychosis. *Schizophr Bull*. 2024 Apr 30;50(3):496-512.
944. Zhi D, Jiang R, **Pearlson GD**, Fu Z, Qi S, Yan W, Feng A, Xu M, Calhoun V, Sui J. Triple interactions between the environment, brain, and behavior in children: An ABCD study. *Biol Psychiatry*. 2024 May 1;95(9):828-838.
945. Quesnel MJ, Labonté A, Picard C, Zetterberg H, Blennow K, Brinkmalm A, Villeneuve S, Poirier J; Alzheimer's Disease Neuroimaging Initiative; PREVENT-AD Research Group. Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains. *Brain*. 2024 May 3;147(5):1680-1695.

### **Books and Book Chapters**

Listed separately

#### **Recent and forthcoming single-author books:**

*Weed Science: Cannabis Controversies and Challenges*. Academic Press/Elsevier, Cambridge Massachusetts 2020. Being republished by Johns Hopkins University Press 2024.

*A World of Their Own: Making Sense of Madness*. HarperCollins, publication date early 2025.

#### **Recent book chapters, multi-author volumes:**

Murray RM, Castle D and D'Souza DC. *Marijuana and Madness*. Cambridge University Press. Fourth edition 2023 in press. Chapter 9: "Is there a cannabis-associated psychosis subtype? Lessons from biological typing in the B-SNIP project and implications for treatment". **Pearlson GD** and Keshavan M.

Tamminga CA, Ivleva EI, Reininghaus U and van Os J. *Psychotic Disorders: Comprehensive Conceptualization and Treatments*. Oxford University press 2021. **Pearlson GD** and Stevens MC. 'Functional connectivity biomarkers of psychosis' chapter 29.